Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)

ABSTRACT

A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide us useful for targeting pTox to cells, such as cancer cells.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The application hereby claims the benefit under 35 U.S.C. § 119(e) of United States provisional application Serial No. 60/265,594, filed Feb. 2, 2001. The entire disclosure of this application is relied upon and incorporated by reference herein.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates generally to cell death regulatory molecules for therapeutic use. More specifically, this invention relates to molecules in which a peptidic or pseudo-peptidic part acting on the permeability transition pore complex (PTPC) is covalently linked to cell-targeting molecules including antibodies, recombinant antibody fragments or homing peptides. The resulting chimeric molecules are polypeptides or peptidomimetic molecules which target the PTPC and/or its major component the adenine nucleotide translocation (ANT) to induce or inhibit cell death (apoptosis). This invention also relates to such chimeric molecules when the PTPC-interacting part is an apoptogenic HIV-1 Vpr-derived peptide (or pseudopeptide) or an ANT-derived peptide (or pseudo-peptide). This invention also relates to nucleic acid sequence construct encoding such chimeric molecule or encoding portions of these chimeric molecules.

[0004] 2. Background

[0005] It is currently agreed that mitochondria play an important role in controlling life and death of cells (apoptosis; Kroemer and Reed 2000, Nature Medicine). It appears both that an increasing number of molecules involved in the transduction of the signal and also many metabolites and certain viral effectors act on mitochondria and influence the permeabilisation of mitochondrial membranes. Using mitochondrial-specific pro-apoptotic agent would seem to be an emerging concept in cancer therapy (Costantini et al 2000, Journal of the National Cancer Institute). Similarly, it might be possible to use cytoprotective molecules, thanks to their ability to stabilize mitochondrial membranes, in the treatment of illnesses where there is excessive apoptosis (neurodegenerative diseases, ischemia, AIDS, fulminant hepatitis, etc.).

[0006] Mitochondrial membrane permeabilisation (MMP) is a key event of apoptotic cell death associated with the release of caspase activators and caspase-independent death effectors from the intermembrane space. dissipation of the inner transmembrane potential (ΔΨm), as well as a perturbation of oxidative phosphonylation (Green and Reed, 1998; Gross et al., 1999; Kroemer and Reed, 2000; Kroemer et al., 1997; Lemasters et al., 1998; Vander Heiden and Thompson, 1999; Wallace, 1999). Pro- and anti-apoptotic members of the Bcl-2 family regulate inner and outer MMP through interactions with the adenine nucleotide translocation (ANT; in the inner membrane, IM), the voltage-dependent anion channel (VDAC; in the outer membrane, OM), and/or through autonomous channel-forming activities (Desagher et al, 1999. Gross et al., 1999; Kroemer and Reed, 2000; Marzo et al., 1998; Shimizu et al., 1999; Vander Heiden and Thompson, 1999). ANT and VDAC are major components of the permeability transition pore complex (PTPC), a polyprotein structure organized at sites at which the two mitochondrial membranes are apposed (Crompton, 1999; Kroemer and Reed, 2000).

[0007] The mitochondrial phase is under the control of Bcl-2 family of oncogenes and anti-oncogenes (for review: 5; 28) involved in more than 50% of cancers (29). All members of Bcl-2 family play an active role in the regulation of apoplosis, some of them being proapoptotic (Bax, Bak, Bcl-X_(s), Bad, etc.) and others, being antiapoptotic (Bcl-2, Bcl-X_(L), Bcl-w, Mcl-1, etc.) (G. Kroemer, Nat Med 3, 614-20 (1997)).

[0008] The mitochondrial megachannel is a polyprotein complex formed in the contact site between the inner and the outer mitochondrial membranes that participate in the regulation of mitochondrial membrane permeability. It is composed of a set of proteins including mitochondrion-associated hexokinase (HK), porin (voltage-dependent anion channel or VDAC), adenine nucleotide translocation (ANT), peripheral benzodiazepin receptor (PBR), creatine kinase (CK), and cyclophilin D, as well as Bcl-2 family members. In physiological conditions, PTPC controls the mitochondrial calcium homeostasis via the regulation of its conductance by the mitochondrial pH, the ΔΨm, NAD/NAD(P)H redox equilibrium and matrix protein thiol oxidation. (M. Zoratti, I. Szabo, Biochim, Biophys Acta 1241, 139-76 (1995). S. Shimizu, M. Narita, Y. Tsujimoto, Nature 399, 483-487 (1999). M. Crompton, Biochem J 341,233-249 (1999). K. Woodfield, A. Ruck, D. Brdiczka, A. P. Halestrap, Biochem J 336,287-90 (1998). P. Bernardi, K. M. Broekemeier, D. R. Pfeiffer, J Bioenerg Biomembr 26, 509-17 (1994). F. Ichas, L. Jouaville, J. Mazat, Cell 89, 1145-53 (1997)).

[0009] Apoplosis and related forms of controlled cell death are involved in a great number of illness. Excess or insufficiency of cell death processes are involved in auto-immune and neurodegenerative diseases, cancers, ischemia, and pathological infections or diseases such as viral and bacterial infections. Just few examples illustrating the virtually ubiquitous involvement of mitochondria in diseases associated with the abnormal control of cell death will be mentioned here.

[0010] In different models of ischemia (heart, liver, kidney or brain), using molecules that are capable of stabilising mitochondrial membranes. such as CsA for example (or its analogous non-immunosuppressor-Me-Val4-CsA) has made it possible to reduce massive apoptosis and its acute consequences at the level of the organ. In addition, VDAC is indispensable for the destruction of neurons of the rat hippocampus after hypoxic reperfusion. In the area of neurodegenerative diseases, a great many observations suggest close links with mitochondrial control of apoptosis (see Kroemer and Reed 2000, Nature Medicine). The neurotoxin-methyl-4-phenylpyridinium induces mitochondrial permeability transition and the exit of cytochrome c. Poisoning by mitochondrial toxins such as nitro-propionic acid or rotenone provokes in primates and rodents a Huntington-disease type of illness.

[0011] PTPC is a dynamic protein complex located at the contact site between the two mitochondrial membranes, its opening allowing the free diffusion of solutes <1500 Da on the inner membrane. Formation of PTPC involves the association of proteins from different compartments, hexokinase (cytosol), porin, also called voltage-dependent anion channel (VDAC, outer membrane), peripheral benzodiazepin receptor (PBR, outer membrane), ANT (inner membrane) and cyclophilin D (matrix). PTPC has been implicated in many examples of apoptosis due to its capacity to integrate multiple pro-apoptotic signal transduction pathways and due to its control by proteins from Bcl-2/Bax family. The Bcl-2 family comprises death inhibitory (Bcl-2-like) and death inducing (Bax-like) members which respectively prevent or facilitate PTPC opening. Bax and Bcl-2 reportedly interact with VDAC and ANT within PTPC. In physiological conditions, ANT is a specific antiporter for ADP and ATP. However, ANT can also form a lethal pore upon interaction with different pro-apoptotic agents. including Ca2+, atractyloside, HIV-1 Vpr-derived peptides and pro-oxidants. Mitochondrial membrane permeabilization may also be regulated by the non-specific VDAC pore modulated by Bcl-2/Bax-like proteins in the outer membrane (12; 16). and/or by changes in the metabolic ATP/ADP gradient between the mitochondrial matrix and the cytoplasm (17).

[0012] There is a need in the art for cytoprotective molecules in ischemia, neurodegenerative diseases, fulminant hepatitis and viral infections.

[0013] Another application of the chimeric molecule according the invention can be contemplated for the preparation of cosmetics or for preventing early death of plants or vegetables or flowers particularly for preventing the opening of the PTPC.

[0014] Conventional chemotherapeutic agents are limited in their therapeutic effectiveness by severe side effects due to their poor selectivity for tumors. The development of monoclonal antibodies (and ScFv) against specific tumor antigens and the identification of homing peptides specific for tumor vascularisation have made it possible to consider enhancing the selectivity of anticancer drugs by a targeted delivery approach. However, such reported attempts using monoclonal antibodies and the anticancer drugs doxorubicin (Trail P. A., et al 1993 Science 261:212), metotrexate (Kanellos J. et al., 1985 J Natl Cancer Inst 75:319), and Vinca alkaloids (Starling J. J. et al., 1991 Cancer Res 41:2965), have been largely unsuccessful. These antibody-drug conjugates were only moderately potent and usually less cytotoxic than the corresponding unconjugaied drugs. In fact, antigen-specific cytotoxicity toward cultured tumor cells was rarely demonstrated. In vivo therapeutic effects with these conjugates in tumor zenograft animal models were in general observed only when the treatments were commenced before the tumors were well established or when exceedingly large doses (up to 90 mg/kg, drug equivalent dse) were used. It is, therefore, not surprising that in human clinical trials, no significant antitumor effects were observed with these agents (Elias D. J. et al., 1994 Am Respir Crit Care Med 150:1114) (Schneck D. et al., 1990). Indeed, the peak circulating serum concentrations of conjugates were only in the same range as their in vitro IC50 value and thus, capable of eliminating at best only about 50% of tumor cells.

[0015] These observations led to the conclusion that the previous anempts at delivering therapeutic doses of cytotoxic drugs via monoclonal antibodies have met with little success in clinical trials because of inappropriate choice of drug. One possible (partial-) solution was to conclude that immunoconjugates must be composed of drugs possessing much higher potency than the clinically used anticancer agents if therapeutic levels of conjugate at the tumor sites are to be achieved in patients. Effectively, such toxins, including maytansinoides, enediynes, or intercalating agents CCl065, were shown to be 100 to 1000-fold more cyctotoxic than the chemotherapeutic agents doxorubicin, methotrexate, and Vinca alkaloids (Chari RVJ et al., 1995 Cancer Res 55:4079) (Chari RVJ et al., 1992, Cancer Res 52:127).

[0016] Another approach termed “Adept” was also designed. This antibody-directed enzyme prodrug therapy (Adept) is based upon the use of a monoclonal antibody to target an enzyme at the tumor cell surface, which ultimately is expected to selectively deliver an antitumor drug from a suitable inactive prodrug. In both cases, clinical trials are in progress; however, since today none of them have been introduced in cancer chemotherapy, there is a need for new tools to kill target tumor cells. Bagshawe K D, 1 990. Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem Soc Trans. 18(5):750-2. Melton R G, Sherwood R F. 1996 Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst, 88(3-4):153-65. Rihova B. 1997; Targeting of drugs to cell surface receptors. Crit Rev Biotechnol. 17(2):149-69. Hudson P J. 2000. Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opin Invesiig Drugs 9(6): 1231-42.

[0017] Recently, the mitochondrion has been proposed as a novel prospective target for chemotherapy-induced apoptosis (1-7). Indeed, four different anti-cancer agents, including the resinoid acid-derivative CD437, lonidamine, betulinic acid, and arsenite, have been shown to induce cancer cell apoptosis by a direct action on mitochondria. The interaction of these anti-cancer agents with mitochondria results in an increase of the permeability of the inner mitochondrial membrane due, at least in part, to the opening of the permeability transition pore complex (PTPC). PTPC opening leads to swelling of the mitochondria matrix, the dissipation of the inner transmembrane potential (ΔΨm), enhanced generation of reactive oxygen species (ROS), and the release of apoptogenic proteins from the intermembrane space to the cytoplasm. Such mitochondrial apoptogenic effectors include the caspase activator cytochrome c, apoptosis inducing factor (AIF), and pro-caspases (2-6). All the signs of apoptosis induced by CD437, lonidamine, betulinic acid, and arsenite are prevented by two agents acting on specific PTPC proteins, namely cyclopsporin A (CsA, a cyclophilin D ligand) and bongkrekic acid (BA, a ligand of the adenine nucleotide translocase (ANT)). It thus appears that PTPC opening is a critical event of apoptosis triggered by these agents.

[0018] Mastoparan, a peptide isolated from wasp venom, is the first peptide known to induce mitochondrial membrane permeabilization via a CsA-inhibitable mechanism and to induce apoptosis via a mitochondrial effect when added to intact cells. This peptide has an α-helical structure and possesses some positive charges that are distributed on one side of the helix. A similar peptide (KLAKLAKKLAKLAK or (KLAKLAK)₂ (K=lysine, L=alanine, and A=leucine) has been found recently to disrupt mitochondrial membranes when it is added to purified mitochondria, although the mechanisms of this effect have not been elucidated.

[0019] The vasculature of individual tissues is highly specialized. The endothelium in lymphoid tissues expresses tissue-specific receptors for lymphocyte homing, and recent work utilizing phage homing has revealed an unprecedented degree of specialization in the vasculature of other normal tissues. In vivo screening of libraries of phage that displace random peptide sequences on their surfaces has yielded specific homing peptides for a large number of normal tissues. The tissue-specific endothelial molecules to which the phage peptides home may serve as receptors for metastasizing malignant cells. Probing of tumor vasculature has yielded peptides that home to endothelial receptors expressed selectively in angiogenic neovasculature. These receptors, and those specific for the vasculature of individual normal tissues, are likely to be useful in targeting therapies to specific sites, Ruoslahti E, Rajone D. 2000; An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol. 18:813-27.

[0020] Ellerby et al. recently have fused the mitochondriotoxic (KLAKLAK)₂ motif to a targeting peptide that interacts with endothelial cells. Such a fusion peptide is internalized and induces mitochondrial membrane permeabilization in angiogenicendothelial cells and kills MDA-MD-435 breast cancer xenografts transplanted into nude mice. Similarly, a recombinant chimeric protein containing interleukin 2 (IL-2) protein fused to Bax selectively binds to and kills IL-2 receptor-bearing cells in vitro. Thus, specific ctotoxic agents that target surface receptors, translocate into the cytoplasm, and induce apoptosis via mitochondrial membrane permeabilization might be useful in treating cancer.

[0021] There is a need in the art for the selective eradication of transformed cells. One strategy is to target a toxic agent to selected cell types, More particularly, there exists a need in the art for method and reagents for regulating mitochondrial permeabilization and apoptosis.

SUMMARY OF THE INVENTION

[0022] In order to overcome at least some of the limitations of the prior art, the present invention provides a peptidic or pseudo-peptidic family of polyfunctional molecules containing a cell-targeting part (termed TARG), a PTPC-interacting part (termed TOX/SAVE), and a facultative mitochondrial localisation sequence (MLS). In a preferred embodiment of the invention, the TOX/SAVE portion of the said polyfunctional molecule is a peptide or peptidomimetic molecule which interact directly with the Adenine Nucleotide Translocator (ANT) a central component of the PTPC

[0023] Thus, the present invention includes two categories of targeted cell death regulatory molecules:

[0024] TARG-(MLS)-TOX is a polyfunctional molecule which induces a PTPC-dependent mitochondrial membrane permeabilisation and consequent cell death.

[0025] TARG-(MLS)-SAVE is a polyfunctional molecule which protects cells from mitochondrial membrane permeabilisation and consequently from cell death through interaction with the PTPC and/or ANT.

[0026] The invention further provides a vector encoding a chimeric polypeptide of the invention.

[0027] Also, the invention provides a recombinant host cell comprising a vector of the invention.

[0028] Further, the invention provides a cancer cell having a tumor-associated antigen on the surface thereof to which the chimeric polypeptide of the invention is bound via the antibody or antibody fragment of the chimeric polypeptide. The invention also provides methods for detecting cancer cells.

[0029] The invention also provides methods for inducing or preventing apoptosis with polypeptides of the invention. The invention provides methods for inducing apoptosis in tumor cells. The invention provides methods for inducing apoptosis in virus infected cells.

[0030] The invention further provides hybridomas producing polypeptides of the invention. The invention also provides monoclonal antibodies produced by these hybridomas.

[0031] The invention also provides methods for identifying active agents of interest that interact with the PTPC. The invention also provides methods for identifying active agents of interest that interact with ANT peptide. The invention also provides methods for identifying mitochondrial antigens.

[0032] The invention also provides methods of treatment or prevention of a pathological infection or disease by administering a polypeptide of the invention to a patient. The invention also provides pharmaceutical compositions comprising a polypeptide of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0033]FIG. 1 shows the nucleotide sequence of vector pACgp67-ScFv461.

[0034]FIG. 2 shows the nucleotide sequence of vector pACgp67-ScFv350.

[0035]FIG. 3 shows the nucleotide sequence of Vh and VL, from the clone therap 99B3.

[0036]FIG. 4 shows the nucleotide sequence of Vh and VL from the clone therap.88E10.

[0037]FIG. 5 shows the nucleotide sequence of Vh and VL from the clone therap.I52C3.

[0038]FIG. 6. 7, 8, 9, 10, 11 show surface plasmon resonance curves.

[0039]FIGS. 12 and 13 show the strategy for obtaining the ScFv-transfert vector.

DETAILED DESCRIPTION OF THE INVENTION

[0040] It was recently discovered that the proapoptotic HIV-1-encoded protein Vpr induces mitochondrial membrane permeabilization via its physical and functional interaction with the mitochondrial inner membrane protein ANT (adenine nucleotide translocation, also called ADP/ATP carrier). This was shown using a variety of different techniques: surface plasmon resonance, electrophysiology, synthetic proteoliposomes, studies on purified mitochondria (respirometry, electron microscopy, organellofluorometry), as well as microinjection of intact cells. These discoveries are described in detail in U.S. Provisional Application No. 60/231,539 filed Sep. 11, 2000, the entire disclosure of which is relied upon and incorporated by reference herein.

[0041] The present invention pertains to novel cytotoxic conjugates based on the association between a peptidic molecule (named pTox) interacting with the mitochondrial permeability transition pore complex (PTPC) and a molecule (named pTarg) able to target cells. The present invention also pertains to novel cntoprotective conjugates based on the association between a peptidic molecule (named SAVE) interacting with the mitochondrial permeability transition pore complex (PTPC) and a molecule (named pTarg) able to target the cells to rescue. In a specific embodiment of this invention, a ctotoxic conjugate of the invention includes a vpiral derived pro-apoptotic peptide.

[0042] In one embodiment of the invention, the polyfunctional molecule TARG-(MLS)-TOX is a tumor specific molecule that selectively interact with a tumor cell or a specific mammalian cell type, where the polyfunctional molecule is selectively intemalised by the mammalian or tumoral cell type, where the polyfunctional molecule interact with the PTPC and/or ANT and exhibits thereto a strong mitochondrio-toxicity leading to apoptosis or any cell death process.

[0043] In one embodiment of the invention, the polyfunctional molecule TARG-(MLS)-TOX exhibits a selective toxicity against angiogenic endothelial cells. In another embodiment of the invention, the polyfunctional molecule TARG-(MLS)-TOX exhibits a selective toxicity against tumor cells.

[0044] In one embodiment of the invention, the TARG part of the polyfunctional molecule TARG-(MLS)-TOX is an antibody or a recombinant antibody fragment. In another embodiment of the invention, the TARG part of the polyfunctional molecule TARG-(MLS)-TOX is tumor horning peptide (example; CNGRC peptide; lung-homing peptide CGFECVRQCPERC).

[0045] In one embodiment of the invention, the TOX part of the polyfunctional molecule TARG-(MLS)-TOX is a peptide or a peptido-mimetic derived from the C-terminal part (amino-acids 52 to 96) of the HIV-1 Vpr protein.

[0046] In one embodiment of the invention, the TOX part of the polyfunctional molecule TARG-(MLS)-TOX is a pro-apoptotic Bcl-2 family member such as the Bax or Bid proteins, or a fragment thereof.

[0047] In one embodiment of the invention, the TOX part of the polyfunctional molecule TARG-(MLS)-TOX is a D-peptide, is a Ψ-peptide or a retro-inverso peptide chosen among the group of peptidic sequences described in table 1: TABLE 1 Name TOX Peptidic Sequences Vpr71-82 HFRIGCRHSRIG Vpr71-82[R73, 77, 80K] HFKIGCKHSKIG Vpr71-96 HFRIGCRHSRIGIIQQRRTRNGASKS Vpr71-96[R73, 77, 80K] HFKIGCKHSKIGIIQQRRTRNGASKS Vpr52-96 DTWTGVEALIRILQQLLFIHFRIGCRH SRIGIIQQRRTRNGASKS Vpr52-96[R73, 77, 80K] DTWTGVEALIRILQQLLFIHFKIGCKH SKIGIIQQRRTRNGASKS Vpr52-96[L60, 67A] DTWTGVEAAIRILQQALFIHFRIGCRH SRIGIIQQRRTRNGASKS Vpr52-82 DTWTGVEALIRILQQLLFIHFRIGCRH SRIG Vpr52-82[R73, 77 80K] DTWTGVEALIRILQQLLFIHFKIGCKH SKIG Histatin5 DSHARKRHHGYKRKFHEKHHSHRGY Candida Albicans Mastoparan INLKALAALAKKIL Vespula Lewisii hNUR77(555-568) LSRLLGKLPELRTL hNTR(368-381) ATLDALLAALRRIQ neutrotrophin receptor Bid(84-100) RNIARHLAQVGDSMRDR Bax(57-72) KKLSECLKRIGDELDS Bax(72-87) GQVGRQLAIIGDDINR HBX(70-78) ALRFTSARR DCC(1376-1390) KTHVKTASLGLAGKA ANT₁(104-116) DRHKQFWRYFAGN ANT₂(104-116) DKRTQFWRYFAGN ANT₃(104-116) DKHTQFWRYFAGN ANT₁(104-116 [A114P] DRHKQFWRYFPGN ANT₂(104-116)[A114P] DKRTQFWRYFPGN ANT₃(104-116)[A114P] DKHTQFWRYFPGN ANT_(1,2,3)(117-134) LASGGAAGATSLCFVYPL ANT₁(104-134) DRHKQFWRYFAGNLASGGAAGATSLCF VYPL ANT₂(104-134) DKRTQFWRYFAGNLASGGAAGATSLCF VYPL ANT₃(104-134) DKHTQFWRYFAGNLASGGAAGATSLCF VYPL ANT₁(104-134)[A114P] DRHKQFWRYFPGNLASGGAAGATSLCF VYPL ANT₂(104-134 [A114P] DKRTQFWRYFPGNLASGGAAGATSLCF VYPL ANT₃(104-134)[A114P] DKHTQFWRYFPGNLASGGAAGATSLCF VYPL Vpr52-96[C76S] DTWTGVEALIRILQQLLFIHFRIGSRH SRIGIIQQRRTRNGASKS HTLV-1p1311 ₁₉PSLRVWRLCARRLV₃₂ Bad 103-127 NLWAAQRYGRELRRMSDEFVDSFKK Bax52-76 QDASTKKLSECLKRIGDELDSNMEL

[0048] In one embodiment of the invention, the SAVE part of the polyfunctional molecule TARG-(MLS)-SAVE is a L-peptide, a D-peptide or a retro-inverso peptide chosen among the group of peptidic sequences described in table II: Name SAVE Peptidic Sequences ANT₁(104-116) DRHKQFWRYFAGN ANT₂(104-116) DKRTQFWRYFAGN ANT₃(104-116) DKHTQFWRYFAGN ANT_(1,2,3)(117-134) LASGGAAGATSLCFVYPL ANT₁(104-134) DRHKQFWRYFAGNLASGGAAGATSLCFVYPL ANT₂(104-134) DKRTQFWRYFAGNLASGGAAGATSLCFVYPL ANT₃(104-134) DKHTQFWRYFAGNLASGGAAGATSLCFVYPL

[0049] In one embodiment of the invention, the TARG part of the polyfunctional molecule TARG-(MIS)-SAVE is a L-peptide, a D-peptide or a retro-inverso peptide chosen among the group of peptidic sequences described in table III: ANTENNAPEDIA RQIKITFQNRRMKTKK third helix (residues 43-58) HIV-1 Vpr 83-96 IIQQRRTRNGASKS transduction domain HIV-1 Tat48-59 GRKKRRQRRRPP transduction domain HIV-1 Tat49-57 RKKRRQRRR transduction domain pep-1 KETWWETWWTEW

[0050] Vpr and peptides containing conserved H(F/S)RIG repeat motifs can rapidly penetrate human CD4 cells, and cause mitochondrial dysfunction and death by apoptosis. More particularly, recombinant Vpr and C-terminal peptides of Vpr containing the conserved sequence HFRIGCRHSRIG can cause permeabilization of CD4⁺ T lymphocytes, a dramatic reduction of mitochondrial membrane potential, and finally cell death. Vpr and Vpr peptides containing the conserved sequence rapidly penetrate cells, co-localize with the DNA, and cause increased granularity and formation of dense apoptotic bodies. Vpr treated cells undergo apoptosis, and this as confirmed by demonstration of DNA fragmentation. See C. Arunagiri, I. Macreadie, D. Hewish and A. Azad, “A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4⁺ lymphocytes,” Apoptosis 1997; 2: 69-76.

[0051] Using a yeast model system, it has been confirmed that there is a cytocidal activity associated with the C-terminal portion of Vpr, particularly the sequence HFRIGCRHSRIG. Vpr and portions of Vpr containing the sequence HFRIGCRHSRIG can kill a range of mammalian cells including human lymphocytes. See 1. G. Macreadie, A, Kirkpatrick, P. M. Strike, and A. A. Azad, “Cytocidal Activities of HIV-1 VPR and Sac 1 p peptides Bioassayed in Yeast,” Protein and Peptide Letters, Vol. 4, No. 3, pp. 181-186, 1997.

[0052] The C-terminal moiety (Vpr52-96), within an α-helical motif of 12 amino acids (Vpr71-82), contain several critical arginine (R) residues (R73, R77, R80), which are strongly conserved among different pathogenic HIV-1 isolates. L. G. Macreadie, et al., Proc. Natl. Acad. Sci. USA 92, 2770-2774 (1995). I. G. Macreadie, et al., FEBS Lett. 410, 145-149 (1997). E. Jacotot, et al., J. Exp. Med. 191, 33-45 (2000). Thus, the pro-apoptotic portion (pTox) of the chimeric polypeptide of the invention can contain, for example, the sequence HFRIGCRHSRIG (HIV-1 Vpr71-82), HFKIGCKHSKIG, Vpr 71-96, Vpr 52-96, or a pseudo peptidic variant such as D[HFRIGCRHSRIG].

[0053] Other variants of Vpr peptides can also be employed in this invention. Peptide fragments of Vpr encompassing a pair of H(F/S)RIG sequence motifs (residues 71-75 and 78-82 of HIV-1 Vpr) have been shown cause cell membrane permeabilization and death in yeast and mammalian cells. Peptide Vpr⁵⁹⁻⁸⁶ (residues 59-86 of Vpr) forms an α-helix encompassing residues 60-77, with a kink in the vicinity of residue 62. It has been shown that the first of the repeated sequence motifs (HFRIG) panicipates in a well-defined α-helical domain, whereas the second (HSRIG) lay outside the helical domain and forms a reverse turn followed by a less ordered region. On the other hand, peptides Vpr⁷¹⁻⁸² and Vpr⁷¹⁻⁹⁶, in which the sequence motifs are located at the N-terminus, were largely unstructured under similar conditions, as judged by their C²H chemical shifts. Thus, it has been shown that the HFRIG and HSRIG motifs adopt α-helical and turn structures, respectively, when preceded by a helical structure, but are largely unstructured in isolation. There are implications of these findings for interpretation of the structure-function relationships of synthetic peptides containing these motifs. For example, since the HFRIG and HSRlG sequence motifs adopt helical and turn structures, respectively, when preceded by a helical structure, as in full-length Vpr, but are largely unstructured in isolation, 7-8 residues, sufficient to support at least 1-2 turns of helix, should be included at the N-terminus of Vpr when used as the pTox component of the chimeric polypeptides of the invention to ensure that they are able to adopt the same structure as in the full-length protein. See Shenggen Yao, Allan M. Torres, Ahmed A. Azad, Ian G. Macreadie and Raymond S. Norton, “Solution Structure of Peptides from HIV-1 Vpr Protein that Cause Membrane Permeabilization and Growth Arrest,” J. Peptide Sci. 4: 426-435 (1998). While the Vpr gene codes for a protein of 96-amino-acids, variations have been observed, e.g., Vprs from HIV-1_(HXB)2 have 97 and 90-amino-acid residues, respectively. It will be understood that these variants can also be employed in this invention.

[0054] For the most effective toxicity, HFRIGCRHSRIG should be surrounded on each side by about eight amino acids from the native sequence. Vpr polypeptides and peptides of greater than 9 amino acids that inhibit or augment Vpr binding, mitochondrial membrane permeabilization, or apoptosis can also be employed in the invention, as well as peptides that are at least 10-20, 20-30, 30-50, 50-100, and 100-365 amino acids in size. DNA fragments encoding these polypeptides and peptides are encompassed by the invention. Flanking residues should not disrupt the helical structures described above.

[0055] The Vpr variants and other viral apoptotic peptides can be assessed for their ability to mediate apoptosis, and thus their suitability for use as pTox in the invention. It is understood that many techniques could be used to assess binding of Vpr or another viral apoptotic peptide to ANT, and that these embodiments in no way limit the scope of the invention. For example, in one embodiment, surface plasmon resonance is used to assess binding of Vpr or another viral apoptotic peptide to ANT. In another embodiment, electrophysiology is used to assess binding of Vpr or another viral apoptotic peptide to ANT. In another embodiment, purified mitochondria are used to assess binding of Vpr or another viral apoptotic peptide to ANT. In another embodiment, synthetic proteoliposomes are used to assess binding of Vpr or another viral apoptotic peptide to ANT. In another embodiment, microinjection of live cells is used to assess binding of Vpr or another viral apoptotic peptide to ANT. These techniques are described in U.S. Provisional Application No. 60/231,539.

[0056] In another embodiment, the yeast two-hybrid system developed at SUNY (described in U.S. Pat. No. 5,282,173 to Fields et al.; J. Luban and S. Goff., Curr Opin. Bioiechnol. 6:59-64, 1995; R. Brachmann and J. Boeke, Curr Opin. Biotechnol. 8:561-568, 1997; R. Brent and R. Finley, Ann. Rev. Genet. 31:663-704, 1997; P. Bartel and S. Fields, Methods Enzymol. 254:241-263, 1995) can be used lo screen for Vpr-ANT interaction as follows. Vpr, or portions thereof, or another viral apoptotic peptide, responsible for interaction, can be fused to the Ga14 DNA binding domain and introduced, together with an ANT molecule fused to the GAL 4 transcriptional activation domain, into a strain that depends on GA14 activity for growth on plates lacking histidine. Interaction of the Vpr polypeptide or another viral apoptotic peptide with an ANT molecule allows growth of the yeast containing both molecules and allows screening for the molecules that inhibit or alter this interaction (i.e., by inhibiting or augmenting growth). In an alternative embodiment, a detectable marker (e.g. β-galactosidase) can be used to measure binding in a yeast two-hybrid assay.

[0057] Alternatively, the binding properties of Vpr peptide fragments or another viral apoptotic peptide can be determined by analyzing the binding of Vpr peptide fragments or another viral apoptotic peptide to ANT-expressing cells by FACS analysis. This allows the characterization of the binding of the peptides, and the discrimination of relative abilities of the peptide to bind to ANT. In vitro binding assays with Vpr or another viral apoptotic peptide can similarly be used to characterize ANT binding activity.

[0058] In another specific embodiment, a cytotoxic conjugate of the invention includes an adenine nucleotide translocation (ANT)-derived pro-apoptotic peptide. The pro-apoptotic portion (pTox) of the conjugate can contain, for example, the sequence DKRTQFWRYFPGN (hANT₂104-116[A114P]) or a pseudo-peptidic variant such as [DKRTQFWRYFPGN].

[0059] In another specific embodiment, a cytoprotective conjugate of the invention includes ANT-derived anti-apoptotic peptides. The anti-apoptotic portion (pSave) of the conjugate can contain, for example, the sequence DKRTQFWRYFAGN (hANT₂104-116), the sequence LASGGAAGATSLCFVYPL (ANT 117-134) or a pseudo-peptidic variant such as D[DKRTQFWRYFPGN].

[0060] The pTarg component of the chimeric polypeptide of the invention can be an antibody or an antibody fragment. The antibody or antibody fragment can be all or part of a polyclonal or monoclonal antibody. The term “antibodies” is meant to include polyclonal antibodies, monoclonal antibodies, fragments thereof, as well as any recombinantly produced binding partners. Antibodies are defined to be specifically binding if they bind with a K_(a) or greater than or equal to about 10⁷ M⁻¹. Affinities of binding partners or antibodies can be readily determined using conventional techniques, for example those described by Scatchard et al., Ann. N.Y. Acad. Sci., 51:660 (1949).

[0061] As used herein, the term “antibody fragment” includes the following: Fc A constant region dimer lacking C_(H)1 Fab A light chain dimerized to V_(H)-C_(H)1 resulting from papain cleavage; this is monomeric since papain cuts above the hinge cystines F(ab)′₂ A dimer of Fab′ resulting from pepsin cleavage below the hinge disulfides; this is bivalent and can precipitate antigen Fab′ A monomer resulting from mild reduction of F(ab)′₂: an Fab with part of the hinge Fd The heavy chain portion of Fab (V_(H)—C_(H)1) obtained following reductive denaturation of Fab Fv The variable part of Fab: a V_(H)-V_(L) dimer Fb The constant part of Fab: a C_(H) 1-C_(L) dimer pFc′ A C_(H)3 dimer

[0062] Fragments of monoclonal antibodies are of particular interest as small antigen targeting molecules. Antibody fragments are also useful for the assembly of the chimeric polypeptides of the invention designed to carry other pTox agents, such as a therapeutic conjugate. For in vivo applications, fragments of antibodies are of interest due to their altered pharmacokinetic behavior, which is useful for cancer therapy with cytotoxic agents, and for their rapid penetration into body tissues, which offer advantages for therapy techniques.

[0063] An antibody fragment of particular interest for use in the invention is a minimal Fv fragment with antigen-binding activity. The two chains of the Fv fragment are less stably associated than the Fd and light chain of the Fab fragment with no covalent bond and less non-covalent interaction, but nevertheless functional Fv fragments have been expressed for a number of different antibodies. Two strategies can be employed to stabilize the Fv fragments used in the invention: firstly, mutating a selected residue on each of the V_(H) and V_(L) chains to a cysteine to allow formation of a disulphide bond between the two domains; and secondly, the introduction of a peptide linker between the C-terminus of one domain and the N-terminus of the other, such that the Fv is produced as a single polypeptide chain known as a single-chain Fv.

[0064] Thus, single-chain Fvs (ScFvs), recombinant V_(L) and V_(H) fragments covalently tethered together by a polypeptide link and forming one polypeptide chain, are useful in this invention. For expression of Fv genes, several systems can be effectively used, including myeloma cells, insect, yeast, and Escherichia coli cells. Expression in E. coli has been a frequently used production method, with both intracellular expression and secretion enabling high yields of ScFv to be made.

[0065] The production of ScFv molecules requires the identification of a suitable peptide linker to span the 35-40 Å distance between the C-terminus of one domain and the N-terminus of the other and allow correct folding and assembly of the Fv structure. Several different types of linkers have been used and shown to result in functional ScFv. Polypeptides with the average length of 3-18 amino acids are usually used as links. They can be rich in serine and/or glycine residues, which introduce flexibility, or in charged glutamic acid and/or lysine residues, which improve solubility. Linkers can be selected from searching existing protein structures for protein fragments of the appropriate length and conformation, or by designing them de novo based on simple, flexible structures, such as the 15 amino acid sequence (Gly₄Ser)₃.

[0066] Active single-chain Fv molecules in both of the two possible orientations, V_(H)-linker-V_(L) or V_(L)-linker-V_(H) are useful in the invention; however, for some antibodies one particular orientation may be preferable as a free N-terminus of one domain, or C-terminus of the other, may be required to retain the native conformation and thus full antigen binding.

[0067] The ScFv may be susceptible to aggregation, with dimers, trimers, and multimers formed. The potential of forming dimers or other multimers with very short linkers, or no linker at all, can be exploited to produce stable pTarg structures. Such an approach can also be used to create pTarg molecules with two different binding specificities by fusing the V_(H) of an antibody of one specificity to the V_(L) of another and vice versa.

[0068] Fv's stabilized by disulphide linkages can also be employed as the pTarg component of the chimeric polypeptide of the invention. The introduction of a disulphide bond between the V_(H) and V_(L) domains to form a disulphide-linked Fv requires the identification of residues in close proximity on each chain, which are unlikely to affect directly the conformation of the binding site when mutated to cysteine, and will be capable of forming a disulphide bond without introducing strain into the structure of the Fv. Sites have been identified in both CDR regions and framework regions, which appear to result in the formation of such disulphide bonds and allow the production of stabilized Fv fragments which retain antigen-binding characteristics.

[0069] Due to small size, rapid clearance in vivo, stability, and easy engineering, ScFvs employed in this invention have various applications in the treatment of diseases, particularly of cancer. ScFvs can exhibit the same affinity and specificity for antigen as monoclonal antibodies. Dozens of ScFvs with different specificities have been constructed. They are useful for genetic fusion to the potent toxins (pTox). If the monovalency of ScFv is a disadvantage, constructs with di- or multivalency with increased combining efficiency can be employed.

[0070] In a preferred embodiment of the invention, the targeting part (pTarg) of the cytotoxic conjugate is a recombinant portion (ScFv) of a tumor specific antibody, such as the ScFv versions of the M350 and V461 monoclonal antibodies. The hybridoma has been deposited at the CNCM on Jan. 24, 2001, under the Accession Number I-2617.

[0071] The pTarg component of the chimeric polypeptide of the invention is preferably a monoclonal antibody or a fragment thereof. Monoclonal antibodies to human cell antigens are preferred. Many tumor-associated antigens are now known and characterized, and antibodies to these allow targeting to different tumor types. Useful tumor-associated antigens are absent on normal tissues and present at high levels on tumor cells, preferably homogeneously on all cells of the tumor. Antigen should also not be shed from the tumor into the blood.

[0072] Commonly used tumor-associated antigens and examples of antibodies raised against them are described in the following Table. Representative Antigen Tumor type antibody Turmor-associated glycoprotein 72 Pancarcinoma B72.3, CC49 (TAG72), 72 kDa glycoprotein Carcinoembryonic antigen (CEA), Pancarcinoma NP-4, A5B7 180 kDa blycoprotein Polymorphic epithelial mucin Ovarian, breast, HMFG1 (PEM), >100 kDa glycoprotein lung Epithelial membrane antigen Colorectal (and 17-1A (EMA), 40 kDa glycoprotein other epithelial tumors) epidermal growth factor receptor Breast, lung 425 (EGFR), 175 kDa glycoprotein p185^(HER2)/c-erb-B2 (185 kDa glycoprotein) Breast, lung 4D5 Prostate-specific membrane antigen Prostrate 7E11-C5.3 (PSMA), 100 kDa glycoprotein CD33 67 kDa glycoprotein Myeloid leukemia P67.6, M195 CD 20 35 kDa glycoprotein Lymphoma C2B8 GD2 ganglioside Melanoma, 14-18 neuroblastoma

[0073] An important consideration is the absolute amount of antibody localized to the tumor site. Therefore, the ideal molecule would localize to the tumor in large amounts, delivering a high dose of pTox while clearing rapidly from the circulation and the rest of the body, minimizing non-specific toxicity. Intact antibodies typically circulate for a long period of time and accumulate high levels of activity at the tumor site, whereas antibody fragments clear more rapidly, sparing the dose to normal tissues.

[0074] The antibody fragments can also be prepared by phage-display technology. Phage display is a selection technique. according to which an antibody fragment (ScFv) is expressed on the surface of the filamentous phage fd. For this, the coding sequence of the antibody variable genes is fused with the gene that encoded the minor coat phage protein III (g3p) located at the end of the phage particle. The fused antibody fragments are displayed on the virion surface and particles with the fragments can be selected by adsorption on insolubilized antigen (panning). The selected particles are used after elution to reinfect bacterial cells. The repeated rounds of adsorbtion and infection lead to enrichment. Bacterial proteases can cleave the bond between the g3p protein and antibody fragments, which results in the production of soluble antibody fragments by infected bacterial cells. To release the soluble ScFvs, an excision of the g3p gene is made or an amber stop codon between the antibody gene and the g3p gene is engineered.

[0075] Immunoglobins and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. Pat. No. 4,745,055; EP 256,654; Faulkner et al., Nature 298:286 (1982); EP 120,694; EP 125,023; Morrison, J. Immun. 123:793 (1979); Köhler et al., P.N.A.S. USA 77:2197 (1980); Raso et al., Cancer Res. 41:2073 (1981); Morrison et al., Ann. Rev. Immunol. 2:239 (1984); Morrison, Science 229:1202 (1985); Morrison el al., P.N.A.S. USA 81:6851 (1984); EP 255,694; EP 266,663; and WO 88/03559. Reassorted immunoglobulin chains also are known. See for example U.S. Pat. No. 4,444,878; WO 88/03565; and EP 68,763 and references cited therein. DNA encoding immunoglobulin light or heavy chain constant regions is known or readily available from cDNA libraries or is synthesized. See for example, Adams el al., Biochemistry 19:2711-2719 (1980); Gough et al., Biochemistry 19:2702-2710 (1980); Dolby et al., P.N.A.S. USA, 77:6027-6031 (1980); Rice et al., P.N.A.S. USA 79:7862-7865 (1982); Falkner et al., Nature 298:286-288 (1982); and Morrison et al., Ann. Rev. Immunol. 2:239-256 (1984). These materials and techniques can be employed to synthesize the pTarg component of the chimeric polypeptide of the invention.

[0076] Polyclonal antibodies employed as the pTarg component of the chimeric polypeptide of the invention can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, using procedures that are well known in the art. In general, purified cell surface proteins or glycoproteins or a peptide based on the amino acid sequence of cell surface proteins or glycoproteins that is appropriately conjugated is administered to the host animal typically through parenteral injection. The immunogenicity of cell surface proteins or glycoproteins can be enhanced through the use of an adjuvant, for example. Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to cell surface proteins or glycoproteins. Examples of various assays useful for such determination include those described in Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures, such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radio-immunoprecipitation, enzyme-linked immunosorbent assays (ELISA), dot blot assays, and sandwich assays. See U.S. Pat. Nos. 4,376,110 and 4,486,530.

[0077] Monoclonal antibodies employed as the pTarg component can be readily prepared using well known procedures. See, for example, the procedures described in U.S. Patent Nos. RE 32,011,4,902,614, 4,543,439, and 4,411,993; Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980. Briefly, the host animals, such as mice, are injected intraperitoneally at least once and preferably at least twice at about 3 week intervals with isolated and purified cell surface proteins or glycoproteins, conjugated cell surface proteins or glycoproteins, optionally in the presence of adjuvant. Mouse sera are then assayed by conventional dot blot technique or antibody capture (ABC) to determine which animal is best to fuse. Approximately two to three weeks later, the mice are given an intravenous boost of cell surface proteins or glycoproteins or conjugated cell surface proteins or glycoproteins. Mice are later sacrificed and spleen cells fused with commercially available myeloma cells, such as Ag8.653 (ATCC), following established protocols. Briefly, the myeloma cells are washed several times in media and fused to mouse spleen cells at a ratio of about three spleen cells to one myeloma cell. The fusing agent can be any suitable agent used in the art, for example, polyethylene glycol (PEG). Fusion is plated out in plates containing media that allows for the selective growth of the fused cells. The fused cells can then be allowed to grow for approximately eight days. Supernatants from resultant hybridomas are collected and added to a plate that is first coated with goat anti-mouse 1 g. Following washes. a label, such as ¹²⁵I-labeled cell surface proteins or glycoproteins, is added to each well followed by incubation. Positive wells can be subsequently detected by autoradiography. Positive clones can be grown in bulk culture and supernatants are subsequently purified over a Protein A column (Pharmacia).

[0078] The monoclonal antibodies for the pTarg component can be produced using alternative techniques. such as those described by Alting-Mees et al., “Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas”, Strategies in Molecular Biology 3:1-9 (1990), which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., Biotechnology, 7:394 (1989).

[0079] The monoclonal antibodies and fragments thereof employed as the pTarg component include chimeric antibodies, e.g., humanized versions of murine monoclonal antibodies. Such humanized antibodies may be prepared by known techniques, and offer the advantage of reduced immunogenicity when the antibodies are administered to humans. In one embodiment, the humanized monoclonal antibody comprises the variable region of a murine antibody (or just the antigen binding site thereof) and a constant region derived from a human antibody.

[0080] Alternatively, a humanized antibody fragment may comprise the antigen binding site of a murine monoclonal antibody and a variable region fragment (lacking the antigen-binding site) derived from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al. (Nature 332:323, 1988), Liu et al. (PNAS 84:3439, 1987), Larrick et al. (Bio/Technology 7:934, 1989), and Winter and Harris (TIPS 14:139, May 1993). Procedures to generate antibodies transgenically can be found in GB 2,272,440, U.S. Pat. Nos. 5,569,825 and 5,545,806 and related patents claiming priority therefrom, all of which are incorporated by reference herein.

[0081] In a further embodiment of the invention, the targeting part (pTarg) of a cytotoxic chimeric polypeptide is a tumor homing peptide. Such a tumor homing peptide include any homing sequence described by Ellerby et al., in example V, VI, VII, VIII of PCT/US00/01 602, the entire disclosure of which is relied upon and incorporated by reference herein. CNGRCGG-HFRIGCRHSRIG, or CNGRCGG-D[HFRIGCRHSRIG], or CNGRCGG-Vpr52-96, or CNGRCGG-DKRTQFWYFPGN, or CNGRCGG-D[DKRTQFWYFPGN], or ACDCRGDCFCGG-HFRIGCRHSRIG, or ACDCRGDCFCGG-D[HFRIGCRHSRIG], or ACDCRGDCFCGG-Vpr52-96, or ACDCRGDCFCGG-DKRTQFWYFPGN, or ACDCRGDCFCGG-[DKRTQFWYFPGN], or M350/ScFv-HFRIGCRHSRIG, or M350/ScFv-D[HFRIGCRHSRIG] or M350/ScF-Vpr52-96, or M350/ScFv-DKRTQFWYFPGN, or or M350/ScFv-D[DKRTQFWYFPGN].

[0082] In preferred embodiments of the invention, the chimeric polypeptide has the sequence

[0083] Chimeric polypeptides of the invention can be generated by a variety of conventional techniques. Such techniques include those described in B. Merrifield, Methods Enzymol, 289:3-13, 1997; H. Ball and P. Mascagni, Int. J. Pept. Protein Res. 48:31-47, 1996; F. Molina et al., Pept. Res. 9:151-155, 1996; J. Fox, Mol. Biotechnol. 3:249-258, 1995; and P. Lepage el al., Anal. Biochem. 213: 40-48, 1993.

[0084] Peptides can be synthesized on a multi-channel peptide synthesizer using classical Fmoc-based and pseudopeptide synthesis. In one embodiment of the invention, Vpr52-96, Vpr71-96 and Vpr 71-82 and all the Tox, Save and TARG peptides described in Table I, II, III, are synthesized by solid phase peptide chemistry. After cleavage from the resin, the peptides are purified and analyzed by reverse-phase HPLC. The purity of the peptides is typically above 98% according to HPLC trace. The integrity of each peptide can be controlled by matrix Assisted Laser Desorption Time of Flight spectrometry. To avoid rapid degradation of the peptides in biological fluids, one or several amide bonds could be advantageously replaced by peptide bond isosters like retro-inverso (NH—CO), methylene amino (CH₂—NH), carba (CH₂—CH₂) or carbaza (CH₂—CH₂—N(R)) bonds.

[0085] Alternatively, the chimeric polypeptides of the invention can be prepared by subcloning a DNA sequence encoding a desired peptide sequence into an expression vector for the production of the desired peptide. The DNA sequence encoding the peptide is advantageously fused to a sequence encoding a suitable leader or signal peptide. Alternatively, the DNA fragment may be chemically synthesized using conventional techniques. The DNA fragment can also be produced by restriction endonuclease digestion of a clone of, for example HIV-1, DNA using known restriction enzymes (New England Biolabs 1997 Catalog, Stratagene 1997 Catalog, Promega 1997 Catalog) and isolated by conventional means, such as by agarose gel electrophoresis.

[0086] In another embodiment, the well known polymerase chain reaction (PCR) procedure can be employed to isolate and amplify a DNA sequence encoding the desired protein or peptide fragment. Oligonucleotides that define the desired termini of the DNA fragment are employed as 5′ and 3′ primers. The oligonucleotides can contain recognition sites for restriction endonucleases, to facilitate insertion of the amplified DNA fragment into an expression vector. PCR techniques are described in Saiki et al., Science 239:487 (1988); Recombinant DNA Methology, Wu et al., eds., Academic Press, Inc., San Diego (1989), p. 189-196; and PCR Protocols: A Guide to Methods and Applications, lnnis et al., eds, Academic Press., (1990). It is understood of course that many techniques could be used to prepare polypeptide and DNA fragments, and that this embodiment in no way limits the scope of the invention.

[0087] Several methods can be used to link TARG to TOX and TARG to SAVE, depending on the particular chemical characteristics of the molecules. For example, methods of linking haptens to carrier proteins as used routinely in the field of applied immunology. In one embodiment, a premade a PTPC regulatory molecule (TOX or SAVE) can be conjugated to an antibody as antibody fragment (pTarg) using, for example, carbodiimide conjugation. Carbodiimides comprise a group of compounds that have the general formula R—N+C=N—R, where R and R can be aliphatic or aromatic, and are used for synthesis of peptide bonds. The preparative procedure is simple, relatively fast, and is carried out under mild conditions. Carbodiimide compounds attack carboxylic groups to change them into reactive sites for free amino groups. Carbodiimide conjugation has been used to conjugate a variety of compounds for the production of antibodies.

[0088] The water soluble carbodimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) can be useful for conjugating a PTPC regulatory molecule (TOX or SAVE) to an antibody or antibody fragment molecule. Such conjugation requires the presence of an amino group, which can be provided, for example, by a PTPC regulatory molecule (TOX or SAVE), and a carboxyl group, which can be provided by an antibody or antibody fragment.

[0089] In addition to using carbodiimides for the direct formation of peptide bonds, EDC also can be used to prepare active esters, such as N-hydroxysucinimide (NHS) ester. The NHS ester, which binds only to amino groups, then can be used to induce the formation of an amide bond with the single amino group of the oxorubicin. The use of EDC and NHS in combination is commonly used for conjugation in order to increase yield of conjugate formation.

[0090] Other methods for conjugating a PTPC regulatory molecule (TOX or SAVE) to an antibody or antibody fragment also can be used. For example, sodium periodate oxidation followed by reductive alkylation of appropriate reactants can be used, as can glutaraldehyde crosslinking. However, it is recognized that, regardless of which method of producing a chimeric polypeptide of the invention is selected, a determination must be made that an antibody or antibody fragment maintains its targeting ability and that a PTPC regulatory molecule (TOX or SAVE) maintains its activity.

[0091] The chimeric polypeptide of the invention may further incorporate a specifically non-cleavable or cleavable linker peptide functionally interposed between the PTPC regulatory molecule (TOX or SAVE) (pTarg) and the antibody or antibody fragment (pTox). Such a linker peptide provides by its inclusion in the chimeric construct, a site within the resulting chimeric polypeptide that may be cleaved in a manner to separate the intact PTPC regulatory molecule (TOX or SAVE) from the intact antibody or antibody fragment. Such a linker peptide may be, for instance, a peptide sensitive to thrombin cleavage, factor X cleavage, or other peptidase cleavage. Alternatively, where the chimeric polypeptide lacks methionine, the antibody or antibody fragment may be separated by a peptide sensitive to cyanogen bromide treatment. In general, such a linker peptide will describe a site, which is uniquely found within the linker peptide, and is not found at any location in either of the TARG, TOX or SAVE fragment constituting the chimeric polypeptide.

[0092] Compositions comprising an effective amount of a chimeric polypeptide of the present invention, in combination with other components, such as a physiologically acceptable diluent, carrier, or excipient, are provided herein. The chimeric polypeptide can be formulated according to known methods used to prepare pharmaceutically useful compositions. They can be combined in admixture, either as the sole active material or with other known materials suitable for a given indication, with pharmaceutically acceptable diluents (e.g., saline, Tris-HCi, acetate, and phosphate buffered solutions), preservatives (e.g., thimerosal, benzyl alcohol, parabens), emulsifiers, solubilizers, adjuvants and/or carriers. Suitable formulations for pharmaceutical compositions include those described in Remington's Pharmaceutical Sciences, 16^(th) ed. 1980, Mack Publishing Company, Easton, Pa.

[0093] In addition, such compositions can be complexed with polyethylene glycol (PEG), metal ions, or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc., or incorporated into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application.

[0094] The compositions of the invention comprising the chimeric polypeptide can be administered in any suitable manner, e.g., topically, parenterally, or by inhalation. The term “parenteral” includes injection, e.g., by subcutaneous, intravenous, or intramuscular routes, also including localized administration, e.g., at a site of disease or injury. Sustained release from implants is also contemplated. One skilled in the pertinent art will recognize that suitable dosages will vary, depending upon such factors as the nature of the disorder to be treated, the patient's body weight, age, and general condition, and the route of administration. Preliminary doses can be determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.

[0095] Compositions comprising nucleic acids in physiologically acceptable formulations are also contemplated. DNA may be formulated for injection, for example.

[0096] In one of its most general applications, the invention relates to a recombinant vector incorporating a DNA segment having a sequence encoding the chimeric polypeptide of the invention. For the purposes of the invention, the term “chimeric polypeptide” is defined as including any polypeptide where at least a portion of a viral apoptotic peptide is coupled to at least a portion of an antibody or antibody fragment. The coupling can be achieved in a manner that provides for a functional transcribing and translating of the DNA segment and message derived therefrom, respectively.

[0097] The vectors of the invention will generally be constructed such that the chimeric polypeptide encoding sequence is positioned adjacent to and under the control of an effective promoter. In certain cases, the promotor will comprise a prokaryotic promoter where the vector is being adapted for expression in a prokaryotic host. In other cases, the promoter will comprise a eukaryotic promoter where the vector is being adapted for expression in a eukaryotic host. In the later cases, the vector will typically further include a polyadenylation signal position 3′ of the carboxy-terminal amino acid, and within a transcriptional unit of the encoded chimeric polypeptide. Promoters of particular utility in the vectors of the invention are cytomegalovirus promoters and baculovirus promoters, depending upon the cell used for expression. Regardless of the exact nature of the vector's promoters, the recombinant vectors of the invention will incorporate a DNA segment as defined below.

[0098] A recombinant host cell is also claimed herein, which incorporates a vector of the invention. The recombinant host cell may be either a eukarvotic cell or a prokarvotic host cell. Where a eukaryotic cell is used, a Chinese Hamster Ovary (CHO) cell has utility. In another embodiment, when used in combination with a baculovirus promoter, the insect cell lines SF9 or SF21 can be used.

[0099] This invention will be described in greater detail in the following Examples.

EXAMPLE 1 Obtaining the Murine Monoclonal Antibody (Ac M350)

[0100] Human fetal cells were chosen as a source of immunization. It was the well-known similarities between fetal and tumoral antigens which inspired us to use fetal cells as a source of immunization to produce monoclonal antibodies directed against the epitopes present on tumoral cells. Oncofetal antigens are glycoproteins which are present during intra-uterine life; they disappear at birth and can be re-expressed in pathological situations, particularly in malignant tumors. There are many examples of this antigen community, the best known models being fetoproiein which is associated with 70% of liver tumors, and <<embryo tumor antigens>>, which is often used in human clinical practice and which is a monitoring parameter for patients suffering from cancers of the digestive tract.

[0101] A. M350 Clone Production

[0102] These fetal cells were obtained from the sterile removal of the mammary buds of 25-week old female fetuses. Once the buds had been mechanically dissociated into 0.5 mm³ fragments, the cells were resuspended in a Dulbecco medium modified with collagenase and hyalurodinase at 37° C. and shaken for between 30 minutes and 4 hours after being monitored under the microscope. As soon as organoids appear, the cells were deposited onto Ficoll, washed, then cultured in a calcium-free DMEM-F12 medium, in hepes, insulin, choleric toxin, cortisol. Once the cells were subcultured once a week. Using this technique the cells duplicated 10 to 20 times giving sufficient cells for immunization purposes.

[0103] Balb/c mice were immunized four times, intraperiotonaly. The fusion was achieved according the classical technic of Kohler and Milstein. The screening was done with fetal mammary cells. adult mammary cells and breast tumors. Several clones appeared and one, M350 clone, was particularly tested on breast tumors and normal breast tissues. 150 tumor sections were tested: (i.e.) infiltrating intra-canalar and intra-lobular adenocarcimonas, infiltrating lobular adenocarcimonas. Tests were performed using an immunoenzymatic technic with alkaline phosphatase. All the tumors tested positive whereas the normal tissues taken from mammary samples tested in parallel were negative for weakly positive. Each slide of normal tissue contained lobular type epithelial structures and cavities inside the paleal tissue.

[0104] B. Other Hybridomes

[0105] Obtaining new murine monoclonal antibodies against associated breast tumor antigens.

[0106] In this technology. C57/B16 mice were immunized four times, intraperitonaly, with a mixture of three different breast tumor cell lines (MCF7, MDA, ZR75-1). After fusion and screening the specificity was studied on normal breast tissues and malignant tumors, other tumor samples and peripheral blood cells. The Monoclonal antibodies showing surface tumor labeling were chosen.

EXAMPLE 2

[0107] A Cell Lines and Viruses

[0108] The insert cells derived from ovarian tissue of Spodoptera frugiperda (Sf9 insect cells, Vaughn et coil., 1977) and insect cells derived from Trichoplusia ni (High Five insect cells) were maintained at 28° C. in TC100 medium supplemented with 5% fetal calf serum and were used for the propagation of recombinant baculoviruses and for the production of recombinant proteins. The recombinant baculoviruses are obtained after co-transfection of insect cells with baculovirus viral DNA (Baculogold, Pharmingen) and recombinant transfer vector DNA.

[0109] B. Recombinant Transfer Vector: PVL-PS-gp671

[0110] The recombinant transfer vector pVL-PSgp671 derived from transfer vector pVLI 392 (Invitrogen) is used as transfer vector to generate recombinant viruses. It includes from 5′ to 3′: the peptide signal sequence of gp67 baculovirus glycoprotein, the sequence coding for a His(6)-Tag, the recognition sequence for the Xa Factor, a polylinker region for subcloning the scFv sequence, a link-sequence: GGC required for the covalent association between cytotoxic peptides and ScFv.

[0111] The signal peptide sequence from gp67 was added by insertion of a PCR product of gp67 (obtained by PCR from a commercial pcGP67-B plasmid as a template and the PSgp67-Back and PSgp67-For as primers) at the Bg/II site of the pVL1392 plasmid. The sequence coding for the His(6)-Tag sequence and the recognition sequence for the Xa factor were then added by using insertion of oligonucleotides at the 3′ end of the gp67 sequence. By the same way the sequence of the peptide motif required for the covalent association between cytotoxic peptides and ScFv: (-Gly-Gly-Cys) was added at the 3′ part of the polylinker (the first G is encoded by the last nucleotide of the Xmal site).

[0112] Insertion at BamH1 and Bg1I of overlaping primers: Th1: GAT CCC ATC ATC ACC ACC ACC AC (BamHI-His(6)) Th2: ATT GAA GGA AGA GAATTC CCATG (Factor Xa cleveage-EcoRI-NcoI) Th3: GCT GCA GCC CGG GGG ATG TTA AA (Pst1-XmaI- GGS-STOP-BamHI) Th4: CTT CCT TCA ATG TGG TGG TGG TGA TGA TGG (link beween Th1 Th2) Th5: GGG CTG CAG CCA TGG GAA TTC T (link between Th2 and Th3) Th6: GAT CTT TAA CAT CCC CC (link between Th3 and pVL, -pg67)

[0113] C Synthesis of ScFv DNA Fragment

[0114] VH and VL Regions of M350:

[0115] Total RNA isolated from M350 hybridome have been used as a template for a reverse transcription using oligo (dT) as primers (Reverse Transcription IBI Fermentas). A PCR realized with those cDNAs and specific primers (mouse Ig-Prime-Kit, Novagen) have led to the selective amplification of VH and VL chains. These regions are then cloned in “blunt” in pST-Blue 1 plasmid and sequenced.

[0116] VH and VI. Regions of Other Hybridomes:

[0117] Total RNA isolated from selected hybridome was used as a template for a reverse transcription using oligo (dT) (Reverse Transcription IBI Fermentas). A PCR with specific primers (mouse 1g-Prime-Kit, Novagen) led to the selective amplification of VH and VL chains. These products are then cloned in pGEMT (TA cloning System front PROMEGA) vector and sequenced. Three new VH and VL sequences were determined from clone therap.99B3 (FIG. 3). clone therap.88E10 (FIG. 4), and therap.152C3 (FIG. 5).

[0118] Obtention of the ScFv-Transfer Vector:

[0119] VH-link-VL chimeric DNA were done by fusion-PCR in two steps (FIG. 12). The first step added a link-sequence (Gly-Gly-Glv-Gly-Ser) at the 3′ of the VH chain and at the 5′ end of the VL chain respectively. The second step was a PCR fusion leading to the chimeric DNA: VH-link-VL. The set of primers used in this second step brings a 5′-EcoRl and a 3′-Xmal sites to VH and VL respectively that will be used for the subcloning of the final product in pVL-PSgp671 vector (FIG. 13).

[0120] D Cotransfection and Purification of Recombinant Baculoviruses

[0121] Sf9 cells were cotransfected with viral DNA (BaculoGold; Pharmingen) and recombinant transfer vector DNA (pVL-PSgp671-ScFv) by the lipofection method (Feloner and Ringold, 1989) (DOTAP; Roche). Screening and purification of recombinant viruses were carried out by the common procedure described by Summers and Smith (Summers and Smith, 1987). The recombinant virus was named BAC-PSgp671-scFv and amplified to constitute a viral stock with an M0I of 10⁸.

[0122] E Analysis of Recombinant Proteins

[0123] Infected cells were collected, washed with cold phosphate-buffered saline (PBS) and resuspended in sample reducing buffer (Laemmli, 1970). After boiling (100° C. for 5 min), proteins samples were resolved by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing conditions (Laemmli, 1970). The apparent molecular weight of the protein was check by coomassie blue staining or the proteins were transferred onto a nitrocellulose filter (Schleicher and Schuell; BAS 85, 0.451 μm) with a semidry bloner apparatus (Ancos). The nitrocellulose membrane was then stained with Ponceau Red (Sigma) and subsequently blocked with a solution of Tris-saline buffer (0.05 M Tris-HCI ph7.4, 0.2 M NaCl) containing 0.05% Tween 20 and 5% non fat milk (TS-sat). ScFv was detected using a mouse monoclonal antibody raised against His(6)-Tag (SIGMA) as primary antibody and a sheep anti-mouse immunoglobulin G (IgG)-horseradish peroxydase conjugate as secondary antibody (1; 3000 Amersham). The immunoreactive bands were visualized by using ECL reagents as described by the manufacturer (Amersham).

[0124] F Protein Production and Purification

[0125] To obtain viral stock, Sf9 insect cells cultured in IPL41 medium and 5% FCS are infected in exponential phase with the recombinant baculoviruses at MOI1. After a 7-day incubation period at 28° in IPL41 medium with 5% FCS, the supernatant is harvested by centrifugation at 8000 RPM during 15 min. Then High-five insect cells cultured in Xpress media (Biowhitaker) are infected with recombinant baculovirus in exponential phase at MOI 10, following Ih30 of infection High Five cells were harvested by centrifugation and resuspended in Xpress media without serum. After a 4-day period of incubation at 28° C., the supernatant is harvested by centrifugation at 8000 RPM during 15 min. These supernatants are then concentrated by two rounds of ammonium sulfate precipitation. The precipitate obtained by sedimentation is dialyzed during 12 hours and purified using batch of Ni-NTA agarose beads as described by the manufacturer (Qiagen). After dialysis (2 days, PBS, 4° C.) and analysis by Coomassie staining purified proteins were used for the covalent association with cytotoxic peptides.

EXAMPLE 3

[0126] Method of Coupling ScFv to pTox

[0127] The peptide was assembled using Fmoc solid phase peptide synthesis, after the last Fmoc deprotection a propionyloxy succinimide ester was allowed to react, in the presence of diisopropyl ethylamine, with the alpha amino group of the peptide. At the end of the reaction (30 min) the peptide resin was washed with methylene chloride and the peptide was classically cleaved and deprotected under acidic conditions. The activated peptide was then purified by HPLC and its integrity was confirmed by mass spectrometry. The activated peptide was then allowed to react with the ScFv with peptide in a molar ratio of 10:1 (pH7, PBS, glass tube over agitation for 3 hours at room temperature). Then, dialysis was done for 48h against PBS a 4° C. Four Tox peptides were coupled to ScFv using this method: Tox 11 ScFv-M350-Jac5 (Vpr71-96[C761]) Ctr1ToX11I ScFv-M350-Jac5M (Vpr71-96[C76S; R73,80A]) Tox 12 ScFv-Vpr52-96[C76S] Ctr1Tox12 ScFv-Vpr52-96[C76S; R73A; R80A]

EXAMPLE 4

[0128] Examples of Targ-Tox or Targ-Save Structures

[0129] All the Tox peptides can have a facultative N-terminal biotin and a facultative C-terminal amide function. Tox0 is a Tox peptide which does not necessarily require an association with a Targ. Tox1, Tox2, Tox 5, Tox6, Save1, Save2 and their respective control can posses a facultative gly-gly-(-GG-)linker between the Targ and the Tox/Save motif. Tox0 Biot-DTWTGVEALIRILQQLLFIHFRIGCRHSRIGIIQQR RTRNGASKS Ctr1Tox0 Biot-DTWTGVEALIRILQQLLFHFAIGCRHSAIGIIQQRR TRNGASKS Tox1 Biot-CNGRC-GG-HFRIGCRHSRIG Ctr1Tox1 Biot-CNGRC-GG-HFAIGCRHSAIG Ctr2Tox1 Biot-CNGRC-GG-CNGRC Ctr3Tox1 Biot-GG-HFRIGCRHSRIG Ctr4Tox1 Biot-CNGRC-GG-Scramble Ctr5Tox1 Biot-KETWWETWWTEW-GG-HFRIGCRHSRIG Tox2 Biot-ACDCRGDCFC-GG-HFRIGCRHSRIG Ctr1Tox2 Biot-ACDCRGDCFC-GG-HFAIGCRHSAIG Tox5 Tox5 Biot-CNGRC-GG-DKRTQFWRYFPGN (hANT2m) Ctr1Tox5 Biot-CNGRC-GG-DKRTQFWRYFAGN (hANT2) Ctr2Tox5 Biot-CNGRC-GG-DRHKQFWRYFPGN (hANT1m) Ctr3Tox5 Biot-CNGRC-GG-DKHTQFWRYFPGN (hANT3m) Ctr4Tox5 Biot-GG-DKRTQFWRYFPGN (hANT2m) Ctr5Tox5 Biot-GG-DRHKQFWRYFPGN (hANT1m) Ctr6Tox5 Biot-GG-DKHTQFWRYFPGN (hANT3m) Ctr7Tox5 Biot-CNGRC-GG-Scramble Tox6 Tox6 Biot-ACDCRGDCFC-GG-DKRTQFWRYFPGN (hANT2m) Ctr1Tox6 Biot-ACDCRGDCFC-GG-DKRTQFWRYFAGN (hANT2) Ctr2Tox6 Biot-ACDCRGDCFC-GG-DRHKQFWRYFPGN (hANT1m) Ctr3Tox6 Biot-ACDCRGDCFC-GG-DKHTQFWRYFPGN (hANT3m) Ctr4Tox6 Biot-ACDCRGDCFC-GG Ctr5Tox6 Biot-ACDCRGDCFC-GG-Scramble Tox 11 Tox 11 ScFv-M350-Jac5(Vpr71-96[C76]) Ctr1Tox11 ScFv-M350-Jac5M(Vpr71-96[C76; R73, 80A]) Save1 Save1 Biot-RKKRRQRRR-DKRTQFWRYFAGN (hANT2) Ctr1Save1 Biot-RKKRRQRRR-DKRTQFWRYFPGN (hANT2m) Ctr2Save1 Biot-RKKRRQRRR-DRHKQFWRYFAGN (hANT1) Ctr3Save1 Biot-RKKRRQRRR-DKHTQFWRYFAGN (hANT3) Ctr4Save1 Biot-RKKRRQRRR Ctr5Save1 Biot-RKKRRQRRR-Scramble Save2 Save 2 Biot-RKKRRQRRR-LASGGAAGATSLCFVYPL (hANT[117-134]) Ctr1Save2 Biot-RKKRRQRRR-GAWSNVLRGMGGAFVLVLY (ANTTM6[271-289]) Ctr2Save2 Biot-RKKRRQRRR-scramble

EXAMPLE 5 Evaluation of Mitochondrial and Nuclear Parameters of Apoptosis in Cells (Cell Lines) and Cell-free Systems

[0130] A. Cells

[0131] MCF-7, MDA-MB231, COS and HeLa cells are cultured in complete culture medium (DMEM supplemented with 2 mM glutamine, 10% FCS, 1 mM Pyruvate, 10 mM Hepes and 100 U/ml pencillin/streptomycin). Jurkat cells expressing CD4 and stably transfected with the human Bcl-2 gene or a Neomycin (Neo) resistance vector [Aillet, et al., 1998 J. Virol. 72:9698-9705] only were kindly provided by N. Israel (Pasteur Institute, Paris). Neo and Bcl-2 U937 cells [Zamzami et al., 1995 J. Exp. Med], and CEM-C7 cells are cultured in RPMI 1640 Glutamax medium supplemented with 10% FCS, antibiotics, and 0.8 μm/ml G418.

[0132] The cell tests that have been implemented determine the pathway (intracellular penetration, then subcellular localization) of the candidates, and the apoptotic status (ΔΨm, activation and relocalization of cell death effectors, content in nuclear DNA) of the target cell. In order to determine these parameters it is necessary to use fluorescent probes to label the cells and/or the candidates molecules and to implement the following two analytical procedures: multi-parameter cytofluorimetry and fluorescent microscopy. As far as neuroprotection is concerned, tests were carried out on primary cultures of cortical neuronal cells from mice embryos. As far as cardioprotection is concerned, tests were carried out on primary cultures of cardiomyocytes from mice embryos.

[0133] Intra-cellular pathway tests:. the TARG-TOX ou TARG-SAVE peptides coupled either with biotin (detected using fluorochromes conjugated with streptavidin ; or by ligand-blot after subcellular fractioning) or with FITC (detected by direct observation of living cells, videomicroscopy and image analysis) are added to the cells. It possible to favor the TOX or SAVE mitochondrial routing by inserting mitochondrial addressing signals (the Apoptosis Inducing Factor or ornithin transcarbamylase, for example). Similarly, the mitochondrial routing is evaluated after modifying sequences and certain lateral chains (phosphorylations, methylations), then replacing the peptides by peptidomimetics.

[0134] Multi-parameter analysis of apoptosis on tumoral and endothelial cell lines, and primary neurons. Fluorescents probes will be used to measure the state of the mitochondrial transmembrane potential (JCI, DioC6, mitoTrackers) and nuclear condensation (Hoescht). Similarly, the post-mitochondrial parameters of apoptosis are evaluated using classical hypoploidy tests and cell surface labeling with annexin V-FITC.

[0135] In this type of tests, we evaluate either the cytotoxic potential of the TARG-TOX, i.e. their capacity to kill (via a mitochondrial effect) tumoral ou endothelial cell lines (the best TARG-TOX must also kill over-expressing Bel-2 cell lines); or the cytoprotective potential of the TARG-SAVE when the neurons are subjected to different apoptogenic treatments.

[0136] B. Apoptosis Modulation

[0137] PBS-washed cells (1-5×10⁵/ml) are incubated with (1 to 5 μM) of pTarg-pTox in complete culture medium supplemented or not with cyclosporin A (CsA; 1 μM), bongkrekic acid (BA; 50 μM), and/or the caspase inhibitors N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk; 50 μM; Bachem Bioscience, Inc.), Boc-Asp-fluoromethylketone (Boc-D.fmk), or N-benzyloxycarbonyl-Phe-Ala-fluoromethylketone (Z-FA.fmk; all used at 100 μM added each 24 h; Enzyme Systems). During exposure to pTarg-pTox, human primary PBLs from healthy donors, purified with Lymphoprep (Pharmacia), are cultured in RPMI 1640 Glutamax medium without any addition of serum. In contrast, PHA blasts (24 h of 1 μg/ml PHA-P [Wellcome Industries]; 48 h with 100 U/ml human recombinant IL-2 [Boehringer Mannheim]) are cultured with 10% FCS.

[0138] C. Cytofluorimetric Determinations of Apoptosis-Associated Alterations in Intact Cells

[0139] For cytofluorometry, the following fluorochromes are employed: 3,3′-dihexyloxacarbo-cyanine iodide (DiOC(6)3; 40 nM) for mitochondrial transmembrane potential (ΔΨm) quantification, hydroethidine (4 μM) for the determination of superoxide anion generation, and propidium. iodide (PI; 5 μM) for the determination of viability (Zamzami, N., et al., 1995. J. Exp. Med. 182:367-377). The frequency of subdiploid cells is determined by PI (50 μg/ml) staining of ethanol-permeabilized cells treated with 500 μg/ml RNase (Sigma Chemical Co.; 30 min, room temperature [RT]) in PBS, pH 7.4, supplemented with 5 mM glucose (Nicoletti, I. et al., 1991. J. Immunol. Methods. 139:271-280).

[0140] D. Fluorescence Staining of Life Cells and Immunofluorescence

[0141] For the assessment of mitochondrial and nuclear features of apoptosis, cells cultured on a cover slip are incubated with the ΔΨm-sensitive dyes chloromethyl-X-rosamine (CMXRos; 50 nM; Molecular Probes, Inc.) or 5,5′, 6,6′-tetrachloro-1,1′, 3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 2 μM, Molecular Probes), the ΔΨm-insensitive dye Mitotracker green (1 μM; Molecular Probes, Inc.), and/or Hoechst 33342 (2 μM, Sigma) for 30 min at 37° C. in complete culture medium (.Marzo, let al. 1998. Science. 281:2027-2031).

[0142] E. For In Situ Determinations of PTarg-pTox Internalisation

[0143] For in situ determinations of TARG-(MLS)-TOX/SAVE Internalisation, cells are incubated at different times with TARG-(MLS)-TOX/SAVE, and then cells are fixed with 4% paraformaldehyde and 0.19% picric acid in PBS (pH 7.4) for 1 h at RT. Fixed cells are permeabilized with 0.1% SDS in PBS at RT (for 5 min), blocked with 10% FCS, and stained with an mAb specific for hexa-histidine tag (clone HIS-1, IgG2a, SIGMA) revealed by a goat anti-mouse PE conjugate [Southern Biotechnology Associates, Inc.]), Hsp60(mAb H4149 [Sigma Chemical Co.], revealed by a goat anti-mouse IgGI FITC conjugate), cytochrome c oxidase (COX; mAb 20E8-C12 [Molecular Probes, Inc.], revealed by a goat anti-mouse lgG2a FITC conjugate), or when the Targ is a biotinylated peptide, a streptavidin-PE reagent is added 30 min. followed by detection of the fluorescence intensity by fluorescence (and/or confocal) microscopy.

[0144] F. Assessment of Mitochondrial Parameters In Vitro

[0145] Mitochondria are purified from rat liver, as described (Costantini et al., 1996), and resuspended in 250 mM sucrose +0.1 mM EGTA +10 mM -tris[hydroxymethyl]methyl-2-Aminoethanesulfonic acid, pH=7.4). For the induction of PT, mitochondria (0.5 mg protein per ml) are resuspended in PT buffer (200 mM sucrose, 10 mM Tris-MOPS (pH 7.4), 5 MM Tris-succinate, 1 mM Tris-phosphate, 2 μM rotenone, and 10 μM EGTA-Tris), and monitored in an F4500 fluorescence spectrometer (Hitachi, Tokyo, Japan) for the 90° light scattering of light (545 nm) to determine large amplitude swelling after addition of 2 mM atractyloside (Atr), 1 μM cyclosporin A (CsA; Novartis, Basel, Switzerland), 5 μM CaCl₂, and/or 0.5 to 20 μM of pTarg-pTox or pTarg-pSave. For the determination of the ΔΨ_(m), mitochondria (0.5 mg protein per ml) are incubated in a buffer supplemented with 1μM rhodamine 123 (Molecular Probes, Eugene, OR) and the dequenching of rhodamine fluorescence (excitation 505 nm, emission 525 nm) is measured as described (Shimizu et al., 1998). Supernatants from mitochondria (6800 g for 15 min; then 20 000 g for 1 h; 4° C.) are frozen at −80° C. until determination of apoptogenic activity on isolated nuclei, DEVD-afc cleaving activity, and immunodetection of cytochrome c and AIF. Cytochrome c and AIF are detected by means of a monoclonal antibody (clone 7H8.2C12, Pharmingen) and a polyclonal rabbit anti-serum (Susin et al. 1999) respectively.

[0146] Swelling of Isolated Mitochondria TABLE F1 Tox0, Tox1, Tox5, Tox6 induce permeability transition pore (PTP) openning Name of Induction of Mitochondrial swelling (sw) molecules +++ rapid sw; ++ low sw ; + very low sw; − no sw 5 μM t 20 min — − Tox0 +++ Tox1 ++ Ctr1Tox1 − Ctr2Tox1 − Ctr3Tox1 + Ctr4Tox1 − Tox5 ++ Tox6 ++

[0147] TABLE F2 Save 1 and Save2 inhibit atractyloside-induced PTP openning Name of molecules Mitrochondrial swelling (sw) % — 2 Ca 2+ 100 μM 100 Atractyloside 600 μM 110 Save I 5 μM 2 Save I 5 μM + Atr 600 μM 5 Save I 20 μM 12 Save I 20 μM + Atr 600 μM 12 Save II 10 μM 2 Save II 20 μM 16 Save II 10 μM + Atr 600 μM 16 Save II 20 μM + Atr 600 μM 16

[0148] G. ANT Purification and Reconstitution In Liposomes

[0149] ANT was purified from rat heart mitochondria as previously described (8). After mechanical shearing, mitochondria were suspended in 220 mM mannitol, 70 mM sucrose, 10 mM Hepes, 200 μM EDTA, 100 mM DTT, 0.5 mg/ml subtilisin, pH7.4, kept 8 min on ice and sedimented twice by differential centrifugations (5 min, 500×g, and 10 min, 10,000×g). Mitochondrial proteins were solubilized by 6% [v:v] Triton X-100 (Boehringer Mannheim) in 40 mM K₂HPO₄, 40 mM KC1, 2 mM EDTA, pH 6.0, for 6 min at RT and solubilized proteins were recovered by ultracentrifugation (30 min, 24,000×g, 4° C.). Then, 2 ml of this Triton X-100 extract was applied to a column filled with 1 g of hydroxyapatite (BioGel HTP, BioRad), eluted with previous buffer and diluted [v:v] with 20 mM MES, 200 μM EDTA, 0.5% Triton X-100, pH6.0. Subsequently, the sample was separated with a Hitrap SP column using a FPLC system (Pharmacia) and a linear NaCl gradient (0-1M). Proteins concentration was determined using microBCA-assay (Pierce, Rockfoll, Ill.). Purified ANT and/or recombinant Bcl-2 were reconstituted in PC/cardiolipin liposomes. Briefly, to prepare liposomes, 45 mg PC and 1 mg cardiolipin were mixed in 1 ml chloroform, and the solvent was evaporated under nitrogen. Dry lipids were resuspended in 1 ml liposome buffer (125 mM sucrose +10 MM -2-hydroxyethylpiperazine-N′-2 ethanesulfonic acid; Hepes, pH 7.4) containing 0.3% n-octyl-β-D-pyranoside and mixed by continuous vortexing for 40 min at RT. ANT (0.1 mg/ml) or recombinant Bcl-2 (0.1 mg/ml) were then mixed with liposomes [v:v] and incubated for 20 min at RT. Proteoliposomes were finally dialysed overnight at 4° C.

[0150] H. Pore Opening Assay

[0151] ANT-proteoliposomes are sonicated in the presence of 1 mM 4-MUP and 10 mM KC1 (50W, 22sec, Branson sonifier 250) on ice as previously described (28). Then, liposomes were separated on Sepadex G-25 columns (PD-10, Pharmacia) from unencapsulated products. 25 μl-aliquots of liposomes were diluted to 3 ml in 10 mM Hepes, 125 mM saccharose, pH 7.4, mixed with various concentrations of the proapoptotic inducers and incubated for 1 h at RT. Potential inhibitors of mitochondrial membranes permeabilization such as BA, ATP and ADP, were added to the liposomes 30 min before treatment. After addition of 10 μl-alkaline phosphatase (5 U/ml, Boehringer Mannheim) diluted in liposomes buffer +0.5 mM MgCl₂, samples were incubated for 15 min at 37° C. under agitation and the enzymatic conversion of 4-MUP in 4-MU was stopped by addition of 150 μl Stop buffer (10 mM Hepes-NaOH, 200 mM EDTA, pH 10). The 4-MU-dependent fluorescence (360/450 nm) was subsequently quantitated (28) using a Perkin Elmer spectrofluorimeter. Atractyloside, a pro-apoptotic permeability transition inducer, was used in each experiment as a standard to determine the 100% response. The percentage of 4-MUP release induced by Vpr-derived peptides or pTarg-pTox was calculated as following:

[(fluorescence of liposomes treated by pTar-pTox−fluorescence of untreated liposomes)/(fluorescence of liposomes treated by atractyloside−fluorescence of untreated liposomes)]×100.

[0152] ANT Pore Opening Assay: TABLE H1 examples of fuctionnal interaction between ANT and Tox or Save constructs. Tox0 and Tox6 induce ANT-proteoliposomes permeabilisation. Save1 and Save2 block Atractyloside (Atra)-induced ANT-proteoliposomes permeabilisation Permeabilisation of ANT - proteoliposomes +++ high UMP release; ++ UMP release; molecules + low UMP release; − no UMP release — − Atra 50 μM + Atra 100 μM ++ Atra 200 μM +++ Tox0 (Biotin-Vpr52-96) 2 μM +++ Tox6 5 μM ++ Biotin-Vpr71-96[C76S] 5 μM ++ Save1 5 μM − Atra 200 μM + Save1 5 μM − Save2 5 μM − Atra 200 μM + Save2 5 μM −

[0153] I. Binding Assays and Western Blot

[0154] Mouse liver mitochondria were isolated as described (zamzami el al., 2000). For the determination of cytochrome C release, supernatants from pTarg-pTox treated mitochondria (6800 g for 15 min; then 20 000 g for 1 h; 4° C.) were frozen at −80° C. until immunodetection f cytochrome c (mouse monoclonal antibody clone 7H8.2CI2, Pharmingen). For binding assays, purified mitochondria were incubated (250 μg of protein in 100 μl swelling buffer) for 30 min at RT 5 μM (binding assay) of pTarg-pTox or biotin-pTarg-pTox. Mitochondria were lysed either after incubation with biotinylated Vpr52-96 (upper panel) or Iysed before (lower panel) with 150 μl of a buffer containing 20 mM Tris/HCl, pH 7.6; 400 mM NaCl, 50 mM KCl, 1mM EDTA, 0.2 mM PMSF, aprotinin (100 U/ml), 1% Triton X-100 and 20% glycerol. Such extracts were diluted with 2 volumes of PBS plus 1 mM EDTA before the addition of 150 μl avidin-agarose (ImmunoPure, from Pierce) to capture the biotin-labeled Vpr52-96 complexed with its mitochondrial ligand(s) (2 hours at 4° C. in a roller drum). The avidin-agarose was washed batchwise with PBS (5×5 ml; 1000 g, 5 min, 4° C.), resuspended in 100 μl of 2 fold concentrated Laemmli buffer containing 4% SDS and 5 mM β-mercaptoethanol, incubated 10 min at RT and centrifuged (1000 g, 10 min, 4° C.). Finally, the supernatants were heated at 95° C. for 5 min and analysed by SDS-PAGE (12%), followed by Western blot and immunodetection with a rabbit polyclonal anti-serum against human ANT (kindly provided by Dr. Heide H. Schmid; The Hornel Institute, University of Minnesota, MI; Ref).

[0155] J. Flow Cytometric Analysis of Purified Mitochondria

[0156] Mouse liver mitochondria are isolated as described (Zamzami et al., 2000). Purified mitochondria are resuspended in PT buffer (200 mM sucrose, 10 mM Tris-MOPS (pH 7.4), 5 mM Tris-succinate, 1 mM Tris-phosphate, 2 μM rotenone, and 10 μM EGTA). Cytofluorometric (FACSVantage, Beckton Dickinson) detection is restricted to mitochondria by gating on the FSC/SSC parameters and on the main peak of the FSC-W parameter. Confirmation aposteriori of the validity of these double gating is obtained by labeling of mitochondria with the ΔΨ_(m)-insensitive mitochondrial dye MitoTracker® Green (75 nM; Molecular Probes; green fluorescence). To determine the percentage of mitochondria having a low ΔΨ_(m), the ΔΨ_(m),-sensitive fluorochrome JC-1 (200 nM; 570-595 nm) is added 10 min before CCCP or pTarg-pTox molecules. Percentage of mitochondria having a lowΔΨ_(m), is determined in dot-plot FSC/FL-2 (red fluorescence) windows.

[0157] K. Cell-Free System of Apoptosis

[0158] AIF activity in the supernatant of mitochondria is tested on HeLa cell nuclei, as described (Susin et at., 1 997b). Briefly, AIF-containing supernatants of mitochondria are added to purified HeLa nuclei (90 min, 37° C.), which are stained with propidium iodide (PI; 10 μg/ml; Sigma Chemical Co.) and analyzed in an Elite n cytofluorometer (Coulter) to determine the frequency of hypoploid nuclei. In some experiments isolated mitochondria, cytosols from Jurkat or CEM cells (prepared as described (Susin et al., 1997a)), and/or pTarg-pTox are added to the nuclei. Caspase activity in the mitochondrial supernatant was measured using Ac-DEVD-amido4-trifluoromethylcoumarin (Bachem Bioscience, Inc.) as fluorogenic substrate.

[0159] L. Purification and Reconstitution of PTPC in Liposomes

[0160] PTPC from Wistar rat brains are purified and reconstituted in liposomes following published protocols (Brenner et al., 1998; Marzo et al., 1998b). Briefly, homogenized brains are subjected to the extraction of triton-soluble proteins, adsorption of proteins to a DE52 resin anion exchange column, elution on a KCl gradient, and incorporation of fractions with maximum hexokinase activity into phosphatidyl choline/cholesterol (5: 1, w:w) vesicles by overnight dialysis. Recombinant human Bcl-2 (1-218) lacking the hydrophobic transmembrane domain (Δ219-239), produced and purified as described (Schendel et al., 1997) are added during the dialysis step at a dose corresponding to 5% of the total PTPC proteins (approximately 10 ng Bcl-2 per mg lipids). Liposomes recovered from dialysis are ultrasonicated. (120 W) during 7 sec in 5 mM malate and 10 mM KCl , charged on a Sephadex G50 columns (Pharmacia), and eluted with 125 mM sucrose +10 mM HEPES (pH 7.4). Aliquots (approx. 10⁷) of liposomes are incubated during 60 min at RT in 125 mM sucrose +10 mM HEPES (pH 7.4) in the presence or absence of pTarg-pTox, [52-96]Vpr or atractyloside. Then, liposomes are equilibrated with 3,3′dihexylocarbocyanine iodide (DiOC₆(3), 80 nM, 20-30 min at RT; Molecular Probes), and analyzed in a FACS-Vantage cytofluorometer (Becton Dickinson, San José, Calif., USA) for DiOC₆(3) retention, as described (Brenner et al., 1998; Marzo et al., 1998b).

[0161] Triplicates of 5×10⁴ liposomes are analyzed and results are expressed as % of reduction of DiOC₆(3) fluorescence, considering the reduction obtained with 0.25% SDS (15 min, RT) in PTPC liposomes as 100% value.

[0162] Examples of specific peptides and constructs relating to this invention that can be utilized in carrying out the foregoing techniques are shown in Tables I, II, and III, as well as any chimeric molecule that is a combination between TARG and TOX or TARG and SAVE peptides or peptidomimetics.

EXAMPLE 6

[0163] Surface Plasmon Resonance Indicates That Tox0, Tox1, Tox5, Tox6, Save1 Binds Purified ANT but not Purified VDAC.

[0164] Methodology.

[0165] Sensor Chips SA (streptavidin coated sensor chips) were used for immobilisation of the different peptides. Tox1 was immobilised at a density of 0.7 ng/mm², Tox0 at a density of 3.7 ng/mm²,. Ctrl Tox0 at a density of 1.4 ng/mm², Tox5 at a density of 1 ng/mm², Tox6 at a density of 1 ng/mm², Save 1 at a density of 1.3 ng/mm², and the control peptide at a density of 0.8 ng/mm². Association and dissociation kinetics of ANT and VDAC interactions were followed at a rate of 10 μL/min for 10 minutes (5 minutes association and 5 minutes dissociation). The ligand was regenerated with a 1 minute flux of KSCN 3M. The obtained sensorgrams were analysed by the B1Aeval 3.1 software using the method of double references (Myszka D.G. 2000. Kinetic, equilibrium and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzymol. 323:325-340). From the sensorgrams with the ligands were first substracted the sensorgrams obtained with the corresponding analyte solvents. A second substraction was performed with the sensorgrams obtained with the control peptide ligand. The control peptide for the Tox and Save peptides was biot-H19C corresponding to the sequence of the β2-adrenergic receptor (Lebesgue D., Wallukat G., Mijares A., Granier C., Argibay J., and Hoebeke J. (1998) An agonist-like monoclonal antibody to the human β 2-adrenergic receptor. Eur.J. Pharmacol. 348:123-133). The control peptide for Tox0 was Ctr1 Tox0.

[0166] Results.

[0167]FIG. 6 shows the interaction between ANT and Vpr for 4 ANT concentrations (6.25 to 50 nM). The sensorgrams were best analysed using the simple Lagmuir model with drifting baseline and resulted in a Kd of 0.15 nM with a Rmax of 160 (_(x)2=7.24). The same analysis was performed for the sensorgrams showing the interaction between ANT and Tox1 (FIG. 7). Studying the VDAC interaction both with Tox0 and Tox1 at VDAC concentrations which were ten times higher (FIG. 8 and 9), the sensorgrams showed only extremely low association with the peptide ligand and the obtained curves could not be analysed by the different Langmuir bindings models.

[0168] Thee other peptides were tested for their interaction with ANT at a concentration of 50 nM (FIG. 10). Purified ANT recognised Tox5, Tox6, and Save1 with relative affinities of respectively 0.1, 0.7, and 0.01 nM. These value being obtained at only one ANT concentration only give the relative affinity of ANT for the three peptides. Again, the use of 50 nM VDAC to interact with the same peptides did not result in any specific binding as shown in FIG. 11.

[0169] The following references have been cited herein. The entire disclosure of each reference cited herein is relied upon and incorporated by reference herein.

[0170] 1-D. Decaudin, I. Marzo, C. Brenner and G. Kroemer. Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy. Int J Oncol, 12: 141-52, 1998.

[0171] 2-S. Fulda, S. A. Susin, G. Kroemer and K. M. Debatin. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res, 58: 4453-60, 1998a.

[0172] 3-S. Fulda, C. Scaffidi, S. A. Susin, P. H. Krammer, G. Kroemer, M. E. Peter and K. M. 4-Debatin. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem, 273: 33942-8, 1998b.

[0173] 4-L. Ravagnan, I. Marno, P. Costantini, S. A. Susin, N. Zarnzami, P. X. Petit, F. Hirsch, M. Goulbem, M. F. Poupon, L. Miccoli, Z. Xie, J. C. Reed and G. Kroemer. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene, 18: 2537-46, 1999.

[0174] 5-N. Larochette, D. Decaudin, E. Jacotot, C. Brenner, I. Marzo, S. A. Susin, N. Zamzami, Z. Xie, J. Reed and G. Kroemer. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res, 249: 413-21, 1999.

[0175] 6-P. Marchetti, N. Zamzami, B. Joseph, S. Schraen-Maschke, C. Mereau-Richard, P. Costantini, D. Metivier, S. A. Susin, G. Kroemer and P. Formstecher. The novel retinoid 6-[3-(1-adamantyl)4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res, 59: 6257-66, 1999.

[0176] 7-P. Costantini, E. Jacotot, D. Decaudin and G. Kroemer. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst., 92: 1042-1053, 2000.

[0177] 8-I. Marzo, C. Brenner, N. Zamzami, S. A. Susin, G. Beutner, D. Brdiczka, R. Remy, Z. H. Xie, J. C. Reed and G. Kroemer. The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2-related proteins. J Exp Med, 187: 1261-71, 1998a.

[0178] 9-I. Marzo, C. Brenner, N. Zamzami, J. M. Jurgensmeier, S. A. Susin, H. L. A. Vieira, M. C. Prévost, Z. Xie, S. Matsuyama, J. C. Reed and G. Kroemer. Bax and Adenine Nucleotide Translocator Cooperate in the Mitochondrial Control of Apoptosis. Science, 281: 2027-2031, 1998b.

[0179] 10-Y. Tsujimoto, L. R. Finger, J. Yunis, P. C. Nowell and C. M. Croce. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;1 8) chromosome translocation. Science, 226: 1097-9, 1984.

[0180] 11-J. C. Reed, M. Cuddy, T. Slabiak, C. M. Croce and P. C. Nowell. Oncogenic potential of Bcl-2 demonstrated by gene transfer. Nature, 336: 259-61, 1988.

[0181]12-M. Narita, S. Shimizu, T. Ito, T. Chittenden, R. J. Lutz, H. Matsuda and Y. Tsujimoto. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A, 95: 14681-6, 1998.

[0182] 13-C. Brenner, H. Cadiou, H. L. Vieira, N. Zamzami, 1. Marzo, Z. Xie, B. Leber, D. Andrews, H. Duclohier, J. C. Reed and G. Kroemer. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene, 19: 329-36, 2000.

[0183] 14-E. Jacotot, L. Ravagnan, M. Loeffler, K. F. Ferri, H. L. Vieira, N. Zamnzami, P. Costantini, S. Druillennec, J. Hoebeke, J. P. Briand, T. lrinopoulou, E. Daugas, S. A. Susin, D. Cointe, Z. H. Xie, J. C. Reed, B. P. Roques and G. Kroemer. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med, 191: 33-46, 2000.

[0184] 15-P. Costantini, A. S. Belzacq, H. L. Vieira, N. Larochette, M. A. de Pablo, N. Zamzari, S. A. Susin, C. Brenner'and G. Kroemer. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene, 19: 307-14, 2000.

[0185] 16-S. Shimizu, A. Konishi, T. Kodama and Y. Tsujimoto. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci U S A, 97: 3100-5, 2000.

[0186] 17-M. G. VanderHeiden, N. S. Chandel, P. T. Schumacker and C. B. Thompson. Bcl-X(_(L)) prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Molecular Cell, 3: 159-167, 1999.

[0187] 18-Griffioen, A. W., Molema, G. (2000). Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation. Pharmacological Reviews 52:237-268.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 325 <210> SEQ ID NO 1 <211> LENGTH: 10517 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 nucleotide sequence <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(10515) <400> SEQUENCE: 1 aag ctt tac tcg taa agc gag ttg aag gat cat att tag ttg cgt tta 48 Lys Leu Tyr Ser Ser Glu Leu Lys Asp His Ile Leu Arg Leu 1 5 10 tga gat aag att gaa agc acg tgt aaa atg ttt ccc gcg cgt tgg cac 96 Asp Lys Ile Glu Ser Thr Cys Lys Met Phe Pro Ala Arg Trp His 15 20 25 aac tat tta caa tgc ggc caa gtt ata aaa gat tct aat ctg ata tgt 144 Asn Tyr Leu Gln Cys Gly Gln Val Ile Lys Asp Ser Asn Leu Ile Cys 30 35 40 45 ttt aaa aca cct ttg cgg ccc gag ttg ttt gcg tac gtg act agc gaa 192 Phe Lys Thr Pro Leu Arg Pro Glu Leu Phe Ala Tyr Val Thr Ser Glu 50 55 60 gaa gat gtg tgg acc gca gaa cag ata gta aaa caa aac cct agt att 240 Glu Asp Val Trp Thr Ala Glu Gln Ile Val Lys Gln Asn Pro Ser Ile 65 70 75 gga gca ata atc gat tta acc aac acg tct aaa tat tat gat ggt gtg 288 Gly Ala Ile Ile Asp Leu Thr Asn Thr Ser Lys Tyr Tyr Asp Gly Val 80 85 90 cat ttt ttg cgg gcg ggc ctg tta tac aaa aaa att caa gta cct ggc 336 His Phe Leu Arg Ala Gly Leu Leu Tyr Lys Lys Ile Gln Val Pro Gly 95 100 105 cag act ttg ccg cct gaa agc ata gtt caa gaa ttt att gac acg gta 384 Gln Thr Leu Pro Pro Glu Ser Ile Val Gln Glu Phe Ile Asp Thr Val 110 115 120 125 aaa gaa ttt aca gaa aag tgt ccc ggc atg ttg gtg ggc gtg cac tgc 432 Lys Glu Phe Thr Glu Lys Cys Pro Gly Met Leu Val Gly Val His Cys 130 135 140 aca cac ggt att aat cgc acc ggt tac atg gtg tgc aga tat tta atg 480 Thr His Gly Ile Asn Arg Thr Gly Tyr Met Val Cys Arg Tyr Leu Met 145 150 155 cac acc ctg ggt att gcg ccg cag gaa gcc ata gat aga ttc gaa aaa 528 His Thr Leu Gly Ile Ala Pro Gln Glu Ala Ile Asp Arg Phe Glu Lys 160 165 170 gcc aga ggt cac aaa att gaa aga caa aat tac gtt caa gat tta tta 576 Ala Arg Gly His Lys Ile Glu Arg Gln Asn Tyr Val Gln Asp Leu Leu 175 180 185 att taa tta ata tta ttt gca ttc ttt aac aaa tac ttt atc cta ttt 624 Ile Leu Ile Leu Phe Ala Phe Phe Asn Lys Tyr Phe Ile Leu Phe 190 195 200 tca aat tgt tgc gct tct tcc agc gaa cca aaa cta tgc ttc gct tgc 672 Ser Asn Cys Cys Ala Ser Ser Ser Glu Pro Lys Leu Cys Phe Ala Cys 205 210 215 220 tcc gtt tag ctt gta gcc gat cag tgg cgt tgt tcc aat cga cgg tag 720 Ser Val Leu Val Ala Asp Gln Trp Arg Cys Ser Asn Arg Arg 225 230 gat tag gcc gga tat tct cca cca caa tgt tgg caa cgt tga tgt tac 768 Asp Ala Gly Tyr Ser Pro Pro Gln Cys Trp Gln Arg Cys Tyr 235 240 245 gtt tat gct ttt ggt ttt cca cgt acg tct ttt ggc cgg taa tag ccg 816 Val Tyr Ala Phe Gly Phe Pro Arg Thr Ser Phe Gly Arg Pro 250 255 260 taa acg tag tgc cgt cgc gcg tca cgc aca aca ccg gat gtt tgc gct 864 Thr Cys Arg Arg Ala Ser Arg Thr Thr Pro Asp Val Cys Ala 265 270 275 tgt ccg cgg ggt att gaa ccg cgc gat ccg aca aat cca cca ctt tgg 912 Cys Pro Arg Gly Ile Glu Pro Arg Asp Pro Thr Asn Pro Pro Leu Trp 280 285 290 caa cta aat cgg tga cct gcg cgt ctt ttt tct gca tta ttt cgt ctt 960 Gln Leu Asn Arg Pro Ala Arg Leu Phe Ser Ala Leu Phe Arg Leu 295 300 305 tct ttt gca tgg ttt cct gga agc cgg tgt aca tgc ggt tta gat cag 1008 Ser Phe Ala Trp Phe Pro Gly Ser Arg Cys Thr Cys Gly Leu Asp Gln 310 315 320 tca tga cgc gcg tga cct gca aat ctt tgg cct cga tct gct tgt cct 1056 Ser Arg Ala Pro Ala Asn Leu Trp Pro Arg Ser Ala Cys Pro 325 330 335 tga tgg caa cga tgc gtt caa taa act ctt gtt ttt taa caa gtt cct 1104 Trp Gln Arg Cys Val Gln Thr Leu Val Phe Gln Val Pro 340 345 350 cgg ttt ttt gcg cca cca ccg ctt gca gcg cgt ttg tgt gct cgg tga 1152 Arg Phe Phe Ala Pro Pro Pro Leu Ala Ala Arg Leu Cys Ala Arg 355 360 365 atg tcg caa tca gct tag tca cca act gtt tgc tct cct cct ccc gtt 1200 Met Ser Gln Ser Ala Ser Pro Thr Val Cys Ser Pro Pro Pro Val 370 375 380 gtt tga tcg cgg gat cgt act tgc cgg tgc aga gca ctt gag gaa tta 1248 Val Ser Arg Asp Arg Thr Cys Arg Cys Arg Ala Leu Glu Glu Leu 385 390 395 ctt ctt cta aaa gcc att ctt gta att cta tgg cgt aag gca att tgg 1296 Leu Leu Leu Lys Ala Ile Leu Val Ile Leu Trp Arg Lys Ala Ile Trp 400 405 410 act tca taa tca gct gaa tca cgc cgg att tag taa tga gca ctg tat 1344 Thr Ser Ser Ala Glu Ser Arg Arg Ile Ala Leu Tyr 415 420 gcg gct gca aat aca gcg ggt cgc ccc ttt tca cga cgc tgt tag agg 1392 Ala Ala Ala Asn Thr Ala Gly Arg Pro Phe Ser Arg Arg Cys Arg 425 430 435 tag ggc ccc cat ttt gga tgg tct gct caa ata acg att tgt att tat 1440 Gly Pro His Phe Gly Trp Ser Ala Gln Ile Thr Ile Cys Ile Tyr 440 445 450 tgt cta cat gaa cac gta tag ctt tat cac aaa ctg tat att tta aac 1488 Cys Leu His Glu His Val Leu Tyr His Lys Leu Tyr Ile Leu Asn 455 460 465 tgt tag cga cgt cct tgg cca cga acc gga cct gtt ggt cgc gct cta 1536 Cys Arg Arg Pro Trp Pro Arg Thr Gly Pro Val Gly Arg Ala Leu 470 475 480 gca cgt acc gca ggt tga acg tat ctt ctc caa att taa att ctc caa 1584 Ala Arg Thr Ala Gly Thr Tyr Leu Leu Gln Ile Ile Leu Gln 485 490 495 ttt taa cgc gag cca ttt tga tac acg tgt gtc gat ttt gca aca act 1632 Phe Arg Glu Pro Phe Tyr Thr Cys Val Asp Phe Ala Thr Thr 500 505 510 att gtt ttt taa cgc aaa cta aac tta ttg tgg taa gca ata att aaa 1680 Ile Val Phe Arg Lys Leu Asn Leu Leu Trp Ala Ile Ile Lys 515 520 525 tat ggg gga aca tgc gcc gct aca aca ctc gtc gtt atg aac gca gac 1728 Tyr Gly Gly Thr Cys Ala Ala Thr Thr Leu Val Val Met Asn Ala Asp 530 535 540 ggc gcc ggt ctc ggc gca agc ggc taa aac gtg ttg cgc gtt caa cgc 1776 Gly Ala Gly Leu Gly Ala Ser Gly Asn Val Leu Arg Val Gln Arg 545 550 555 ggc aaa cat cgc aaa agc caa tag tac agt ttt gat ttg cat att aac 1824 Gly Lys His Arg Lys Ser Gln Tyr Ser Phe Asp Leu His Ile Asn 560 565 570 ggc gat ttt tta aat tat ctt att taa taa ata gtt atg acg cct aca 1872 Gly Asp Phe Leu Asn Tyr Leu Ile Ile Val Met Thr Pro Thr 575 580 585 act ccc cgc ccg cgt tga ctc gct gca cct cga gca gtt cgt tga cgc 1920 Thr Pro Arg Pro Arg Leu Ala Ala Pro Arg Ala Val Arg Arg 590 595 ctt cct ccg tgt ggc cga aca cgt cga gcg ggt ggt cga tga cca gcg 1968 Leu Pro Pro Cys Gly Arg Thr Arg Arg Ala Gly Gly Arg Pro Ala 600 605 610 gcg tgc cgc acg cga cgc aca agt atc tgt aca ccg aat gat cgt cgg 2016 Ala Cys Arg Thr Arg Arg Thr Ser Ile Cys Thr Pro Asn Asp Arg Arg 615 620 625 630 gcg aag gca cgt cgg cct cca agt ggc aat att ggc aaa ttc gaa aat 2064 Ala Lys Ala Arg Arg Pro Pro Ser Gly Asn Ile Gly Lys Phe Glu Asn 635 640 645 ata tac agt tgg gtt gtt tgc gca tat cta tcg tgg cgt tgg gca tgt 2112 Ile Tyr Ser Trp Val Val Cys Ala Tyr Leu Ser Trp Arg Trp Ala Cys 650 655 660 acg tcc gaa cgt tga ttt gca tgc aag ccg aaa tta aat cat tgc gat 2160 Thr Ser Glu Arg Phe Ala Cys Lys Pro Lys Leu Asn His Cys Asp 665 670 675 tag tgc gat taa aac gtt gta cat cct cgc ttt taa tca tgc cgt cga 2208 Cys Asp Asn Val Val His Pro Arg Phe Ser Cys Arg Arg 680 685 690 tta aat cgc gca atc gag tca agt gat caa agt gtg gaa taa tgt ttt 2256 Leu Asn Arg Ala Ile Glu Ser Ser Asp Gln Ser Val Glu Cys Phe 695 700 705 ctt tgt att ccc gag tca agc gca gcg cgt att tta aca aac tag cca 2304 Leu Cys Ile Pro Glu Ser Ser Ala Ala Arg Ile Leu Thr Asn Pro 710 715 720 tct tgt aag tta gtt tca ttt aat gca act tta tcc aat aat ata tta 2352 Ser Cys Lys Leu Val Ser Phe Asn Ala Thr Leu Ser Asn Asn Ile Leu 725 730 735 tgt atc gca cgt caa gaa tta aca atg cgc ccg ttg tcg cat ctc aac 2400 Cys Ile Ala Arg Gln Glu Leu Thr Met Arg Pro Leu Ser His Leu Asn 740 745 750 acg act atg ata gag atc aaa taa agc gcg aat taa ata gct tgc gac 2448 Thr Thr Met Ile Glu Ile Lys Ser Ala Asn Ile Ala Cys Asp 755 760 765 gca acg tgc acg atc tgt gca cgc gtt ccg gca cga gct ttg att gta 2496 Ala Thr Cys Thr Ile Cys Ala Arg Val Pro Ala Arg Ala Leu Ile Val 770 775 780 ata agt ttt tac gaa gcg atg aca tga ccc ccg tag tga caa cga tca 2544 Ile Ser Phe Tyr Glu Ala Met Thr Pro Pro Gln Arg Ser 785 790 795 cgc cca aaa gaa ctg ccg act aca aaa tta ccg agt atg tcg gtg acg 2592 Arg Pro Lys Glu Leu Pro Thr Thr Lys Leu Pro Ser Met Ser Val Thr 800 805 810 tta aaa cta tta agc cat cca atc gac cgt tag tcg aat cag gac cgc 2640 Leu Lys Leu Leu Ser His Pro Ile Asp Arg Ser Asn Gln Asp Arg 815 820 825 tgg tgc gag aag ccg cga agt atg gcg aat gca tcg tat aac gtg tgg 2688 Trp Cys Glu Lys Pro Arg Ser Met Ala Asn Ala Ser Tyr Asn Val Trp 830 835 840 agt ccg ctc att aga gcg tca tgt tta gac aag aaa gct aca tat tta 2736 Ser Pro Leu Ile Arg Ala Ser Cys Leu Asp Lys Lys Ala Thr Tyr Leu 845 850 855 att gat ccc gat gat ttt att gat aaa ttg acc cta act cca tac acg 2784 Ile Asp Pro Asp Asp Phe Ile Asp Lys Leu Thr Leu Thr Pro Tyr Thr 860 865 870 gta ttc tac aat ggc ggg gtt ttg gtc aaa att tcc gga ctg cga ttg 2832 Val Phe Tyr Asn Gly Gly Val Leu Val Lys Ile Ser Gly Leu Arg Leu 875 880 885 890 tac atg ctg tta acg gct ccg ccc act att aat gaa att aaa aat tcc 2880 Tyr Met Leu Leu Thr Ala Pro Pro Thr Ile Asn Glu Ile Lys Asn Ser 895 900 905 aat ttt aaa aaa cgc agc aag aga aac att tgt atg aaa gaa tgc gta 2928 Asn Phe Lys Lys Arg Ser Lys Arg Asn Ile Cys Met Lys Glu Cys Val 910 915 920 gaa gga aag aaa aat gtc gtc gac atg ctg aac aac aag att aat atg 2976 Glu Gly Lys Lys Asn Val Val Asp Met Leu Asn Asn Lys Ile Asn Met 925 930 935 cct ccg tgt ata aaa aaa ata ttg aac gat ttg aaa gaa aac aat gta 3024 Pro Pro Cys Ile Lys Lys Ile Leu Asn Asp Leu Lys Glu Asn Asn Val 940 945 950 ccg cgc ggc ggt atg tac agg aag agg ttt ata cta aac tgt tac att 3072 Pro Arg Gly Gly Met Tyr Arg Lys Arg Phe Ile Leu Asn Cys Tyr Ile 955 960 965 970 gca aac gtg gtt tcg tgt gcc aag tgt gaa aac cga tgt tta atc aag 3120 Ala Asn Val Val Ser Cys Ala Lys Cys Glu Asn Arg Cys Leu Ile Lys 975 980 985 gct ctg acg cat ttc tac aac cac gac tcc aag tgt gtg ggt gaa gtc 3168 Ala Leu Thr His Phe Tyr Asn His Asp Ser Lys Cys Val Gly Glu Val 990 995 1000 atg cat ctt tta atc aaa tcc caa gat gtg tat aaa cca cca aac 3213 Met His Leu Leu Ile Lys Ser Gln Asp Val Tyr Lys Pro Pro Asn 1005 1010 1015 tgc caa aaa atg aaa act gtc gac aag ctc tgt ccg ttt gct ggc 3258 Cys Gln Lys Met Lys Thr Val Asp Lys Leu Cys Pro Phe Ala Gly 1020 1025 1030 aac tgc aag ggt ctc aat cct att tgt aat tat tga ata ata aaa 3303 Asn Cys Lys Gly Leu Asn Pro Ile Cys Asn Tyr Ile Ile Lys 1035 1040 1045 caa tta taa atg cta aat ttg ttt ttt att aac gat aca aac caa 3348 Gln Leu Met Leu Asn Leu Phe Phe Ile Asn Asp Thr Asn Gln 1050 1055 1060 acg caa caa gaa cat ttg tag tat tat cta taa ttg aaa acg cgt agt 3396 Thr Gln Gln Glu His Leu Tyr Tyr Leu Leu Lys Thr Arg Ser 1065 1070 tat aat cgc tga ggt aat att taa aat cat ttt caa atg att cac 3441 Tyr Asn Arg Gly Asn Ile Asn His Phe Gln Met Ile His 1075 1080 1085 agt taa ttt gcg aca ata taa ttt tat ttt cac ata aac tag acg 3486 Ser Phe Ala Thr Ile Phe Tyr Phe His Ile Asn Thr 1090 1095 cct tgt cgt ctt ctt ctt cgt att cct tct ctt ttt cat ttt tct 3531 Pro Cys Arg Leu Leu Leu Arg Ile Pro Ser Leu Phe His Phe Ser 1100 1105 1110 cct cat aaa aat taa cat agt tat tat cgt atc cat ata tgt atc 3576 Pro His Lys Asn His Ser Tyr Tyr Arg Ile His Ile Cys Ile 1115 1120 1125 tat cgt ata gag taa att ttt tgt tgt cat aaa tat ata tgt ctt 3621 Tyr Arg Ile Glu Ile Phe Cys Cys His Lys Tyr Ile Cys Leu 1130 1135 1140 ttt taa tgg ggt gta tag tac cgc tgc gca tag ttt ttc tgt aat 3666 Phe Trp Gly Val Tyr Arg Cys Ala Phe Phe Cys Asn 1145 1150 tta caa cag tgc tat ttt ctg gta gtt ctt cgg agt gtg ttg ctt 3711 Leu Gln Gln Cys Tyr Phe Leu Val Val Leu Arg Ser Val Leu Leu 1155 1160 1165 taa tta tta aat tta tat aat caa tga att tgg gat cgt cgg ttt 3756 Leu Leu Asn Leu Tyr Asn Gln Ile Trp Asp Arg Arg Phe 1170 1175 1180 tgt aca ata tgt tgc cgg cat agt acg cag ctt ctt cta gtt caa 3801 Cys Thr Ile Cys Cys Arg His Ser Thr Gln Leu Leu Leu Val Gln 1185 1190 1195 tta cac cat ttt tta gca gca ccg gat taa cat aac ttt cca aaa 3846 Leu His His Phe Leu Ala Ala Pro Asp His Asn Phe Pro Lys 1200 1205 1210 tgt tgt acg aac cgt taa aca aaa aca gtt cac ctc cct ttt cta 3891 Cys Cys Thr Asn Arg Thr Lys Thr Val His Leu Pro Phe Leu 1215 1220 1225 tac tat tgt ctg cga gca gtt gtt tgt tgt taa aaa taa cag cca ttg 3939 Tyr Tyr Cys Leu Arg Ala Val Val Cys Cys Lys Gln Pro Leu 1230 1235 taa tga gac gca caa act aat atc aca aac tgg aaa tgt cta tca 3984 Asp Ala Gln Thr Asn Ile Thr Asn Trp Lys Cys Leu Ser 1240 1245 1250 ata tat agt tgc tga tat cat gga gat aat taa aat gat aac cat 4029 Ile Tyr Ser Cys Tyr His Gly Asp Asn Asn Asp Asn His 1255 1260 1265 ctc gca aat aaa taa gta ttt tac tgt ttt cgt aac agt ttt gta 4074 Leu Ala Asn Lys Val Phe Tyr Cys Phe Arg Asn Ser Phe Val 1270 1275 ata aaa aaa cct ata aat att ccg gat tat tca tac cgt ccc acc 4119 Ile Lys Lys Pro Ile Asn Ile Pro Asp Tyr Ser Tyr Arg Pro Thr 1280 1285 1290 atc ggg cgc gga tct atg cta cta gta aat cag tca cac caa ggc 4164 Ile Gly Arg Gly Ser Met Leu Leu Val Asn Gln Ser His Gln Gly 1295 1300 1305 ttc aat aag gaa cac aca agc aag atg gta agc gct att gtt tta 4209 Phe Asn Lys Glu His Thr Ser Lys Met Val Ser Ala Ile Val Leu 1310 1315 1320 tat gtg ctt ttg gcg gcg gcg gcg cat tct gcc ttt gcg gcg gat 4254 Tyr Val Leu Leu Ala Ala Ala Ala His Ser Ala Phe Ala Ala Asp 1325 1330 1335 ctt gga tcc cat cat cac cac cac cac att gaa gga aga gaa ttc 4299 Leu Gly Ser His His His His His His Ile Glu Gly Arg Glu Phe 1340 1345 1350 cag gtg cag ctg aag gag tca gga cct ggc ctg gtg gcg ccc tca 4344 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser 1355 1360 1365 cag agc ctg tcc atc aca tgc act gtc tca ggg ttc tca tta acc 4389 Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr 1370 1375 1380 agc tat ggt gta agc tgg gtt cgc cag cct cca gga aag ggt ctg 4434 Ser Tyr Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu 1385 1390 1395 gag tgg ctg gga gta ata tgg ggt gac ggg agc aca aat tat cat 4479 Glu Trp Leu Gly Val Ile Trp Gly Asp Gly Ser Thr Asn Tyr His 1400 1405 1410 tca gct ctc ata tcc aga ctg agc atc agc aag gat aac tcc aag 4524 Ser Ala Leu Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys 1415 1420 1425 agc caa gtt ttc tca aaa ctg aac agt ctg caa act gat gac aca 4569 Ser Gln Val Phe Ser Lys Leu Asn Ser Leu Gln Thr Asp Asp Thr 1430 1435 1440 gcc acg tac tac tgt gcc aaa agg gga ggc tat ggt aac tac tat 4614 Ala Thr Tyr Tyr Cys Ala Lys Arg Gly Gly Tyr Gly Asn Tyr Tyr 1445 1450 1455 gct atg gac tac tgg ggt caa gga acc tca gtc acc gtc tcc tca 4659 Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 1460 1465 1470 ggt gga ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg 4704 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1475 1480 1485 gac att gtg atg acc cag tct cac aaa ttc atg tcc aca tca gta 4749 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val 1490 1495 1500 gga gac agg gtc agc atc acc tgc aag gcc agt cag gat gtg agt 4794 Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser 1505 1510 1515 act gct gta gcc tgg tat caa caa aaa cca ggg caa tct cct aaa 4839 Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys 1520 1525 1530 cta ctg att tac tgg gca tcc acc cgg cac act gga gtc cct gat 4884 Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp 1535 1540 1545 cgc ttc aca ggc agt gga tct ggg aca gat tat act ctc acc atc 4929 Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile 1550 1555 1560 agc agt gtg cag gct gaa gac ctg gca ctt tat tac tgt cag caa 4974 Ser Ser Val Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln 1565 1570 1575 cat tat agc act cct ccg acg ttc ggt gga ggc acc aag ctg gga 5019 His Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Gly 1580 1585 1590 acc aaa cgg gct ccc ggg gga tgt taa aga tct gat cct ttc ctg 5064 Thr Lys Arg Ala Pro Gly Gly Cys Arg Ser Asp Pro Phe Leu 1595 1600 1605 gga ccc ggc aag aac caa aaa ctc act ctc ttc aag gaa atc cgt 5109 Gly Pro Gly Lys Asn Gln Lys Leu Thr Leu Phe Lys Glu Ile Arg 1610 1615 1620 aat gtt aaa ccc gac acg atg aag ctt gtc gtt gga tgg aaa gga 5154 Asn Val Lys Pro Asp Thr Met Lys Leu Val Val Gly Trp Lys Gly 1625 1630 1635 aaa gag ttc tac agg gaa act tgg acc cgc ttc atg gaa gac agc 5199 Lys Glu Phe Tyr Arg Glu Thr Trp Thr Arg Phe Met Glu Asp Ser 1640 1645 1650 ttc ccc att gtt aac gac caa gaa gtg atg gat gtt ttc ctt gtt 5244 Phe Pro Ile Val Asn Asp Gln Glu Val Met Asp Val Phe Leu Val 1655 1660 1665 gtc aac atg cgt ccc act aga ccc aac cgt tgt tac aaa ttc ctg 5289 Val Asn Met Arg Pro Thr Arg Pro Asn Arg Cys Tyr Lys Phe Leu 1670 1675 1680 gcc caa cac gct ctg cgt tgc gac ccc gac tat gta cct cat gac 5334 Ala Gln His Ala Leu Arg Cys Asp Pro Asp Tyr Val Pro His Asp 1685 1690 1695 gtg att agg atc gtc gag cct tca tgg gtg ggc agc aac aac gag 5379 Val Ile Arg Ile Val Glu Pro Ser Trp Val Gly Ser Asn Asn Glu 1700 1705 1710 tac cgc atc agc ctg gct aag aag ggc ggc ggc tgc cca ata atg 5424 Tyr Arg Ile Ser Leu Ala Lys Lys Gly Gly Gly Cys Pro Ile Met 1715 1720 1725 aac ctt cac tct gag tac acc aac tcg ttc gaa cag ttc atc gat 5469 Asn Leu His Ser Glu Tyr Thr Asn Ser Phe Glu Gln Phe Ile Asp 1730 1735 1740 cgt gtc atc tgg gag aac ttc tac aag ccc atc gtt tac atc ggt 5514 Arg Val Ile Trp Glu Asn Phe Tyr Lys Pro Ile Val Tyr Ile Gly 1745 1750 1755 acc gac tct gct gaa gag gag gaa att ctc ctt gaa gtt tcc ctg 5559 Thr Asp Ser Ala Glu Glu Glu Glu Ile Leu Leu Glu Val Ser Leu 1760 1765 1770 gtg ttc aaa gta aag gag ttt gca cca gac gca cct ctg ttc act 5604 Val Phe Lys Val Lys Glu Phe Ala Pro Asp Ala Pro Leu Phe Thr 1775 1780 1785 ggt ccg gcg tat taa aac acg ata cat tgt tat tag tac att tat 5649 Gly Pro Ala Tyr Asn Thr Ile His Cys Tyr Tyr Ile Tyr 1790 1795 1800 taa gcg cta gat tct gtg cgt tgt tga ttt aca gac aat tgt tgt 5694 Ala Leu Asp Ser Val Arg Cys Phe Thr Asp Asn Cys Cys 1805 1810 acg tat ttt aat aat tca tta aat tta taa tct tta ggg tgg tat 5739 Thr Tyr Phe Asn Asn Ser Leu Asn Leu Ser Leu Gly Trp Tyr 1815 1820 1825 gtt aga gcg aaa atc aaa tga ttt tca gcg tct tta tat ctg aat 5784 Val Arg Ala Lys Ile Lys Phe Ser Ala Ser Leu Tyr Leu Asn 1830 1835 1840 tta aat att aaa tcc tca ata gat ttg taa aat agg ttt cga tta 5829 Leu Asn Ile Lys Ser Ser Ile Asp Leu Asn Arg Phe Arg Leu 1845 1850 1855 gtt tca aac aag ggt tgt ttt tcc gaa ccg atg gct gga cta tct 5874 Val Ser Asn Lys Gly Cys Phe Ser Glu Pro Met Ala Gly Leu Ser 1860 1865 1870 aat gga ttt tcg ctc aac gcc aca aaa ctt gcc aaa tct tgt agc 5919 Asn Gly Phe Ser Leu Asn Ala Thr Lys Leu Ala Lys Ser Cys Ser 1875 1880 1885 agc aat cta gct ttg tcg ata ttc gtt tgt gtt ttg ttt tgt aat 5964 Ser Asn Leu Ala Leu Ser Ile Phe Val Cys Val Leu Phe Cys Asn 1890 1895 1900 aaa ggt tcg acg tcg ttc aaa ata tta tgc gct ttt gta ttt ctt 6009 Lys Gly Ser Thr Ser Phe Lys Ile Leu Cys Ala Phe Val Phe Leu 1905 1910 1915 tca tca ctg tcg tta gtg tac aat tga ctc gac gta aac acg tta 6054 Ser Ser Leu Ser Leu Val Tyr Asn Leu Asp Val Asn Thr Leu 1920 1925 1930 aat aaa gct tgg aca tat tta aca tcg ggc gtg tta gct tta tta 6099 Asn Lys Ala Trp Thr Tyr Leu Thr Ser Gly Val Leu Ala Leu Leu 1935 1940 1945 ggc cga tta tcg tcg tcg tcc caa ccc tcg tcg tta gaa gtt gct 6144 Gly Arg Leu Ser Ser Ser Ser Gln Pro Ser Ser Leu Glu Val Ala 1950 1955 1960 tcc gaa gac gat ttt gcc ata gcc aca cga cgc cta tta att gtg 6189 Ser Glu Asp Asp Phe Ala Ile Ala Thr Arg Arg Leu Leu Ile Val 1965 1970 1975 tcg gct aac acg tcc gcg atc aaa ttt gta gtt gag ctt ttt gga 6234 Ser Ala Asn Thr Ser Ala Ile Lys Phe Val Val Glu Leu Phe Gly 1980 1985 1990 att att tct gat tgc ggg cgt ttt tgg gcg ggt ttc aat cta act 6279 Ile Ile Ser Asp Cys Gly Arg Phe Trp Ala Gly Phe Asn Leu Thr 1995 2000 2005 gtg ccc gat ttt aat tca gac aac acg tta gaa agc gat ggt gca 6324 Val Pro Asp Phe Asn Ser Asp Asn Thr Leu Glu Ser Asp Gly Ala 2010 2015 2020 ggc ggt ggt aac att tca gac ggc aaa tct act aat ggc ggc ggt 6369 Gly Gly Gly Asn Ile Ser Asp Gly Lys Ser Thr Asn Gly Gly Gly 2025 2030 2035 ggt gga gct gat gat aaa tct acc atc ggt gga ggc gca ggc ggg 6414 Gly Gly Ala Asp Asp Lys Ser Thr Ile Gly Gly Gly Ala Gly Gly 2040 2045 2050 gct ggc ggc gga ggc gga ggc gga ggt ggt ggc ggt gat gca gac 6459 Ala Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Asp Ala Asp 2055 2060 2065 ggc ggt tta ggc tca aat gtc tct tta ggc aac aca gtc ggc acc 6504 Gly Gly Leu Gly Ser Asn Val Ser Leu Gly Asn Thr Val Gly Thr 2070 2075 2080 tca act att gta ctg gtt tcg ggc gcc gtt ttt ggt ttg acc ggt 6549 Ser Thr Ile Val Leu Val Ser Gly Ala Val Phe Gly Leu Thr Gly 2085 2090 2095 ctg aga cga gtg cga ttt ttt tcg ttt cta ata gct tcc aac aat 6594 Leu Arg Arg Val Arg Phe Phe Ser Phe Leu Ile Ala Ser Asn Asn 2100 2105 2110 tgt tgt ctg tcg tct aaa ggt gca gcg ggt tga ggt tcc gtc ggc 6639 Cys Cys Leu Ser Ser Lys Gly Ala Ala Gly Gly Ser Val Gly 2115 2120 att ggt gga gcg ggc ggc aat tca gac atc gat ggt ggt ggt ggt 6684 Ile Gly Gly Ala Gly Gly Asn Ser Asp Ile Asp Gly Gly Gly Gly 2125 2130 2135 ggt gga ggc gct gga atg tta ggc acg gga gaa ggt ggt ggc ggc 6729 Gly Gly Gly Ala Gly Met Leu Gly Thr Gly Glu Gly Gly Gly Gly 2140 2145 2150 ggt gcc gcc ggt ata att tgt tct ggt tta gtt tgt tcg cgc acg 6774 Gly Ala Ala Gly Ile Ile Cys Ser Gly Leu Val Cys Ser Arg Thr 2155 2160 2165 att gtg ggc acc ggc gca ggc gcc gct ggc tgc aca acg gaa ggt 6819 Ile Val Gly Thr Gly Ala Gly Ala Ala Gly Cys Thr Thr Glu Gly 2170 2175 2180 cgt ctg ctt cga ggc agc gct tgg ggt ggt ggc aat tca ata tta 6864 Arg Leu Leu Arg Gly Ser Ala Trp Gly Gly Gly Asn Ser Ile Leu 2185 2190 2195 taa ttg gaa tac aaa tcg taa aaa tct gct ata agc att gta att 6909 Leu Glu Tyr Lys Ser Lys Ser Ala Ile Ser Ile Val Ile 2200 2205 2210 tcg cta tcg ttt acc gtg ccg ata ttt aac aac cgc tca atg taa 6954 Ser Leu Ser Phe Thr Val Pro Ile Phe Asn Asn Arg Ser Met 2215 2220 2225 gca att gta ttg taa aga gat tgt ctc aag ctc cgc acg ccg ata 6999 Ala Ile Val Leu Arg Asp Cys Leu Lys Leu Arg Thr Pro Ile 2230 2235 2240 aca agc ctt ttc att ttt act aca gca ttg tag tgg cga gac act 7044 Thr Ser Leu Phe Ile Phe Thr Thr Ala Leu Trp Arg Asp Thr 2245 2250 tcg ctg tcg tcg acg tac atg tat gct ttg ttg tca aaa acg tcg 7089 Ser Leu Ser Ser Thr Tyr Met Tyr Ala Leu Leu Ser Lys Thr Ser 2255 2260 2265 ttg gca agc ttt aaa ata ttt aaa aga aca tct ctg ttc agc acc 7134 Leu Ala Ser Phe Lys Ile Phe Lys Arg Thr Ser Leu Phe Ser Thr 2270 2275 2280 act gtg ttg tcg taa atg ttg ttt ttg ata att tgc gct tcc gca 7179 Thr Val Leu Ser Met Leu Phe Leu Ile Ile Cys Ala Ser Ala 2285 2290 2295 gta tcg aca cgt tca aaa aat tga tgc gca tca att ttg ttg ttc 7224 Val Ser Thr Arg Ser Lys Asn Cys Ala Ser Ile Leu Leu Phe 2300 2305 2310 cta tta ttg aat aaa taa gat tgt aca gat tca tat cta cga ttc 7269 Leu Leu Leu Asn Lys Asp Cys Thr Asp Ser Tyr Leu Arg Phe 2315 2320 2325 gtc atg gcc acc aca aat gct acg ctg caa acg ctg gta caa ttt 7314 Val Met Ala Thr Thr Asn Ala Thr Leu Gln Thr Leu Val Gln Phe 2330 2335 2340 tac gaa aac tgc aaa aac gtc aaa act cgg tat aaa ata atc aac 7359 Tyr Glu Asn Cys Lys Asn Val Lys Thr Arg Tyr Lys Ile Ile Asn 2345 2350 2355 ggg cgc ttt ggc aaa ata tct att tta tcg cac aag ccc act agc 7404 Gly Arg Phe Gly Lys Ile Ser Ile Leu Ser His Lys Pro Thr Ser 2360 2365 2370 aaa ttg tat ttg cag aaa aca att tcg gcg cac aat ttt aac gct 7449 Lys Leu Tyr Leu Gln Lys Thr Ile Ser Ala His Asn Phe Asn Ala 2375 2380 2385 gac gaa ata aaa gtt cac cag tta atg agc gac cac cca aat ttt 7494 Asp Glu Ile Lys Val His Gln Leu Met Ser Asp His Pro Asn Phe 2390 2395 2400 ata aaa atc tat ttt aat cac ggt tcc atc aac aac caa gtg atc 7539 Ile Lys Ile Tyr Phe Asn His Gly Ser Ile Asn Asn Gln Val Ile 2405 2410 2415 gtg atg gac tac att gac tgt ccc gat tta ttt gaa aca cta caa 7584 Val Met Asp Tyr Ile Asp Cys Pro Asp Leu Phe Glu Thr Leu Gln 2420 2425 2430 att aaa ggc gag ctt tcg tac caa ctt gtt agc aat att att aga 7629 Ile Lys Gly Glu Leu Ser Tyr Gln Leu Val Ser Asn Ile Ile Arg 2435 2440 2445 cag ctg tgt gaa gcg ctc aac gat ttg cac aag cac aat ttc ata 7674 Gln Leu Cys Glu Ala Leu Asn Asp Leu His Lys His Asn Phe Ile 2450 2455 2460 cac aac gac ata aaa ctc gaa aat gtc tta tat ttc gaa gca ctt 7719 His Asn Asp Ile Lys Leu Glu Asn Val Leu Tyr Phe Glu Ala Leu 2465 2470 2475 gat cgc gtg tat gtt tgc gat tac gga ttg tgc aaa cac gaa aac 7764 Asp Arg Val Tyr Val Cys Asp Tyr Gly Leu Cys Lys His Glu Asn 2480 2485 2490 tca ctt agc gtg cac gac ggc acg ttg gag tat ttt agt ccg gaa 7809 Ser Leu Ser Val His Asp Gly Thr Leu Glu Tyr Phe Ser Pro Glu 2495 2500 2505 aaa att cga cac aca act atg cac gtt tcg ttt gac tgg tac gcg 7854 Lys Ile Arg His Thr Thr Met His Val Ser Phe Asp Trp Tyr Ala 2510 2515 2520 gcg tgt taa cat aca agt tgc taa ccg gcg gtt cgt aat cat ggt 7899 Ala Cys His Thr Ser Cys Pro Ala Val Arg Asn His Gly 2525 2530 cat agc tgt ttc ctg tgt gaa att gtt atc cgc tca caa ttc cac 7944 His Ser Cys Phe Leu Cys Glu Ile Val Ile Arg Ser Gln Phe His 2535 2540 2545 aca aca tac gag ccg gaa gca taa agt gta aag cct ggg gtg cct 7989 Thr Thr Tyr Glu Pro Glu Ala Ser Val Lys Pro Gly Val Pro 2550 2555 2560 aat gag tga gct aac tca cat taa ttg cgt tgc gct cac tgc ccg 8034 Asn Glu Ala Asn Ser His Leu Arg Cys Ala His Cys Pro 2565 2570 2575 ctt tcc agt cgg gaa acc tgt cgt gcc agc tgc att aat gaa tcg 8079 Leu Ser Ser Arg Glu Thr Cys Arg Ala Ser Cys Ile Asn Glu Ser 2580 2585 2590 gcc aac gcg cgg gga gag gcg gtt tgc gta ttg ggc gct ctt ccg 8124 Ala Asn Ala Arg Gly Glu Ala Val Cys Val Leu Gly Ala Leu Pro 2595 2600 2605 ctt cct cgc tca ctg act cgc tgc gct cgg tcg ttc ggc tgc ggc 8169 Leu Pro Arg Ser Leu Thr Arg Cys Ala Arg Ser Phe Gly Cys Gly 2610 2615 2620 gag cgg tat cag ctc act caa agg cgg taa tac ggt tat cca cag 8214 Glu Arg Tyr Gln Leu Thr Gln Arg Arg Tyr Gly Tyr Pro Gln 2625 2630 2635 aat cag ggg ata acg cag gaa aga aca tgt gag caa aag gcc agc 8259 Asn Gln Gly Ile Thr Gln Glu Arg Thr Cys Glu Gln Lys Ala Ser 2640 2645 2650 aaa agg cca gga acc gta aaa agg ccg cgt tgc tgg cgt ttt tcc 8304 Lys Arg Pro Gly Thr Val Lys Arg Pro Arg Cys Trp Arg Phe Ser 2655 2660 2665 ata ggc tcc gcc ccc ctg acg agc atc aca aaa atc gac gct caa 8349 Ile Gly Ser Ala Pro Leu Thr Ser Ile Thr Lys Ile Asp Ala Gln 2670 2675 2680 gtc aga ggt ggc gaa acc cga cag gac tat aaa gat acc agg cgt 8394 Val Arg Gly Gly Glu Thr Arg Gln Asp Tyr Lys Asp Thr Arg Arg 2685 2690 2695 ttc ccc ctg gaa gct ccc tcg tgc gct ctc ctg ttc cga ccc tgc 8439 Phe Pro Leu Glu Ala Pro Ser Cys Ala Leu Leu Phe Arg Pro Cys 2700 2705 2710 cgc tta ccg gat acc tgt ccg cct ttc tcc ctt cgg gaa gcg tgg 8484 Arg Leu Pro Asp Thr Cys Pro Pro Phe Ser Leu Arg Glu Ala Trp 2715 2720 2725 cgc ttt ctc ata gct cac gct gta ggt atc tca gtt cgg tgt agg 8529 Arg Phe Leu Ile Ala His Ala Val Gly Ile Ser Val Arg Cys Arg 2730 2735 2740 tcg ttc gct cca agc tgg gct gtg tgc acg aac ccc ccg ttc agc 8574 Ser Phe Ala Pro Ser Trp Ala Val Cys Thr Asn Pro Pro Phe Ser 2745 2750 2755 ccg acc gct gcg cct tat ccg gta act atc gtc ttg agt cca acc 8619 Pro Thr Ala Ala Pro Tyr Pro Val Thr Ile Val Leu Ser Pro Thr 2760 2765 2770 cgg taa gac acg act tat cgc cac tgg cag cag cca ctg gta aca 8664 Arg Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val Thr 2775 2780 gga tta gca gag cga ggt atg tag gcg gtg cta cag agt tct tga 8709 Gly Leu Ala Glu Arg Gly Met Ala Val Leu Gln Ser Ser 2785 2790 2795 agt ggt ggc cta act acg gct aca cta gaa gga cag tat ttg gta 8754 Ser Gly Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val 2800 2805 2810 tct gcg ctc tgc tga agc cag tta cct tcg gaa aaa gag ttg gta 8799 Ser Ala Leu Cys Ser Gln Leu Pro Ser Glu Lys Glu Leu Val 2815 2820 2825 gct ctt gat ccg gca aac aaa cca ccg ctg gta gcg gtg gtt ttt 8844 Ala Leu Asp Pro Ala Asn Lys Pro Pro Leu Val Ala Val Val Phe 2830 2835 2840 ttg ttt gca agc agc aga tta cgc gca gaa aaa aag gat ctc aag 8889 Leu Phe Ala Ser Ser Arg Leu Arg Ala Glu Lys Lys Asp Leu Lys 2845 2850 2855 aag atc ctt tga tct ttt cta cgg ggt ctg acg ctc agt gga acg 8934 Lys Ile Leu Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr 2860 2865 2870 aaa act cac gtt aag gga ttt tgg tca tga gat tat caa aaa gga 8979 Lys Thr His Val Lys Gly Phe Trp Ser Asp Tyr Gln Lys Gly 2875 2880 tct tca cct aga tcc ttt taa att aaa aat gaa gtt tta aat caa 9024 Ser Ser Pro Arg Ser Phe Ile Lys Asn Glu Val Leu Asn Gln 2885 2890 2895 tct aaa gta tat atg agt aaa ctt ggt ctg aca gtt acc aat gct 9069 Ser Lys Val Tyr Met Ser Lys Leu Gly Leu Thr Val Thr Asn Ala 2900 2905 2910 taa tca gtg agg cac cta tct cag cga tct gtc tat ttc gtt cat 9114 Ser Val Arg His Leu Ser Gln Arg Ser Val Tyr Phe Val His 2915 2920 2925 cca tag ttg cct gac tcc ccg tcg tgt aga taa cta cga tac ggg 9159 Pro Leu Pro Asp Ser Pro Ser Cys Arg Leu Arg Tyr Gly 2930 2935 2940 agg gct tac cat ctg gcc cca gtg ctg caa tga tac cgc gag acc 9204 Arg Ala Tyr His Leu Ala Pro Val Leu Gln Tyr Arg Glu Thr 2945 2950 cac gct cac cgg ctc cag att tat cag caa taa acc agc cag ccg 9249 His Ala His Arg Leu Gln Ile Tyr Gln Gln Thr Ser Gln Pro 2955 2960 2965 gaa ggg ccg agc gca gaa gtg gtc ctg caa ctt tat ccg cct cca 9294 Glu Gly Pro Ser Ala Glu Val Val Leu Gln Leu Tyr Pro Pro Pro 2970 2975 2980 tcc agt cta tta att gtt gcc ggg aag cta gag taa gta gtt cgc 9339 Ser Ser Leu Leu Ile Val Ala Gly Lys Leu Glu Val Val Arg 2985 2990 2995 cag tta ata gtt tgc gca acg ttg ttg cca ttg cta cag gca tcg 9384 Gln Leu Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln Ala Ser 3000 3005 3010 tgg tgt cac gct cgt cgt ttg gta tgg ctt cat tca gct ccg gtt 9429 Trp Cys His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro Val 3015 3020 3025 ccc aac gat caa ggc gag tta cat gat ccc cca tgt tgt gca aaa 9474 Pro Asn Asp Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys 3030 3035 3040 aag cgg tta gct cct tcg gtc ctc cga tcg ttg tca gaa gta agt 9519 Lys Arg Leu Ala Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser 3045 3050 3055 tgg ccg cag tgt tat cac tca tgg tta tgg cag cac tgc ata att 9564 Trp Pro Gln Cys Tyr His Ser Trp Leu Trp Gln His Cys Ile Ile 3060 3065 3070 ctc tta ctg tca tgc cat ccg taa gat gct ttt ctg tga ctg gtg 9609 Leu Leu Leu Ser Cys His Pro Asp Ala Phe Leu Leu Val 3075 3080 3085 agt act caa cca agt cat tct gag aat agt gta tgc ggc gac cga 9654 Ser Thr Gln Pro Ser His Ser Glu Asn Ser Val Cys Gly Asp Arg 3090 3095 3100 gtt gct ctt gcc cgg cgt caa tac ggg ata ata ccg cgc cac ata 9699 Val Ala Leu Ala Arg Arg Gln Tyr Gly Ile Ile Pro Arg His Ile 3105 3110 3115 gca gaa ctt taa aag tgc tca tca ttg gaa aac gtt ctt cgg ggc 9744 Ala Glu Leu Lys Cys Ser Ser Leu Glu Asn Val Leu Arg Gly 3120 3125 gaa aac tct caa gga tct tac cgc tgt tga gat cca gtt cga tgt 9789 Glu Asn Ser Gln Gly Ser Tyr Arg Cys Asp Pro Val Arg Cys 3130 3135 3140 aac cca ctc gtg cac cca act gat ctt cag cat ctt tta ctt tca 9834 Asn Pro Leu Val His Pro Thr Asp Leu Gln His Leu Leu Leu Ser 3145 3150 3155 cca gcg ttt ctg ggt gag caa aaa cag gaa ggc aaa atg ccg caa 9879 Pro Ala Phe Leu Gly Glu Gln Lys Gln Glu Gly Lys Met Pro Gln 3160 3165 3170 aaa agg gaa taa ggg cga cac gga aat gtt gaa tac tca tac tct 9924 Lys Arg Glu Gly Arg His Gly Asn Val Glu Tyr Ser Tyr Ser 3175 3180 3185 tcc ttt ttc aat att att gaa gca ttt atc agg gtt att gtc tca 9969 Ser Phe Phe Asn Ile Ile Glu Ala Phe Ile Arg Val Ile Val Ser 3190 3195 3200 tga gcg gat aca tat ttg aat gta ttt aga aaa ata aac aaa tag 10014 Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys 3205 3210 3215 ggg ttc cgc gca cat ttc ccc gaa aag tgc cac ctg acg tct aag 10059 Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys 3220 3225 3230 aaa cca tta tta tca tga cat taa cct ata aaa ata ggc gta tca cga 10107 Lys Pro Leu Leu Ser His Pro Ile Lys Ile Gly Val Ser Arg 3235 3240 ggc cct ttc gtc tcg cgc gtt tcg gtg atg acg gtg aaa acc tct 10152 Gly Pro Phe Val Ser Arg Val Ser Val Met Thr Val Lys Thr Ser 3245 3250 3255 gac aca tgc agc tcc cgg aga cgg tca cag ctt gtc tgt aag cgg 10197 Asp Thr Cys Ser Ser Arg Arg Arg Ser Gln Leu Val Cys Lys Arg 3260 3265 3270 atg ccg gga gca gac aag ccc gtc agg gcg cgt cag cgg gtg ttg 10242 Met Pro Gly Ala Asp Lys Pro Val Arg Ala Arg Gln Arg Val Leu 3275 3280 3285 gcg ggt gtc ggg gct ggc tta act atg cgg cat cag agc aga ttg 10287 Ala Gly Val Gly Ala Gly Leu Thr Met Arg His Gln Ser Arg Leu 3290 3295 3300 tac tga gag tgc acc ata tgc ggt gtg aaa tac cgc aca gat gcg 10332 Tyr Glu Cys Thr Ile Cys Gly Val Lys Tyr Arg Thr Asp Ala 3305 3310 3315 taa gga gaa aat acc gca tca ggc gcc att cgc cat tca ggc tgc 10377 Gly Glu Asn Thr Ala Ser Gly Ala Ile Arg His Ser Gly Cys 3320 3325 3330 gca act gtt ggg aag ggc gat cgg tgc ggg cct ctt cgc tat tac 10422 Ala Thr Val Gly Lys Gly Asp Arg Cys Gly Pro Leu Arg Tyr Tyr 3335 3340 3345 gcc agc tgg cga aag ggg gat gtg ctg caa ggc gat taa gtt ggg 10467 Ala Ser Trp Arg Lys Gly Asp Val Leu Gln Gly Asp Val Gly 3350 3355 3360 taa cgc cag ggt ttt ccc agt cac gac gtt gta aaa cga cgg cca 10512 Arg Gln Gly Phe Pro Ser His Asp Val Val Lys Arg Arg Pro 3365 3370 3375 gtg cc 10517 Val <210> SEQ ID NO 2 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 2 Lys Leu Tyr Ser 1 <210> SEQ ID NO 3 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 3 Ser Glu Leu Lys Asp His Ile 1 5 <210> SEQ ID NO 4 <211> LENGTH: 176 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 4 Asp Lys Ile Glu Ser Thr Cys Lys Met Phe Pro Ala Arg Trp His Asn 1 5 10 15 Tyr Leu Gln Cys Gly Gln Val Ile Lys Asp Ser Asn Leu Ile Cys Phe 20 25 30 Lys Thr Pro Leu Arg Pro Glu Leu Phe Ala Tyr Val Thr Ser Glu Glu 35 40 45 Asp Val Trp Thr Ala Glu Gln Ile Val Lys Gln Asn Pro Ser Ile Gly 50 55 60 Ala Ile Ile Asp Leu Thr Asn Thr Ser Lys Tyr Tyr Asp Gly Val His 65 70 75 80 Phe Leu Arg Ala Gly Leu Leu Tyr Lys Lys Ile Gln Val Pro Gly Gln 85 90 95 Thr Leu Pro Pro Glu Ser Ile Val Gln Glu Phe Ile Asp Thr Val Lys 100 105 110 Glu Phe Thr Glu Lys Cys Pro Gly Met Leu Val Gly Val His Cys Thr 115 120 125 His Gly Ile Asn Arg Thr Gly Tyr Met Val Cys Arg Tyr Leu Met His 130 135 140 Thr Leu Gly Ile Ala Pro Gln Glu Ala Ile Asp Arg Phe Glu Lys Ala 145 150 155 160 Arg Gly His Lys Ile Glu Arg Gln Asn Tyr Val Gln Asp Leu Leu Ile 165 170 175 <210> SEQ ID NO 5 <211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 5 Leu Ile Leu Phe Ala Phe Phe Asn Lys Tyr Phe Ile Leu Phe Ser Asn 1 5 10 15 Cys Cys Ala Ser Ser Ser Glu Pro Lys Leu Cys Phe Ala Cys Ser Val 20 25 30 <210> SEQ ID NO 6 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 6 Leu Val Ala Asp Gln Trp Arg Cys Ser Asn Arg Arg 1 5 10 <210> SEQ ID NO 7 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 7 Ala Gly Tyr Ser Pro Pro Gln Cys Trp Gln Arg 1 5 10 <210> SEQ ID NO 8 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 8 Cys Tyr Val Tyr Ala Phe Gly Phe Pro Arg Thr Ser Phe Gly Arg 1 5 10 15 <210> SEQ ID NO 9 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 9 Cys Arg Arg Ala Ser Arg Thr Thr Pro Asp Val Cys Ala Cys Pro Arg 1 5 10 15 Gly Ile Glu Pro Arg Asp Pro Thr Asn Pro Pro Leu Trp Gln Leu Asn 20 25 30 Arg <210> SEQ ID NO 10 <211> LENGTH: 28 <2 12> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 10 Pro Ala Arg Leu Phe Ser Ala Leu Phe Arg Leu Ser Phe Ala Trp Phe 1 5 10 15 Pro Gly Ser Arg Cys Thr Cys Gly Leu Asp Gln Ser 20 25 <210> SEQ ID NO 11 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 11 Pro Ala Asn Leu Trp Pro Arg Ser Ala Cys Pro 1 5 10 <210> SEQ ID NO 12 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 12 Trp Gln Arg Cys Val Gln 1 5 <210> SEQ ID NO 13 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 13 Thr Leu Val Phe 1 <210> SEQ ID NO 14 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 14 Gln Val Pro Arg Phe Phe Ala Pro Pro Pro Leu Ala Ala Arg Leu Cys 1 5 10 15 Ala Arg <210> SEQ ID NO 15 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 15 Met Ser Gln Ser Ala 1 5 <210> SEQ ID NO 16 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 16 Ser Pro Thr Val Cys Ser Pro Pro Pro Val Val 1 5 10 <210> SEQ ID NO 17 <211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 17 Ser Arg Asp Arg Thr Cys Arg Cys Arg Ala Leu Glu Glu Leu Leu Leu 1 5 10 15 Leu Lys Ala Ile Leu Val Ile Leu Trp Arg Lys Ala Ile Trp Thr Ser 20 25 30 <210> SEQ ID NO 18 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 18 Ser Ala Glu Ser Arg Arg Ile 1 5 <210> SEQ ID NO 19 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 19 Ala Leu Tyr Ala Ala Ala Asn Thr Ala Gly Arg Pro Phe Ser Arg Arg 1 5 10 15 Cys <210> SEQ ID NO 20 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 20 Gly Pro His Phe Gly Trp Ser Ala Gln Ile Thr Ile Cys Ile Tyr Cys 1 5 10 15 Leu His Glu His Val 20 <210> SEQ ID NO 21 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 21 Leu Tyr His Lys Leu Tyr Ile Leu Asn Cys 1 5 10 <210> SEQ ID NO 22 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 22 Arg Arg Pro Trp Pro Arg Thr Gly Pro Val Gly Arg Ala Leu Ala Arg 1 5 10 15 Thr Ala Gly <210> SEQ ID NO 23 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 23 Thr Tyr Leu Leu Gln Ile 1 5 <210> SEQ ID NO 24 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 24 Ile Leu Gln Phe 1 <210> SEQ ID NO 25 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 25 Arg Glu Pro Phe 1 <210> SEQ ID NO 26 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 26 Tyr Thr Cys Val Asp Phe Ala Thr Thr Ile Val Phe 1 5 10 <210> SEQ ID NO 27 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 27 Arg Lys Leu Asn Leu Leu Trp 1 5 <210> SEQ ID NO 28 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 28 Ala Ile Ile Lys Tyr Gly Gly Thr Cys Ala Ala Thr Thr Leu Val Val 1 5 10 15 Met Asn Ala Asp Gly Ala Gly Leu Gly Ala Ser Gly 20 25 <210> SEQ ID NO 29 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 29 Asn Val Leu Arg Val Gln Arg Gly Lys His Arg Lys Ser Gln 1 5 10 <210> SEQ ID NO 30 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 30 Tyr Ser Phe Asp Leu His Ile Asn Gly Asp Phe Leu Asn Tyr Leu Ile 1 5 10 15 <210> SEQ ID NO 31 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 31 Ile Val Met Thr Pro Thr Thr Pro Arg Pro Arg 1 5 10 <210> SEQ ID NO 32 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 32 Leu Ala Ala Pro Arg Ala Val Arg 1 5 <210> SEQ ID NO 33 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 33 Arg Leu Pro Pro Cys Gly Arg Thr Arg Arg Ala Gly Gly Arg 1 5 10 <210> SEQ ID NO 34 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 34 Pro Ala Ala Cys Arg Thr Arg Arg Thr Ser Ile Cys Thr Pro Asn Asp 1 5 10 15 Arg Arg Ala Lys Ala Arg Arg Pro Pro Ser Gly Asn Ile Gly Lys Phe 20 25 30 Glu Asn Ile Tyr Ser Trp Val Val Cys Ala Tyr Leu Ser Trp Arg Trp 35 40 45 Ala Cys Thr Ser Glu Arg 50 <210> SEQ ID NO 35 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 35 Phe Ala Cys Lys Pro Lys Leu Asn His Cys Asp 1 5 10 <210> SEQ ID NO 36 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 36 Asn Val Val His Pro Arg Phe 1 5 <210> SEQ ID NO 37 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 37 Ser Cys Arg Arg Leu Asn Arg Ala Ile Glu Ser Ser Asp Gln Ser Val 1 5 10 15 Glu <210> SEQ ID NO 38 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 38 Cys Phe Leu Cys Ile Pro Glu Ser Ser Ala Ala Arg Ile Leu Thr Asn 1 5 10 15 <210> SEQ ID NO 39 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 39 Pro Ser Cys Lys Leu Val Ser Phe Asn Ala Thr Leu Ser Asn Asn Ile 1 5 10 15 Leu Cys Ile Ala Arg Gln Glu Leu Thr Met Arg Pro Leu Ser His Leu 20 25 30 Asn Thr Thr Met Ile Glu Ile Lys 35 40 <210> SEQ ID NO 40 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 40 Ile Ala Cys Asp Ala Thr Cys Thr Ile Cys Ala Arg Val Pro Ala Arg 1 5 10 15 Ala Leu Ile Val Ile Ser Phe Tyr Glu Ala Met Thr 20 25 <210> SEQ ID NO 41 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 41 Gln Arg Ser Arg Pro Lys Glu Leu Pro Thr Thr Lys Leu Pro Ser Met 1 5 10 15 Ser Val Thr Leu Lys Leu Leu Ser His Pro Ile Asp Arg 20 25 <210> SEQ ID NO 42 <211> LENGTH: 222 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 42 Ser Asn Gln Asp Arg Trp Cys Glu Lys Pro Arg Ser Met Ala Asn Ala 1 5 10 15 Ser Tyr Asn Val Trp Ser Pro Leu Ile Arg Ala Ser Cys Leu Asp Lys 20 25 30 Lys Ala Thr Tyr Leu Ile Asp Pro Asp Asp Phe Ile Asp Lys Leu Thr 35 40 45 Leu Thr Pro Tyr Thr Val Phe Tyr Asn Gly Gly Val Leu Val Lys Ile 50 55 60 Ser Gly Leu Arg Leu Tyr Met Leu Leu Thr Ala Pro Pro Thr Ile Asn 65 70 75 80 Glu Ile Lys Asn Ser Asn Phe Lys Lys Arg Ser Lys Arg Asn Ile Cys 85 90 95 Met Lys Glu Cys Val Glu Gly Lys Lys Asn Val Val Asp Met Leu Asn 100 105 110 Asn Lys Ile Asn Met Pro Pro Cys Ile Lys Lys Ile Leu Asn Asp Leu 115 120 125 Lys Glu Asn Asn Val Pro Arg Gly Gly Met Tyr Arg Lys Arg Phe Ile 130 135 140 Leu Asn Cys Tyr Ile Ala Asn Val Val Ser Cys Ala Lys Cys Glu Asn 145 150 155 160 Arg Cys Leu Ile Lys Ala Leu Thr His Phe Tyr Asn His Asp Ser Lys 165 170 175 Cys Val Gly Glu Val Met His Leu Leu Ile Lys Ser Gln Asp Val Tyr 180 185 190 Lys Pro Pro Asn Cys Gln Lys Met Lys Thr Val Asp Lys Leu Cys Pro 195 200 205 Phe Ala Gly Asn Cys Lys Gly Leu Asn Pro Ile Cys Asn Tyr 210 215 220 <210> SEQ ID NO 43 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 43 Ile Ile Lys Gln Leu 1 5 <210> SEQ ID NO 44 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 44 Met Leu Asn Leu Phe Phe Ile Asn Asp Thr Asn Gln Thr Gln Gln Glu 1 5 10 15 His Leu <210> SEQ ID NO 45 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 45 Leu Lys Thr Arg Ser Tyr Asn Arg 1 5 <210> SEQ ID NO 46 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 46 Asn His Phe Gln Met Ile His Ser 1 5 <210> SEQ ID NO 47 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 47 Phe Ala Thr Ile 1 <210> SEQ ID NO 48 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 48 Phe Tyr Phe His Ile Asn 1 5 <210> SEQ ID NO 49 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 49 Thr Pro Cys Arg Leu Leu Leu Arg Ile Pro Ser Leu Phe His Phe Ser 1 5 10 15 Pro His Lys Asn 20 <210> SEQ ID NO 50 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 50 His Ser Tyr Tyr Arg Ile His Ile Cys Ile Tyr Arg Ile Glu 1 5 10 <210> SEQ ID NO 51 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 51 Ile Phe Cys Cys His Lys Tyr Ile Cys Leu Phe 1 5 10 <210> SEQ ID NO 52 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 52 Tyr Arg Cys Ala 1 <210> SEQ ID NO 53 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 53 Phe Phe Cys Asn Leu Gln Gln Cys Tyr Phe Leu Val Val Leu Arg Ser 1 5 10 15 Val Leu Leu <210> SEQ ID NO 54 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 54 Leu Leu Asn Leu Tyr Asn Gln 1 5 <210> SEQ ID NO 55 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 55 Ile Trp Asp Arg Arg Phe Cys Thr Ile Cys Cys Arg His Ser Thr Gln 1 5 10 15 Leu Leu Leu Val Gln Leu His His Phe Leu Ala Ala Pro Asp 20 25 30 <210> SEQ ID NO 56 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 56 His Asn Phe Pro Lys Cys Cys Thr Asn Arg 1 5 10 <210> SEQ ID NO 57 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 57 Thr Lys Thr Val His Leu Pro Phe Leu Tyr Tyr Cys Leu Arg Ala Val 1 5 10 15 Val Cys Cys <210> SEQ ID NO 58 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 58 Asp Ala Gln Thr Asn Ile Thr Asn Trp Lys Cys Leu Ser Ile Tyr Ser 1 5 10 15 Cys <210> SEQ ID NO 59 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 59 Tyr His Gly Asp Asn 1 5 <210> SEQ ID NO 60 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 60 Asn Asp Asn His Leu Ala Asn Lys 1 5 <210> SEQ ID NO 61 <211> LENGTH: 333 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 61 Val Phe Tyr Cys Phe Arg Asn Ser Phe Val Ile Lys Lys Pro Ile Asn 1 5 10 15 Ile Pro Asp Tyr Ser Tyr Arg Pro Thr Ile Gly Arg Gly Ser Met Leu 20 25 30 Leu Val Asn Gln Ser His Gln Gly Phe Asn Lys Glu His Thr Ser Lys 35 40 45 Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His 50 55 60 Ser Ala Phe Ala Ala Asp Leu Gly Ser His His His His His His Ile 65 70 75 80 Glu Gly Arg Glu Phe Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu 85 90 95 Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe 100 105 110 Ser Leu Thr Ser Tyr Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys 115 120 125 Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Asp Gly Ser Thr Asn Tyr 130 135 140 His Ser Ala Leu Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys 145 150 155 160 Ser Gln Val Phe Ser Lys Leu Asn Ser Leu Gln Thr Asp Asp Thr Ala 165 170 175 Thr Tyr Tyr Cys Ala Lys Arg Gly Gly Tyr Gly Asn Tyr Tyr Ala Met 180 185 190 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly 195 200 205 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met 210 215 220 Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser 225 230 235 240 Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala Trp Tyr 245 250 255 Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser 260 265 270 Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly 275 280 285 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala 290 295 300 Leu Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gly 305 310 315 320 Gly Thr Lys Leu Gly Thr Lys Arg Ala Pro Gly Gly Cys 325 330 <210> SEQ ID NO 62 <211> LENGTH: 190 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 62 Arg Ser Asp Pro Phe Leu Gly Pro Gly Lys Asn Gln Lys Leu Thr Leu 1 5 10 15 Phe Lys Glu Ile Arg Asn Val Lys Pro Asp Thr Met Lys Leu Val Val 20 25 30 Gly Trp Lys Gly Lys Glu Phe Tyr Arg Glu Thr Trp Thr Arg Phe Met 35 40 45 Glu Asp Ser Phe Pro Ile Val Asn Asp Gln Glu Val Met Asp Val Phe 50 55 60 Leu Val Val Asn Met Arg Pro Thr Arg Pro Asn Arg Cys Tyr Lys Phe 65 70 75 80 Leu Ala Gln His Ala Leu Arg Cys Asp Pro Asp Tyr Val Pro His Asp 85 90 95 Val Ile Arg Ile Val Glu Pro Ser Trp Val Gly Ser Asn Asn Glu Tyr 100 105 110 Arg Ile Ser Leu Ala Lys Lys Gly Gly Gly Cys Pro Ile Met Asn Leu 115 120 125 His Ser Glu Tyr Thr Asn Ser Phe Glu Gln Phe Ile Asp Arg Val Ile 130 135 140 Trp Glu Asn Phe Tyr Lys Pro Ile Val Tyr Ile Gly Thr Asp Ser Ala 145 150 155 160 Glu Glu Glu Glu Ile Leu Leu Glu Val Ser Leu Val Phe Lys Val Lys 165 170 175 Glu Phe Ala Pro Asp Ala Pro Leu Phe Thr Gly Pro Ala Tyr 180 185 190 <210> SEQ ID NO 63 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 63 Asn Thr Ile His Cys Tyr 1 5 <210> SEQ ID NO 64 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 64 Ala Leu Asp Ser Val Arg Cys 1 5 <210> SEQ ID NO 65 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 65 Phe Thr Asp Asn Cys Cys Thr Tyr Phe Asn Asn Ser Leu Asn Leu 1 5 10 15 <210> SEQ ID NO 66 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 66 Ser Leu Gly Trp Tyr Val Arg Ala Lys Ile Lys 1 5 10 <210> SEQ ID NO 67 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 67 Phe Ser Ala Ser Leu Tyr Leu Asn Leu Asn Ile Lys Ser Ser Ile Asp 1 5 10 15 Leu <210> SEQ ID NO 68 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 68 Asn Arg Phe Arg Leu Val Ser Asn Lys Gly Cys Phe Ser Glu Pro Met 1 5 10 15 Ala Gly Leu Ser Asn Gly Phe Ser Leu Asn Ala Thr Lys Leu Ala Lys 20 25 30 Ser Cys Ser Ser Asn Leu Ala Leu Ser Ile Phe Val Cys Val Leu Phe 35 40 45 Cys Asn Lys Gly Ser Thr Ser Phe Lys Ile Leu Cys Ala Phe Val Phe 50 55 60 Leu Ser Ser Leu Ser Leu Val Tyr Asn 65 70 <210> SEQ ID NO 69 <211> LENGTH: 196 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 69 Leu Asp Val Asn Thr Leu Asn Lys Ala Trp Thr Tyr Leu Thr Ser Gly 1 5 10 15 Val Leu Ala Leu Leu Gly Arg Leu Ser Ser Ser Ser Gln Pro Ser Ser 20 25 30 Leu Glu Val Ala Ser Glu Asp Asp Phe Ala Ile Ala Thr Arg Arg Leu 35 40 45 Leu Ile Val Ser Ala Asn Thr Ser Ala Ile Lys Phe Val Val Glu Leu 50 55 60 Phe Gly Ile Ile Ser Asp Cys Gly Arg Phe Trp Ala Gly Phe Asn Leu 65 70 75 80 Thr Val Pro Asp Phe Asn Ser Asp Asn Thr Leu Glu Ser Asp Gly Ala 85 90 95 Gly Gly Gly Asn Ile Ser Asp Gly Lys Ser Thr Asn Gly Gly Gly Gly 100 105 110 Gly Ala Asp Asp Lys Ser Thr Ile Gly Gly Gly Ala Gly Gly Ala Gly 115 120 125 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Asp Ala Asp Gly Gly Leu 130 135 140 Gly Ser Asn Val Ser Leu Gly Asn Thr Val Gly Thr Ser Thr Ile Val 145 150 155 160 Leu Val Ser Gly Ala Val Phe Gly Leu Thr Gly Leu Arg Arg Val Arg 165 170 175 Phe Phe Ser Phe Leu Ile Ala Ser Asn Asn Cys Cys Leu Ser Ser Lys 180 185 190 Gly Ala Ala Gly 195 <210> SEQ ID NO 70 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 70 Gly Ser Val Gly Ile Gly Gly Ala Gly Gly Asn Ser Asp Ile Asp Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ala Gly Met Leu Gly Thr Gly Glu Gly Gly 20 25 30 Gly Gly Gly Ala Ala Gly Ile Ile Cys Ser Gly Leu Val Cys Ser Arg 35 40 45 Thr Ile Val Gly Thr Gly Ala Gly Ala Ala Gly Cys Thr Thr Glu Gly 50 55 60 Arg Leu Leu Arg Gly Ser Ala Trp Gly Gly Gly Asn Ser Ile Leu 65 70 75 <210> SEQ ID NO 71 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 71 Leu Glu Tyr Lys Ser 1 5 <210> SEQ ID NO 72 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 72 Lys Ser Ala Ile Ser Ile Val Ile Ser Leu Ser Phe Thr Val Pro Ile 1 5 10 15 Phe Asn Asn Arg Ser Met 20 <210> SEQ ID NO 73 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 73 Ala Ile Val Leu 1 <210> SEQ ID NO 74 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 74 Arg Asp Cys Leu Lys Leu Arg Thr Pro Ile Thr Ser Leu Phe Ile Phe 1 5 10 15 Thr Thr Ala Leu 20 <210> SEQ ID NO 75 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 75 Trp Arg Asp Thr Ser Leu Ser Ser Thr Tyr Met Tyr Ala Leu Leu Ser 1 5 10 15 Lys Thr Ser Leu Ala Ser Phe Lys Ile Phe Lys Arg Thr Ser Leu Phe 20 25 30 Ser Thr Thr Val Leu Ser 35 <210> SEQ ID NO 76 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 76 Met Leu Phe Leu Ile Ile Cys Ala Ser Ala Val Ser Thr Arg Ser Lys 1 5 10 15 Asn <210> SEQ ID NO 77 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 77 Cys Ala Ser Ile Leu Leu Phe Leu Leu Leu Asn Lys 1 5 10 <210> SEQ ID NO 78 <211> LENGTH: 206 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 78 Asp Cys Thr Asp Ser Tyr Leu Arg Phe Val Met Ala Thr Thr Asn Ala 1 5 10 15 Thr Leu Gln Thr Leu Val Gln Phe Tyr Glu Asn Cys Lys Asn Val Lys 20 25 30 Thr Arg Tyr Lys Ile Ile Asn Gly Arg Phe Gly Lys Ile Ser Ile Leu 35 40 45 Ser His Lys Pro Thr Ser Lys Leu Tyr Leu Gln Lys Thr Ile Ser Ala 50 55 60 His Asn Phe Asn Ala Asp Glu Ile Lys Val His Gln Leu Met Ser Asp 65 70 75 80 His Pro Asn Phe Ile Lys Ile Tyr Phe Asn His Gly Ser Ile Asn Asn 85 90 95 Gln Val Ile Val Met Asp Tyr Ile Asp Cys Pro Asp Leu Phe Glu Thr 100 105 110 Leu Gln Ile Lys Gly Glu Leu Ser Tyr Gln Leu Val Ser Asn Ile Ile 115 120 125 Arg Gln Leu Cys Glu Ala Leu Asn Asp Leu His Lys His Asn Phe Ile 130 135 140 His Asn Asp Ile Lys Leu Glu Asn Val Leu Tyr Phe Glu Ala Leu Asp 145 150 155 160 Arg Val Tyr Val Cys Asp Tyr Gly Leu Cys Lys His Glu Asn Ser Leu 165 170 175 Ser Val His Asp Gly Thr Leu Glu Tyr Phe Ser Pro Glu Lys Ile Arg 180 185 190 His Thr Thr Met His Val Ser Phe Asp Trp Tyr Ala Ala Cys 195 200 205 <210> SEQ ID NO 79 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 79 His Thr Ser Cys 1 <210> SEQ ID NO 80 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 80 Pro Ala Val Arg Asn His Gly His Ser Cys Phe Leu Cys Glu Ile Val 1 5 10 15 Ile Arg Ser Gln Phe His Thr Thr Tyr Glu Pro Glu Ala 20 25 <210> SEQ ID NO 81 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 81 Ser Val Lys Pro Gly Val Pro Asn Glu 1 5 <210> SEQ ID NO 82 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 82 Ala Asn Ser His 1 <210> SEQ ID NO 83 <211> LENGTH: 61 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 83 Leu Arg Cys Ala His Cys Pro Leu Ser Ser Arg Glu Thr Cys Arg Ala 1 5 10 15 Ser Cys Ile Asn Glu Ser Ala Asn Ala Arg Gly Glu Ala Val Cys Val 20 25 30 Leu Gly Ala Leu Pro Leu Pro Arg Ser Leu Thr Arg Cys Ala Arg Ser 35 40 45 Phe Gly Cys Gly Glu Arg Tyr Gln Leu Thr Gln Arg Arg 50 55 60 <210> SEQ ID NO 84 <211> LENGTH: 141 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 84 Tyr Gly Tyr Pro Gln Asn Gln Gly Ile Thr Gln Glu Arg Thr Cys Glu 1 5 10 15 Gln Lys Ala Ser Lys Arg Pro Gly Thr Val Lys Arg Pro Arg Cys Trp 20 25 30 Arg Phe Ser Ile Gly Ser Ala Pro Leu Thr Ser Ile Thr Lys Ile Asp 35 40 45 Ala Gln Val Arg Gly Gly Glu Thr Arg Gln Asp Tyr Lys Asp Thr Arg 50 55 60 Arg Phe Pro Leu Glu Ala Pro Ser Cys Ala Leu Leu Phe Arg Pro Cys 65 70 75 80 Arg Leu Pro Asp Thr Cys Pro Pro Phe Ser Leu Arg Glu Ala Trp Arg 85 90 95 Phe Leu Ile Ala His Ala Val Gly Ile Ser Val Arg Cys Arg Ser Phe 100 105 110 Ala Pro Ser Trp Ala Val Cys Thr Asn Pro Pro Phe Ser Pro Thr Ala 115 120 125 Ala Pro Tyr Pro Val Thr Ile Val Leu Ser Pro Thr Arg 130 135 140 <210> SEQ ID NO 85 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 85 Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val Thr Gly Leu Ala 1 5 10 15 Glu Arg Gly Met 20 <210> SEQ ID NO 86 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 86 Ala Val Leu Gln Ser Ser 1 5 <210> SEQ ID NO 87 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 87 Ser Gly Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val Ser 1 5 10 15 Ala Leu Cys <210> SEQ ID NO 88 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 ppeptie sequence <400> SEQUENCE: 88 Ser Gln Leu Pro Ser Glu Lys Glu Leu Val Ala Leu Asp Pro Ala Asn 1 5 10 15 Lys Pro Pro Leu Val Ala Val Val Phe Leu Phe Ala Ser Ser Arg Leu 20 25 30 Arg Ala Glu Lys Lys Asp Leu Lys Lys Ile Leu 35 40 <210> SEQ ID NO 89 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 89 Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr Lys Thr His Val Lys 1 5 10 15 Gly Phe Trp Ser 20 <210> SEQ ID NO 90 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 90 Asp Tyr Gln Lys Gly Ser Ser Pro Arg Ser Phe 1 5 10 <210> SEQ ID NO 91 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 91 Ile Lys Asn Glu Val Leu Asn Gln Ser Lys Val Tyr Met Ser Lys Leu 1 5 10 15 Gly Leu Thr Val Thr Asn Ala 20 <210> SEQ ID NO 92 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 92 Ser Val Arg His Leu Ser Gln Arg Ser Val Tyr Phe Val His Pro 1 5 10 15 <210> SEQ ID NO 93 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 93 Leu Pro Asp Ser Pro Ser Cys Arg 1 5 <210> SEQ ID NO 94 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 94 Leu Arg Tyr Gly Arg Ala Tyr His Leu Ala Pro Val Leu Gln 1 5 10 <210> SEQ ID NO 95 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 95 Tyr Arg Glu Thr His Ala His Arg Leu Gln Ile Tyr Gln Gln 1 5 10 <210> SEQ ID NO 96 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 96 Thr Ser Gln Pro Glu Gly Pro Ser Ala Glu Val Val Leu Gln Leu Tyr 1 5 10 15 Pro Pro Pro Ser Ser Leu Leu Ile Val Ala Gly Lys Leu Glu 20 25 30 <210> SEQ ID NO 97 <211> LENGTH: 85 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 97 Val Val Arg Gln Leu Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln 1 5 10 15 Ala Ser Trp Cys His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro 20 25 30 Val Pro Asn Asp Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys 35 40 45 Lys Arg Leu Ala Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser Trp 50 55 60 Pro Gln Cys Tyr His Ser Trp Leu Trp Gln His Cys Ile Ile Leu Leu 65 70 75 80 Leu Ser Cys His Pro 85 <210> SEQ ID NO 98 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 98 Asp Ala Phe Leu 1 <210> SEQ ID NO 99 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 99 Leu Val Ser Thr Gln Pro Ser His Ser Glu Asn Ser Val Cys Gly Asp 1 5 10 15 Arg Val Ala Leu Ala Arg Arg Gln Tyr Gly Ile Ile Pro Arg His Ile 20 25 30 Ala Glu Leu 35 <210> SEQ ID NO 100 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 100 Lys Cys Ser Ser Leu Glu Asn Val Leu Arg Gly Glu Asn Ser Gln Gly 1 5 10 15 Ser Tyr Arg Cys 20 <210> SEQ ID NO 101 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 101 Asp Pro Val Arg Cys Asn Pro Leu Val His Pro Thr Asp Leu Gln His 1 5 10 15 Leu Leu Leu Ser Pro Ala Phe Leu Gly Glu Gln Lys Gln Glu Gly Lys 20 25 30 Met Pro Gln Lys Arg Glu 35 <210> SEQ ID NO 102 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 102 Gly Arg His Gly Asn Val Glu Tyr Ser Tyr Ser Ser Phe Phe Asn Ile 1 5 10 15 Ile Glu Ala Phe Ile Arg Val Ile Val Ser 20 25 <210> SEQ ID NO 103 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 103 Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys 1 5 10 <210> SEQ ID NO 104 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 104 Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys Lys 1 5 10 15 Pro Leu Leu Ser 20 <210> SEQ ID NO 105 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 105 Pro Ile Lys Ile Gly Val Ser Arg Gly Pro Phe Val Ser Arg Val Ser 1 5 10 15 Val Met Thr Val Lys Thr Ser Asp Thr Cys Ser Ser Arg Arg Arg Ser 20 25 30 Gln Leu Val Cys Lys Arg Met Pro Gly Ala Asp Lys Pro Val Arg Ala 35 40 45 Arg Gln Arg Val Leu Ala Gly Val Gly Ala Gly Leu Thr Met Arg His 50 55 60 Gln Ser Arg Leu Tyr 65 <210> SEQ ID NO 106 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 106 Glu Cys Thr Ile Cys Gly Val Lys Tyr Arg Thr Asp Ala 1 5 10 <210> SEQ ID NO 107 <211> LENGTH: 41 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 107 Gly Glu Asn Thr Ala Ser Gly Ala Ile Arg His Ser Gly Cys Ala Thr 1 5 10 15 Val Gly Lys Gly Asp Arg Cys Gly Pro Leu Arg Tyr Tyr Ala Ser Trp 20 25 30 Arg Lys Gly Asp Val Leu Gln Gly Asp 35 40 <210> SEQ ID NO 108 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv461 peptide sequence <400> SEQUENCE: 108 Arg Gln Gly Phe Pro Ser His Asp Val Val Lys Arg Arg Pro Val 1 5 10 15 <210> SEQ ID NO 109 <211> LENGTH: 10511 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 nucleotide sequence <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(10509) <400> SEQUENCE: 109 aag ctt tac tcg taa agc gag ttg aag gat cat att tag ttg cgt tta 48 Lys Leu Tyr Ser Ser Glu Leu Lys Asp His Ile Leu Arg Leu 1 5 10 tga gat aag att gaa agc acg tgt aaa atg ttt ccc gcg cgt tgg cac 96 Asp Lys Ile Glu Ser Thr Cys Lys Met Phe Pro Ala Arg Trp His 15 20 25 aac tat tta caa tgc ggc caa gtt ata aaa gat tct aat ctg ata tgt 144 Asn Tyr Leu Gln Cys Gly Gln Val Ile Lys Asp Ser Asn Leu Ile Cys 30 35 40 45 ttt aaa aca cct ttg cgg ccc gag ttg ttt gcg tac gtg act agc gaa 192 Phe Lys Thr Pro Leu Arg Pro Glu Leu Phe Ala Tyr Val Thr Ser Glu 50 55 60 gaa gat gtg tgg acc gca gaa cag ata gta aaa caa aac cct agt att 240 Glu Asp Val Trp Thr Ala Glu Gln Ile Val Lys Gln Asn Pro Ser Ile 65 70 75 gga gca ata atc gat tta acc aac acg tct aaa tat tat gat ggt gtg 288 Gly Ala Ile Ile Asp Leu Thr Asn Thr Ser Lys Tyr Tyr Asp Gly Val 80 85 90 cat ttt ttg cgg gcg ggc ctg tta tac aaa aaa att caa gta cct ggc 336 His Phe Leu Arg Ala Gly Leu Leu Tyr Lys Lys Ile Gln Val Pro Gly 95 100 105 cag act ttg ccg cct gaa agc ata gtt caa gaa ttt att gac acg gta 384 Gln Thr Leu Pro Pro Glu Ser Ile Val Gln Glu Phe Ile Asp Thr Val 110 115 120 125 aaa gaa ttt aca gaa aag tgt ccc ggc atg ttg gtg ggc gtg cac tgc 432 Lys Glu Phe Thr Glu Lys Cys Pro Gly Met Leu Val Gly Val His Cys 130 135 140 aca cac ggt att aat cgc acc ggt tac atg gtg tgc aga tat tta atg 480 Thr His Gly Ile Asn Arg Thr Gly Tyr Met Val Cys Arg Tyr Leu Met 145 150 155 cac acc ctg ggt att gcg ccg cag gaa gcc ata gat aga ttc gaa aaa 528 His Thr Leu Gly Ile Ala Pro Gln Glu Ala Ile Asp Arg Phe Glu Lys 160 165 170 gcc aga ggt cac aaa att gaa aga caa aat tac gtt caa gat tta tta 576 Ala Arg Gly His Lys Ile Glu Arg Gln Asn Tyr Val Gln Asp Leu Leu 175 180 185 att taa tta ata tta ttt gca ttc ttt aac aaa tac ttt atc cta ttt 624 Ile Leu Ile Leu Phe Ala Phe Phe Asn Lys Tyr Phe Ile Leu Phe 190 195 200 tca aat tgt tgc gct tct tcc agc gaa cca aaa cta tgc ttc gct tgc 672 Ser Asn Cys Cys Ala Ser Ser Ser Glu Pro Lys Leu Cys Phe Ala Cys 205 210 215 220 tcc gtt tag ctt gta gcc gat cag tgg cgt tgt tcc aat cga cgg tag 720 Ser Val Leu Val Ala Asp Gln Trp Arg Cys Ser Asn Arg Arg 225 230 gat tag gcc gga tat tct cca cca caa tgt tgg caa cgt tga tgt tac 768 Asp Ala Gly Tyr Ser Pro Pro Gln Cys Trp Gln Arg Cys Tyr 235 240 245 gtt tat gct ttt ggt ttt cca cgt acg tct ttt ggc cgg taa tag ccg 816 Val Tyr Ala Phe Gly Phe Pro Arg Thr Ser Phe Gly Arg Pro 250 255 260 taa acg tag tgc cgt cgc gcg tca cgc aca aca ccg gat gtt tgc gct 864 Thr Cys Arg Arg Ala Ser Arg Thr Thr Pro Asp Val Cys Ala 265 270 275 tgt ccg cgg ggt att gaa ccg cgc gat ccg aca aat cca cca ctt tgg 912 Cys Pro Arg Gly Ile Glu Pro Arg Asp Pro Thr Asn Pro Pro Leu Trp 280 285 290 caa cta aat cgg tga cct gcg cgt ctt ttt tct gca tta ttt cgt ctt 960 Gln Leu Asn Arg Pro Ala Arg Leu Phe Ser Ala Leu Phe Arg Leu 295 300 305 tct ttt gca tgg ttt cct gga agc cgg tgt aca tgc ggt tta gat cag 1008 Ser Phe Ala Trp Phe Pro Gly Ser Arg Cys Thr Cys Gly Leu Asp Gln 310 315 320 tca tga cgc gcg tga cct gca aat ctt tgg cct cga tct gct tgt cct 1056 Ser Arg Ala Pro Ala Asn Leu Trp Pro Arg Ser Ala Cys Pro 325 330 335 tga tgg caa cga tgc gtt caa taa act ctt gtt ttt taa caa gtt cct 1104 Trp Gln Arg Cys Val Gln Thr Leu Val Phe Gln Val Pro 340 345 350 cgg ttt ttt gcg cca cca ccg ctt gca gcg cgt ttg tgt gct cgg tga 1152 Arg Phe Phe Ala Pro Pro Pro Leu Ala Ala Arg Leu Cys Ala Arg 355 360 365 atg tcg caa tca gct tag tca cca act gtt tgc tct cct cct ccc gtt 1200 Met Ser Gln Ser Ala Ser Pro Thr Val Cys Ser Pro Pro Pro Val 370 375 380 gtt tga tcg cgg gat cgt act tgc cgg tgc aga gca ctt gag gaa tta 1248 Val Ser Arg Asp Arg Thr Cys Arg Cys Arg Ala Leu Glu Glu Leu 385 390 395 ctt ctt cta aaa gcc att ctt gta att cta tgg cgt aag gca att tgg 1296 Leu Leu Leu Lys Ala Ile Leu Val Ile Leu Trp Arg Lys Ala Ile Trp 400 405 410 act tca taa tca gct gaa tca cgc cgg att tag taa tga gca ctg tat 1344 Thr Ser Ser Ala Glu Ser Arg Arg Ile Ala Leu Tyr 415 420 gcg gct gca aat aca gcg ggt cgc ccc ttt tca cga cgc tgt tag agg 1392 Ala Ala Ala Asn Thr Ala Gly Arg Pro Phe Ser Arg Arg Cys Arg 425 430 435 tag ggc ccc cat ttt gga tgg tct gct caa ata acg att tgt att tat 1440 Gly Pro His Phe Gly Trp Ser Ala Gln Ile Thr Ile Cys Ile Tyr 440 445 450 tgt cta cat gaa cac gta tag ctt tat cac aaa ctg tat att tta aac 1488 Cys Leu His Glu His Val Leu Tyr His Lys Leu Tyr Ile Leu Asn 455 460 465 tgt tag cga cgt cct tgg cca cga acc gga cct gtt ggt cgc gct cta 1536 Cys Arg Arg Pro Trp Pro Arg Thr Gly Pro Val Gly Arg Ala Leu 470 475 480 gca cgt acc gca ggt tga acg tat ctt ctc caa att taa att ctc caa 1584 Ala Arg Thr Ala Gly Thr Tyr Leu Leu Gln Ile Ile Leu Gln 485 490 495 ttt taa cgc gag cca ttt tga tac acg tgt gtc gat ttt gca aca act 1632 Phe Arg Glu Pro Phe Tyr Thr Cys Val Asp Phe Ala Thr Thr 500 505 510 att gtt ttt taa cgc aaa cta aac tta ttg tgg taa gca ata att aaa 1680 Ile Val Phe Arg Lys Leu Asn Leu Leu Trp Ala Ile Ile Lys 515 520 525 tat ggg gga aca tgc gcc gct aca aca ctc gtc gtt atg aac gca gac 1728 Tyr Gly Gly Thr Cys Ala Ala Thr Thr Leu Val Val Met Asn Ala Asp 530 535 540 ggc gcc ggt ctc ggc gca agc ggc taa aac gtg ttg cgc gtt caa cgc 1776 Gly Ala Gly Leu Gly Ala Ser Gly Asn Val Leu Arg Val Gln Arg 545 550 555 ggc aaa cat cgc aaa agc caa tag tac agt ttt gat ttg cat att aac 1824 Gly Lys His Arg Lys Ser Gln Tyr Ser Phe Asp Leu His Ile Asn 560 565 570 ggc gat ttt tta aat tat ctt att taa taa ata gtt atg acg cct aca 1872 Gly Asp Phe Leu Asn Tyr Leu Ile Ile Val Met Thr Pro Thr 575 580 585 act ccc cgc ccg cgt tga ctc gct gca cct cga gca gtt cgt tga cgc 1920 Thr Pro Arg Pro Arg Leu Ala Ala Pro Arg Ala Val Arg Arg 590 595 ctt cct ccg tgt ggc cga aca cgt cga gcg ggt ggt cga tga cca gcg 1968 Leu Pro Pro Cys Gly Arg Thr Arg Arg Ala Gly Gly Arg Pro Ala 600 605 610 gcg tgc cgc acg cga cgc aca agt atc tgt aca ccg aat gat cgt cgg 2016 Ala Cys Arg Thr Arg Arg Thr Ser Ile Cys Thr Pro Asn Asp Arg Arg 615 620 625 630 gcg aag gca cgt cgg cct cca agt ggc aat att ggc aaa ttc gaa aat 2064 Ala Lys Ala Arg Arg Pro Pro Ser Gly Asn Ile Gly Lys Phe Glu Asn 635 640 645 ata tac agt tgg gtt gtt tgc gca tat cta tcg tgg cgt tgg gca tgt 2112 Ile Tyr Ser Trp Val Val Cys Ala Tyr Leu Ser Trp Arg Trp Ala Cys 650 655 660 acg tcc gaa cgt tga ttt gca tgc aag ccg aaa tta aat cat tgc gat 2160 Thr Ser Glu Arg Phe Ala Cys Lys Pro Lys Leu Asn His Cys Asp 665 670 675 tag tgc gat taa aac gtt gta cat cct cgc ttt taa tca tgc cgt cga 2208 Cys Asp Asn Val Val His Pro Arg Phe Ser Cys Arg Arg 680 685 690 tta aat cgc gca atc gag tca agt gat caa agt gtg gaa taa tgt ttt 2256 Leu Asn Arg Ala Ile Glu Ser Ser Asp Gln Ser Val Glu Cys Phe 695 700 705 ctt tgt att ccc gag tca agc gca gcg cgt att tta aca aac tag cca 2304 Leu Cys Ile Pro Glu Ser Ser Ala Ala Arg Ile Leu Thr Asn Pro 710 715 720 tct tgt aag tta gtt tca ttt aat gca act tta tcc aat aat ata tta 2352 Ser Cys Lys Leu Val Ser Phe Asn Ala Thr Leu Ser Asn Asn Ile Leu 725 730 735 tgt atc gca cgt caa gaa tta aca atg cgc ccg ttg tcg cat ctc aac 2400 Cys Ile Ala Arg Gln Glu Leu Thr Met Arg Pro Leu Ser His Leu Asn 740 745 750 acg act atg ata gag atc aaa taa agc gcg aat taa ata gct tgc gac 2448 Thr Thr Met Ile Glu Ile Lys Ser Ala Asn Ile Ala Cys Asp 755 760 765 gca acg tgc acg atc tgt gca cgc gtt ccg gca cga gct ttg att gta 2496 Ala Thr Cys Thr Ile Cys Ala Arg Val Pro Ala Arg Ala Leu Ile Val 770 775 780 ata agt ttt tac gaa gcg atg aca tga ccc ccg tag tga caa cga tca 2544 Ile Ser Phe Tyr Glu Ala Met Thr Pro Pro Gln Arg Ser 785 790 795 cgc cca aaa gaa ctg ccg act aca aaa tta ccg agt atg tcg gtg acg 2592 Arg Pro Lys Glu Leu Pro Thr Thr Lys Leu Pro Ser Met Ser Val Thr 800 805 810 tta aaa cta tta agc cat cca atc gac cgt tag tcg aat cag gac cgc 2640 Leu Lys Leu Leu Ser His Pro Ile Asp Arg Ser Asn Gln Asp Arg 815 820 825 tgg tgc gag aag ccg cga agt atg gcg aat gca tcg tat aac gtg tgg 2688 Trp Cys Glu Lys Pro Arg Ser Met Ala Asn Ala Ser Tyr Asn Val Trp 830 835 840 agt ccg ctc att aga gcg tca tgt tta gac aag aaa gct aca tat tta 2736 Ser Pro Leu Ile Arg Ala Ser Cys Leu Asp Lys Lys Ala Thr Tyr Leu 845 850 855 att gat ccc gat gat ttt att gat aaa ttg acc cta act cca tac acg 2784 Ile Asp Pro Asp Asp Phe Ile Asp Lys Leu Thr Leu Thr Pro Tyr Thr 860 865 870 gta ttc tac aat ggc ggg gtt ttg gtc aaa att tcc gga ctg cga ttg 2832 Val Phe Tyr Asn Gly Gly Val Leu Val Lys Ile Ser Gly Leu Arg Leu 875 880 885 890 tac atg ctg tta acg gct ccg ccc act att aat gaa att aaa aat tcc 2880 Tyr Met Leu Leu Thr Ala Pro Pro Thr Ile Asn Glu Ile Lys Asn Ser 895 900 905 aat ttt aaa aaa cgc agc aag aga aac att tgt atg aaa gaa tgc gta 2928 Asn Phe Lys Lys Arg Ser Lys Arg Asn Ile Cys Met Lys Glu Cys Val 910 915 920 gaa gga aag aaa aat gtc gtc gac atg ctg aac aac aag att aat atg 2976 Glu Gly Lys Lys Asn Val Val Asp Met Leu Asn Asn Lys Ile Asn Met 925 930 935 cct ccg tgt ata aaa aaa ata ttg aac gat ttg aaa gaa aac aat gta 3024 Pro Pro Cys Ile Lys Lys Ile Leu Asn Asp Leu Lys Glu Asn Asn Val 940 945 950 ccg cgc ggc ggt atg tac agg aag agg ttt ata cta aac tgt tac att 3072 Pro Arg Gly Gly Met Tyr Arg Lys Arg Phe Ile Leu Asn Cys Tyr Ile 955 960 965 970 gca aac gtg gtt tcg tgt gcc aag tgt gaa aac cga tgt tta atc aag 3120 Ala Asn Val Val Ser Cys Ala Lys Cys Glu Asn Arg Cys Leu Ile Lys 975 980 985 gct ctg acg cat ttc tac aac cac gac tcc aag tgt gtg ggt gaa gtc 3168 Ala Leu Thr His Phe Tyr Asn His Asp Ser Lys Cys Val Gly Glu Val 990 995 1000 atg cat ctt tta atc aaa tcc caa gat gtg tat aaa cca cca aac 3213 Met His Leu Leu Ile Lys Ser Gln Asp Val Tyr Lys Pro Pro Asn 1005 1010 1015 tgc caa aaa atg aaa act gtc gac aag ctc tgt ccg ttt gct ggc 3258 Cys Gln Lys Met Lys Thr Val Asp Lys Leu Cys Pro Phe Ala Gly 1020 1025 1030 aac tgc aag ggt ctc aat cct att tgt aat tat tga ata ata aaa 3303 Asn Cys Lys Gly Leu Asn Pro Ile Cys Asn Tyr Ile Ile Lys 1035 1040 1045 caa tta taa atg cta aat ttg ttt ttt att aac gat aca aac caa 3348 Gln Leu Met Leu Asn Leu Phe Phe Ile Asn Asp Thr Asn Gln 1050 1055 1060 acg caa caa gaa cat ttg tag tat tat cta taa ttg aaa acg cgt agt 3396 Thr Gln Gln Glu His Leu Tyr Tyr Leu Leu Lys Thr Arg Ser 1065 1070 tat aat cgc tga ggt aat att taa aat cat ttt caa atg att cac 3441 Tyr Asn Arg Gly Asn Ile Asn His Phe Gln Met Ile His 1075 1080 1085 agt taa ttt gcg aca ata taa ttt tat ttt cac ata aac tag acg 3486 Ser Phe Ala Thr Ile Phe Tyr Phe His Ile Asn Thr 1090 1095 cct tgt cgt ctt ctt ctt cgt att cct tct ctt ttt cat ttt tct 3531 Pro Cys Arg Leu Leu Leu Arg Ile Pro Ser Leu Phe His Phe Ser 1100 1105 1110 cct cat aaa aat taa cat agt tat tat cgt atc cat ata tgt atc 3576 Pro His Lys Asn His Ser Tyr Tyr Arg Ile His Ile Cys Ile 1115 1120 1125 tat cgt ata gag taa att ttt tgt tgt cat aaa tat ata tgt ctt 3621 Tyr Arg Ile Glu Ile Phe Cys Cys His Lys Tyr Ile Cys Leu 1130 1135 1140 ttt taa tgg ggt gta tag tac cgc tgc gca tag ttt ttc tgt aat 3666 Phe Trp Gly Val Tyr Arg Cys Ala Phe Phe Cys Asn 1145 1150 tta caa cag tgc tat ttt ctg gta gtt ctt cgg agt gtg ttg ctt 3711 Leu Gln Gln Cys Tyr Phe Leu Val Val Leu Arg Ser Val Leu Leu 1155 1160 1165 taa tta tta aat tta tat aat caa tga att tgg gat cgt cgg ttt 3756 Leu Leu Asn Leu Tyr Asn Gln Ile Trp Asp Arg Arg Phe 1170 1175 1180 tgt aca ata tgt tgc cgg cat agt acg cag ctt ctt cta gtt caa 3801 Cys Thr Ile Cys Cys Arg His Ser Thr Gln Leu Leu Leu Val Gln 1185 1190 1195 tta cac cat ttt tta gca gca ccg gat taa cat aac ttt cca aaa 3846 Leu His His Phe Leu Ala Ala Pro Asp His Asn Phe Pro Lys 1200 1205 1210 tgt tgt acg aac cgt taa aca aaa aca gtt cac ctc cct ttt cta 3891 Cys Cys Thr Asn Arg Thr Lys Thr Val His Leu Pro Phe Leu 1215 1220 1225 tac tat tgt ctg cga gca gtt gtt tgt tgt taa aaa taa cag cca ttg 3939 Tyr Tyr Cys Leu Arg Ala Val Val Cys Cys Lys Gln Pro Leu 1230 1235 taa tga gac gca caa act aat atc aca aac tgg aaa tgt cta tca 3984 Asp Ala Gln Thr Asn Ile Thr Asn Trp Lys Cys Leu Ser 1240 1245 1250 ata tat agt tgc tga tat cat gga gat aat taa aat gat aac cat 4029 Ile Tyr Ser Cys Tyr His Gly Asp Asn Asn Asp Asn His 1255 1260 1265 ctc gca aat aaa taa gta ttt tac tgt ttt cgt aac agt ttt gta 4074 Leu Ala Asn Lys Val Phe Tyr Cys Phe Arg Asn Ser Phe Val 1270 1275 ata aaa aaa cct ata aat att ccg gat tat tca tac cgt ccc acc 4119 Ile Lys Lys Pro Ile Asn Ile Pro Asp Tyr Ser Tyr Arg Pro Thr 1280 1285 1290 atc ggg cgc gga tct atg cta cta gta aat cag tca cac caa ggc 4164 Ile Gly Arg Gly Ser Met Leu Leu Val Asn Gln Ser His Gln Gly 1295 1300 1305 ttc aat aag gaa cac aca agc aag atg gta agc gct att gtt tta 4209 Phe Asn Lys Glu His Thr Ser Lys Met Val Ser Ala Ile Val Leu 1310 1315 1320 tat gtg ctt ttg gcg gcg gcg gcg cat tct gcc ttt gcg gcg gat 4254 Tyr Val Leu Leu Ala Ala Ala Ala His Ser Ala Phe Ala Ala Asp 1325 1330 1335 ctt gga tcc cat cat cac cac cac cac att gaa gga aga gaa ttc 4299 Leu Gly Ser His His His His His His Ile Glu Gly Arg Glu Phe 1340 1345 1350 cag gtc caa ctg cag cag tct ggg gct gaa ctg gca aaa cct ggg 4344 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly 1355 1360 1365 gcc tca gtg aag ctg tcc tgc aag gct tct ggc cac acc ttt act 4389 Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly His Thr Phe Thr 1370 1375 1380 agc tac tgg atg cac tgg gta aaa cag agg cct gga cag ggt ctg 4434 Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 1385 1390 1395 gaa tgg att gga tac att aat ctt agc agt ggt tat att aag tac 4479 Glu Trp Ile Gly Tyr Ile Asn Leu Ser Ser Gly Tyr Ile Lys Tyr 1400 1405 1410 aat cag gag ttc aag gac aag gcc aca ttg act gca gac aaa tcc 4524 Asn Gln Glu Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser 1415 1420 1425 tcc aac aca gcc tac atg cat ctg agc agc ctg aca tat gag gac 4569 Ser Asn Thr Ala Tyr Met His Leu Ser Ser Leu Thr Tyr Glu Asp 1430 1435 1440 tct gca gtc tat tac tgt gca agg gca gct cag gct acg acc ttt 4614 Ser Ala Val Tyr Tyr Cys Ala Arg Ala Ala Gln Ala Thr Thr Phe 1445 1450 1455 gac tac tgg ggc caa ggc acc act ctc aca gtc tcc tca ggt gga 4659 Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly 1460 1465 1470 ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg gac att 4704 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 1475 1480 1485 gtg atg atc cag tct cac aaa ttc atg tcc aca tca gta gga gac 4749 Val Met Ile Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp 1490 1495 1500 agg gtc agc atc acc tgc aag gcc agt cag gat gtg agt act gct 4794 Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 1505 1510 1515 gta ggc tgg tat caa caa aaa cca ggg caa tct cct aaa cta ctg 4839 Val Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu 1520 1525 1530 att tac tgg gca tcc acc cgg cac act gga gtc cct gat cgc ttc 4884 Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe 1535 1540 1545 aca ggc agt gga tct ggg aca gat tat act ctc acc atc agc agt 4929 Thr Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser 1550 1555 1560 gtg cag gct gaa gac ctg gca ctt tat tac tgt cag caa cat tat 4974 Val Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr 1565 1570 1575 agc act cct ccg acg ttc ggt gga ggc acc aag ctg gga atc aaa 5019 Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Gly Ile Lys 1580 1585 1590 cgg gct ccc ggg gga tgt taa aga tct gat cct ttc ctg gga ccc 5064 Arg Ala Pro Gly Gly Cys Arg Ser Asp Pro Phe Leu Gly Pro 1595 1600 1605 ggc aag aac caa aaa ctc act ctc ttc aag gaa atc cgt aat gtt 5109 Gly Lys Asn Gln Lys Leu Thr Leu Phe Lys Glu Ile Arg Asn Val 1610 1615 1620 aaa ccc gac acg atg aag ctt gtc gtt gga tgg aaa gga aaa gag 5154 Lys Pro Asp Thr Met Lys Leu Val Val Gly Trp Lys Gly Lys Glu 1625 1630 1635 ttc tac agg gaa act tgg acc cgc ttc atg gaa gac agc ttc ccc 5199 Phe Tyr Arg Glu Thr Trp Thr Arg Phe Met Glu Asp Ser Phe Pro 1640 1645 1650 att gtt aac gac caa gaa gtg atg gat gtt ttc ctt gtt gtc aac 5244 Ile Val Asn Asp Gln Glu Val Met Asp Val Phe Leu Val Val Asn 1655 1660 1665 atg cgt ccc act aga ccc aac cgt tgt tac aaa ttc ctg gcc caa 5289 Met Arg Pro Thr Arg Pro Asn Arg Cys Tyr Lys Phe Leu Ala Gln 1670 1675 1680 cac gct ctg cgt tgc gac ccc gac tat gta cct cat gac gtg att 5334 His Ala Leu Arg Cys Asp Pro Asp Tyr Val Pro His Asp Val Ile 1685 1690 1695 agg atc gtc gag cct tca tgg gtg ggc agc aac aac gag tac cgc 5379 Arg Ile Val Glu Pro Ser Trp Val Gly Ser Asn Asn Glu Tyr Arg 1700 1705 1710 atc agc ctg gct aag aag ggc ggc ggc tgc cca ata atg aac ctt 5424 Ile Ser Leu Ala Lys Lys Gly Gly Gly Cys Pro Ile Met Asn Leu 1715 1720 1725 cac tct gag tac acc aac tcg ttc gaa cag ttc atc gat cgt gtc 5469 His Ser Glu Tyr Thr Asn Ser Phe Glu Gln Phe Ile Asp Arg Val 1730 1735 1740 atc tgg gag aac ttc tac aag ccc atc gtt tac atc ggt acc gac 5514 Ile Trp Glu Asn Phe Tyr Lys Pro Ile Val Tyr Ile Gly Thr Asp 1745 1750 1755 tct gct gaa gag gag gaa att ctc ctt gaa gtt tcc ctg gtg ttc 5559 Ser Ala Glu Glu Glu Glu Ile Leu Leu Glu Val Ser Leu Val Phe 1760 1765 1770 aaa gta aag gag ttt gca cca gac gca cct ctg ttc act ggt ccg 5604 Lys Val Lys Glu Phe Ala Pro Asp Ala Pro Leu Phe Thr Gly Pro 1775 1780 1785 gcg tat taa aac acg ata cat tgt tat tag tac att tat taa gcg 5649 Ala Tyr Asn Thr Ile His Cys Tyr Tyr Ile Tyr Ala 1790 1795 1800 cta gat tct gtg cgt tgt tga ttt aca gac aat tgt tgt acg tat 5694 Leu Asp Ser Val Arg Cys Phe Thr Asp Asn Cys Cys Thr Tyr 1805 1810 ttt aat aat tca tta aat tta taa tct tta ggg tgg tat gtt aga 5739 Phe Asn Asn Ser Leu Asn Leu Ser Leu Gly Trp Tyr Val Arg 1815 1820 1825 gcg aaa atc aaa tga ttt tca gcg tct tta tat ctg aat tta aat 5784 Ala Lys Ile Lys Phe Ser Ala Ser Leu Tyr Leu Asn Leu Asn 1830 1835 1840 att aaa tcc tca ata gat ttg taa aat agg ttt cga tta gtt tca 5829 Ile Lys Ser Ser Ile Asp Leu Asn Arg Phe Arg Leu Val Ser 1845 1850 1855 aac aag ggt tgt ttt tcc gaa ccg atg gct gga cta tct aat gga 5874 Asn Lys Gly Cys Phe Ser Glu Pro Met Ala Gly Leu Ser Asn Gly 1860 1865 1870 ttt tcg ctc aac gcc aca aaa ctt gcc aaa tct tgt agc agc aat 5919 Phe Ser Leu Asn Ala Thr Lys Leu Ala Lys Ser Cys Ser Ser Asn 1875 1880 1885 cta gct ttg tcg ata ttc gtt tgt gtt ttg ttt tgt aat aaa ggt 5964 Leu Ala Leu Ser Ile Phe Val Cys Val Leu Phe Cys Asn Lys Gly 1890 1895 1900 tcg acg tcg ttc aaa ata tta tgc gct ttt gta ttt ctt tca tca 6009 Ser Thr Ser Phe Lys Ile Leu Cys Ala Phe Val Phe Leu Ser Ser 1905 1910 1915 ctg tcg tta gtg tac aat tga ctc gac gta aac acg tta aat aaa 6054 Leu Ser Leu Val Tyr Asn Leu Asp Val Asn Thr Leu Asn Lys 1920 1925 1930 gct tgg aca tat tta aca tcg ggc gtg tta gct tta tta ggc cga 6099 Ala Trp Thr Tyr Leu Thr Ser Gly Val Leu Ala Leu Leu Gly Arg 1935 1940 1945 tta tcg tcg tcg tcc caa ccc tcg tcg tta gaa gtt gct tcc gaa 6144 Leu Ser Ser Ser Ser Gln Pro Ser Ser Leu Glu Val Ala Ser Glu 1950 1955 1960 gac gat ttt gcc ata gcc aca cga cgc cta tta att gtg tcg gct 6189 Asp Asp Phe Ala Ile Ala Thr Arg Arg Leu Leu Ile Val Ser Ala 1965 1970 1975 aac acg tcc gcg atc aaa ttt gta gtt gag ctt ttt gga att att 6234 Asn Thr Ser Ala Ile Lys Phe Val Val Glu Leu Phe Gly Ile Ile 1980 1985 1990 tct gat tgc ggg cgt ttt tgg gcg ggt ttc aat cta act gtg ccc 6279 Ser Asp Cys Gly Arg Phe Trp Ala Gly Phe Asn Leu Thr Val Pro 1995 2000 2005 gat ttt aat tca gac aac acg tta gaa agc gat ggt gca ggc ggt 6324 Asp Phe Asn Ser Asp Asn Thr Leu Glu Ser Asp Gly Ala Gly Gly 2010 2015 2020 ggt aac att tca gac ggc aaa tct act aat ggc ggc ggt ggt gga 6369 Gly Asn Ile Ser Asp Gly Lys Ser Thr Asn Gly Gly Gly Gly Gly 2025 2030 2035 gct gat gat aaa tct acc atc ggt gga ggc gca ggc ggg gct ggc 6414 Ala Asp Asp Lys Ser Thr Ile Gly Gly Gly Ala Gly Gly Ala Gly 2040 2045 2050 ggc gga ggc gga ggc gga ggt ggt ggc ggt gat gca gac ggc ggt 6459 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Asp Ala Asp Gly Gly 2055 2060 2065 tta ggc tca aat gtc tct tta ggc aac aca gtc ggc acc tca act 6504 Leu Gly Ser Asn Val Ser Leu Gly Asn Thr Val Gly Thr Ser Thr 2070 2075 2080 att gta ctg gtt tcg ggc gcc gtt ttt ggt ttg acc ggt ctg aga 6549 Ile Val Leu Val Ser Gly Ala Val Phe Gly Leu Thr Gly Leu Arg 2085 2090 2095 cga gtg cga ttt ttt tcg ttt cta ata gct tcc aac aat tgt tgt 6594 Arg Val Arg Phe Phe Ser Phe Leu Ile Ala Ser Asn Asn Cys Cys 2100 2105 2110 ctg tcg tct aaa ggt gca gcg ggt tga ggt tcc gtc ggc att ggt 6639 Leu Ser Ser Lys Gly Ala Ala Gly Gly Ser Val Gly Ile Gly 2115 2120 gga gcg ggc ggc aat tca gac atc gat ggt ggt ggt ggt ggt gga 6684 Gly Ala Gly Gly Asn Ser Asp Ile Asp Gly Gly Gly Gly Gly Gly 2125 2130 2135 ggc gct gga atg tta ggc acg gga gaa ggt ggt ggc ggc ggt gcc 6729 Gly Ala Gly Met Leu Gly Thr Gly Glu Gly Gly Gly Gly Gly Ala 2140 2145 2150 gcc ggt ata att tgt tct ggt tta gtt tgt tcg cgc acg att gtg 6774 Ala Gly Ile Ile Cys Ser Gly Leu Val Cys Ser Arg Thr Ile Val 2155 2160 2165 ggc acc ggc gca ggc gcc gct ggc tgc aca acg gaa ggt cgt ctg 6819 Gly Thr Gly Ala Gly Ala Ala Gly Cys Thr Thr Glu Gly Arg Leu 2170 2175 2180 ctt cga ggc agc gct tgg ggt ggt ggc aat tca ata tta taa ttg 6864 Leu Arg Gly Ser Ala Trp Gly Gly Gly Asn Ser Ile Leu Leu 2185 2190 2195 gaa tac aaa tcg taa aaa tct gct ata agc att gta att tcg cta 6909 Glu Tyr Lys Ser Lys Ser Ala Ile Ser Ile Val Ile Ser Leu 2200 2205 2210 tcg ttt acc gtg ccg ata ttt aac aac cgc tca atg taa gca att 6954 Ser Phe Thr Val Pro Ile Phe Asn Asn Arg Ser Met Ala Ile 2215 2220 2225 gta ttg taa aga gat tgt ctc aag ctc cgc acg ccg ata aca agc 6999 Val Leu Arg Asp Cys Leu Lys Leu Arg Thr Pro Ile Thr Ser 2230 2235 2240 ctt ttc att ttt act aca gca ttg tag tgg cga gac act tcg ctg 7044 Leu Phe Ile Phe Thr Thr Ala Leu Trp Arg Asp Thr Ser Leu 2245 2250 tcg tcg acg tac atg tat gct ttg ttg tca aaa acg tcg ttg gca 7089 Ser Ser Thr Tyr Met Tyr Ala Leu Leu Ser Lys Thr Ser Leu Ala 2255 2260 2265 agc ttt aaa ata ttt aaa aga aca tct ctg ttc agc acc act gtg 7134 Ser Phe Lys Ile Phe Lys Arg Thr Ser Leu Phe Ser Thr Thr Val 2270 2275 2280 ttg tcg taa atg ttg ttt ttg ata att tgc gct tcc gca gta tcg 7179 Leu Ser Met Leu Phe Leu Ile Ile Cys Ala Ser Ala Val Ser 2285 2290 2295 aca cgt tca aaa aat tga tgc gca tca att ttg ttg ttc cta tta 7224 Thr Arg Ser Lys Asn Cys Ala Ser Ile Leu Leu Phe Leu Leu 2300 2305 2310 ttg aat aaa taa gat tgt aca gat tca tat cta cga ttc gtc atg 7269 Leu Asn Lys Asp Cys Thr Asp Ser Tyr Leu Arg Phe Val Met 2315 2320 2325 gcc acc aca aat gct acg ctg caa acg ctg gta caa ttt tac gaa 7314 Ala Thr Thr Asn Ala Thr Leu Gln Thr Leu Val Gln Phe Tyr Glu 2330 2335 2340 aac tgc aaa aac gtc aaa act cgg tat aaa ata atc aac ggg cgc 7359 Asn Cys Lys Asn Val Lys Thr Arg Tyr Lys Ile Ile Asn Gly Arg 2345 2350 2355 ttt ggc aaa ata tct att tta tcg cac aag ccc act agc aaa ttg 7404 Phe Gly Lys Ile Ser Ile Leu Ser His Lys Pro Thr Ser Lys Leu 2360 2365 2370 tat ttg cag aaa aca att tcg gcg cac aat ttt aac gct gac gaa 7449 Tyr Leu Gln Lys Thr Ile Ser Ala His Asn Phe Asn Ala Asp Glu 2375 2380 2385 ata aaa gtt cac cag tta atg agc gac cac cca aat ttt ata aaa 7494 Ile Lys Val His Gln Leu Met Ser Asp His Pro Asn Phe Ile Lys 2390 2395 2400 atc tat ttt aat cac ggt tcc atc aac aac caa gtg atc gtg atg 7539 Ile Tyr Phe Asn His Gly Ser Ile Asn Asn Gln Val Ile Val Met 2405 2410 2415 gac tac att gac tgt ccc gat tta ttt gaa aca cta caa att aaa 7584 Asp Tyr Ile Asp Cys Pro Asp Leu Phe Glu Thr Leu Gln Ile Lys 2420 2425 2430 ggc gag ctt tcg tac caa ctt gtt agc aat att att aga cag ctg 7629 Gly Glu Leu Ser Tyr Gln Leu Val Ser Asn Ile Ile Arg Gln Leu 2435 2440 2445 tgt gaa gcg ctc aac gat ttg cac aag cac aat ttc ata cac aac 7674 Cys Glu Ala Leu Asn Asp Leu His Lys His Asn Phe Ile His Asn 2450 2455 2460 gac ata aaa ctc gaa aat gtc tta tat ttc gaa gca ctt gat cgc 7719 Asp Ile Lys Leu Glu Asn Val Leu Tyr Phe Glu Ala Leu Asp Arg 2465 2470 2475 gtg tat gtt tgc gat tac gga ttg tgc aaa cac gaa aac tca ctt 7764 Val Tyr Val Cys Asp Tyr Gly Leu Cys Lys His Glu Asn Ser Leu 2480 2485 2490 agc gtg cac gac ggc acg ttg gag tat ttt agt ccg gaa aaa att 7809 Ser Val His Asp Gly Thr Leu Glu Tyr Phe Ser Pro Glu Lys Ile 2495 2500 2505 cga cac aca act atg cac gtt tcg ttt gac tgg tac gcg gcg tgt 7854 Arg His Thr Thr Met His Val Ser Phe Asp Trp Tyr Ala Ala Cys 2510 2515 2520 taa cat aca agt tgc taa ccg gcg gtt cgt aat cat ggt cat agc 7899 His Thr Ser Cys Pro Ala Val Arg Asn His Gly His Ser 2525 2530 tgt ttc ctg tgt gaa att gtt atc cgc tca caa ttc cac aca aca 7944 Cys Phe Leu Cys Glu Ile Val Ile Arg Ser Gln Phe His Thr Thr 2535 2540 2545 tac gag ccg gaa gca taa agt gta aag cct ggg gtg cct aat gag 7989 Tyr Glu Pro Glu Ala Ser Val Lys Pro Gly Val Pro Asn Glu 2550 2555 2560 tga gct aac tca cat taa ttg cgt tgc gct cac tgc ccg ctt tcc 8034 Ala Asn Ser His Leu Arg Cys Ala His Cys Pro Leu Ser 2565 2570 2575 agt cgg gaa acc tgt cgt gcc agc tgc att aat gaa tcg gcc aac 8079 Ser Arg Glu Thr Cys Arg Ala Ser Cys Ile Asn Glu Ser Ala Asn 2580 2585 2590 gcg cgg gga gag gcg gtt tgc gta ttg ggc gct ctt ccg ctt cct 8124 Ala Arg Gly Glu Ala Val Cys Val Leu Gly Ala Leu Pro Leu Pro 2595 2600 2605 cgc tca ctg act cgc tgc gct cgg tcg ttc ggc tgc ggc gag cgg 8169 Arg Ser Leu Thr Arg Cys Ala Arg Ser Phe Gly Cys Gly Glu Arg 2610 2615 2620 tat cag ctc act caa agg cgg taa tac ggt tat cca cag aat cag 8214 Tyr Gln Leu Thr Gln Arg Arg Tyr Gly Tyr Pro Gln Asn Gln 2625 2630 2635 ggg ata acg cag gaa aga aca tgt gag caa aag gcc agc aaa agg 8259 Gly Ile Thr Gln Glu Arg Thr Cys Glu Gln Lys Ala Ser Lys Arg 2640 2645 2650 cca gga acc gta aaa agg ccg cgt tgc tgg cgt ttt tcc ata ggc 8304 Pro Gly Thr Val Lys Arg Pro Arg Cys Trp Arg Phe Ser Ile Gly 2655 2660 2665 tcc gcc ccc ctg acg agc atc aca aaa atc gac gct caa gtc aga 8349 Ser Ala Pro Leu Thr Ser Ile Thr Lys Ile Asp Ala Gln Val Arg 2670 2675 2680 ggt ggc gaa acc cga cag gac tat aaa gat acc agg cgt ttc ccc 8394 Gly Gly Glu Thr Arg Gln Asp Tyr Lys Asp Thr Arg Arg Phe Pro 2685 2690 2695 ctg gaa gct ccc tcg tgc gct ctc ctg ttc cga ccc tgc cgc tta 8439 Leu Glu Ala Pro Ser Cys Ala Leu Leu Phe Arg Pro Cys Arg Leu 2700 2705 2710 ccg gat acc tgt ccg cct ttc tcc ctt cgg gaa gcg tgg cgc ttt 8484 Pro Asp Thr Cys Pro Pro Phe Ser Leu Arg Glu Ala Trp Arg Phe 2715 2720 2725 ctc ata gct cac gct gta ggt atc tca gtt cgg tgt agg tcg ttc 8529 Leu Ile Ala His Ala Val Gly Ile Ser Val Arg Cys Arg Ser Phe 2730 2735 2740 gct cca agc tgg gct gtg tgc acg aac ccc ccg ttc agc ccg acc 8574 Ala Pro Ser Trp Ala Val Cys Thr Asn Pro Pro Phe Ser Pro Thr 2745 2750 2755 gct gcg cct tat ccg gta act atc gtc ttg agt cca acc cgg taa 8619 Ala Ala Pro Tyr Pro Val Thr Ile Val Leu Ser Pro Thr Arg 2760 2765 gac acg act tat cgc cac tgg cag cag cca ctg gta aca gga tta 8664 Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val Thr Gly Leu 2770 2775 2780 gca gag cga ggt atg tag gcg gtg cta cag agt tct tga agt ggt 8709 Ala Glu Arg Gly Met Ala Val Leu Gln Ser Ser Ser Gly 2785 2790 2795 ggc cta act acg gct aca cta gaa gga cag tat ttg gta tct gcg 8754 Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val Ser Ala 2800 2805 2810 ctc tgc tga agc cag tta cct tcg gaa aaa gag ttg gta gct ctt 8799 Leu Cys Ser Gln Leu Pro Ser Glu Lys Glu Leu Val Ala Leu 2815 2820 2825 gat ccg gca aac aaa cca ccg ctg gta gcg gtg gtt ttt ttg ttt 8844 Asp Pro Ala Asn Lys Pro Pro Leu Val Ala Val Val Phe Leu Phe 2830 2835 2840 gca agc agc aga tta cgc gca gaa aaa aag gat ctc aag aag atc 8889 Ala Ser Ser Arg Leu Arg Ala Glu Lys Lys Asp Leu Lys Lys Ile 2845 2850 2855 ctt tga tct ttt cta cgg ggt ctg acg ctc agt gga acg aaa act 8934 Leu Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr Lys Thr 2860 2865 2870 cac gtt aag gga ttt tgg tca tga gat tat caa aaa gga tct tca 8979 His Val Lys Gly Phe Trp Ser Asp Tyr Gln Lys Gly Ser Ser 2875 2880 cct aga tcc ttt taa att aaa aat gaa gtt tta aat caa tct aaa 9024 Pro Arg Ser Phe Ile Lys Asn Glu Val Leu Asn Gln Ser Lys 2885 2890 2895 gta tat atg agt aaa ctt ggt ctg aca gtt acc aat gct taa tca 9069 Val Tyr Met Ser Lys Leu Gly Leu Thr Val Thr Asn Ala Ser 2900 2905 2910 gtg agg cac cta tct cag cga tct gtc tat ttc gtt cat cca tag 9114 Val Arg His Leu Ser Gln Arg Ser Val Tyr Phe Val His Pro 2915 2920 2925 ttg cct gac tcc ccg tcg tgt aga taa cta cga tac ggg agg gct 9159 Leu Pro Asp Ser Pro Ser Cys Arg Leu Arg Tyr Gly Arg Ala 2930 2935 2940 tac cat ctg gcc cca gtg ctg caa tga tac cgc gag acc cac gct 9204 Tyr His Leu Ala Pro Val Leu Gln Tyr Arg Glu Thr His Ala 2945 2950 cac cgg ctc cag att tat cag caa taa acc agc cag ccg gaa ggg 9249 His Arg Leu Gln Ile Tyr Gln Gln Thr Ser Gln Pro Glu Gly 2955 2960 2965 ccg agc gca gaa gtg gtc ctg caa ctt tat ccg cct cca tcc agt 9294 Pro Ser Ala Glu Val Val Leu Gln Leu Tyr Pro Pro Pro Ser Ser 2970 2975 2980 cta tta att gtt gcc ggg aag cta gag taa gta gtt cgc cag tta 9339 Leu Leu Ile Val Ala Gly Lys Leu Glu Val Val Arg Gln Leu 2985 2990 2995 ata gtt tgc gca acg ttg ttg cca ttg cta cag gca tcg tgg tgt 9384 Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln Ala Ser Trp Cys 3000 3005 3010 cac gct cgt cgt ttg gta tgg ctt cat tca gct ccg gtt ccc aac 9429 His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro Val Pro Asn 3015 3020 3025 gat caa ggc gag tta cat gat ccc cca tgt tgt gca aaa aag cgg 9474 Asp Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys Lys Arg 3030 3035 3040 tta gct cct tcg gtc ctc cga tcg ttg tca gaa gta agt tgg ccg 9519 Leu Ala Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser Trp Pro 3045 3050 3055 cag tgt tat cac tca tgg tta tgg cag cac tgc ata att ctc tta 9564 Gln Cys Tyr His Ser Trp Leu Trp Gln His Cys Ile Ile Leu Leu 3060 3065 3070 ctg tca tgc cat ccg taa gat gct ttt ctg tga ctg gtg agt act 9609 Leu Ser Cys His Pro Asp Ala Phe Leu Leu Val Ser Thr 3075 3080 3085 caa cca agt cat tct gag aat agt gta tgc ggc gac cga gtt gct 9654 Gln Pro Ser His Ser Glu Asn Ser Val Cys Gly Asp Arg Val Ala 3090 3095 3100 ctt gcc cgg cgt caa tac ggg ata ata ccg cgc cac ata gca gaa 9699 Leu Ala Arg Arg Gln Tyr Gly Ile Ile Pro Arg His Ile Ala Glu 3105 3110 3115 ctt taa aag tgc tca tca ttg gaa aac gtt ctt cgg ggc gaa aac 9744 Leu Lys Cys Ser Ser Leu Glu Asn Val Leu Arg Gly Glu Asn 3120 3125 tct caa gga tct tac cgc tgt tga gat cca gtt cga tgt aac cca 9789 Ser Gln Gly Ser Tyr Arg Cys Asp Pro Val Arg Cys Asn Pro 3130 3135 3140 ctc gtg cac cca act gat ctt cag cat ctt tta ctt tca cca gcg 9834 Leu Val His Pro Thr Asp Leu Gln His Leu Leu Leu Ser Pro Ala 3145 3150 3155 ttt ctg ggt gag caa aaa cag gaa ggc aaa atg ccg caa aaa agg 9879 Phe Leu Gly Glu Gln Lys Gln Glu Gly Lys Met Pro Gln Lys Arg 3160 3165 3170 gaa taa ggg cga cac gga aat gtt gaa tac tca tac tct tcc ttt 9924 Glu Gly Arg His Gly Asn Val Glu Tyr Ser Tyr Ser Ser Phe 3175 3180 3185 ttc aat att att gaa gca ttt atc agg gtt att gtc tca tga gcg 9969 Phe Asn Ile Ile Glu Ala Phe Ile Arg Val Ile Val Ser Ala 3190 3195 3200 gat aca tat ttg aat gta ttt aga aaa ata aac aaa tag ggg ttc 10014 Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys Gly Phe 3205 3210 3215 cgc gca cat ttc ccc gaa aag tgc cac ctg acg tct aag aaa cca 10059 Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys Lys Pro 3220 3225 3230 tta tta tca tga cat taa cct ata aaa ata ggc gta tca cga ggc cct 10107 Leu Leu Ser His Pro Ile Lys Ile Gly Val Ser Arg Gly Pro 3235 3240 ttc gtc tcg cgc gtt tcg gtg atg acg gtg aaa acc tct gac aca 10152 Phe Val Ser Arg Val Ser Val Met Thr Val Lys Thr Ser Asp Thr 3245 3250 3255 tgc agc tcc cgg aga cgg tca cag ctt gtc tgt aag cgg atg ccg 10197 Cys Ser Ser Arg Arg Arg Ser Gln Leu Val Cys Lys Arg Met Pro 3260 3265 3270 gga gca gac aag ccc gtc agg gcg cgt cag cgg gtg ttg gcg ggt 10242 Gly Ala Asp Lys Pro Val Arg Ala Arg Gln Arg Val Leu Ala Gly 3275 3280 3285 gtc ggg gct ggc tta act atg cgg cat cag agc aga ttg tac tga 10287 Val Gly Ala Gly Leu Thr Met Arg His Gln Ser Arg Leu Tyr 3290 3295 3300 gag tgc acc ata tgc ggt gtg aaa tac cgc aca gat gcg taa gga 10332 Glu Cys Thr Ile Cys Gly Val Lys Tyr Arg Thr Asp Ala Gly 3305 3310 3315 gaa aat acc gca tca ggc gcc att cgc cat tca ggc tgc gca act 10377 Glu Asn Thr Ala Ser Gly Ala Ile Arg His Ser Gly Cys Ala Thr 3320 3325 3330 gtt ggg aag ggc gat cgg tgc ggg cct ctt cgc tat tac gcc agc 10422 Val Gly Lys Gly Asp Arg Cys Gly Pro Leu Arg Tyr Tyr Ala Ser 3335 3340 3345 tgg cga aag ggg gat gtg ctg caa ggc gat taa gtt ggg taa cgc 10467 Trp Arg Lys Gly Asp Val Leu Gln Gly Asp Val Gly Arg 3350 3355 3360 cag ggt ttt ccc agt cac gac gtt gta aaa cga cgg cca gtg cc 10511 Gln Gly Phe Pro Ser His Asp Val Val Lys Arg Arg Pro Val 3365 3370 <210> SEQ ID NO 110 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 110 Lys Leu Tyr Ser 1 <210> SEQ ID NO 111 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 111 Ser Glu Leu Lys Asp His Ile 1 5 <210> SEQ ID NO 112 <211> LENGTH: 176 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 112 Asp Lys Ile Glu Ser Thr Cys Lys Met Phe Pro Ala Arg Trp His Asn 1 5 10 15 Tyr Leu Gln Cys Gly Gln Val Ile Lys Asp Ser Asn Leu Ile Cys Phe 20 25 30 Lys Thr Pro Leu Arg Pro Glu Leu Phe Ala Tyr Val Thr Ser Glu Glu 35 40 45 Asp Val Trp Thr Ala Glu Gln Ile Val Lys Gln Asn Pro Ser Ile Gly 50 55 60 Ala Ile Ile Asp Leu Thr Asn Thr Ser Lys Tyr Tyr Asp Gly Val His 65 70 75 80 Phe Leu Arg Ala Gly Leu Leu Tyr Lys Lys Ile Gln Val Pro Gly Gln 85 90 95 Thr Leu Pro Pro Glu Ser Ile Val Gln Glu Phe Ile Asp Thr Val Lys 100 105 110 Glu Phe Thr Glu Lys Cys Pro Gly Met Leu Val Gly Val His Cys Thr 115 120 125 His Gly Ile Asn Arg Thr Gly Tyr Met Val Cys Arg Tyr Leu Met His 130 135 140 Thr Leu Gly Ile Ala Pro Gln Glu Ala Ile Asp Arg Phe Glu Lys Ala 145 150 155 160 Arg Gly His Lys Ile Glu Arg Gln Asn Tyr Val Gln Asp Leu Leu Ile 165 170 175 <210> SEQ ID NO 113 <211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 113 Leu Ile Leu Phe Ala Phe Phe Asn Lys Tyr Phe Ile Leu Phe Ser Asn 1 5 10 15 Cys Cys Ala Ser Ser Ser Glu Pro Lys Leu Cys Phe Ala Cys Ser Val 20 25 30 <210> SEQ ID NO 114 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 114 Leu Val Ala Asp Gln Trp Arg Cys Ser Asn Arg Arg 1 5 10 <210> SEQ ID NO 115 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 115 Ala Gly Tyr Ser Pro Pro Gln Cys Trp Gln Arg 1 5 10 <210> SEQ ID NO 116 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 116 Cys Tyr Val Tyr Ala Phe Gly Phe Pro Arg Thr Ser Phe Gly Arg 1 5 10 15 <210> SEQ ID NO 117 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 117 Cys Arg Arg Ala Ser Arg Thr Thr Pro Asp Val Cys Ala Cys Pro Arg 1 5 10 15 Gly Ile Glu Pro Arg Asp Pro Thr Asn Pro Pro Leu Trp Gln Leu Asn 20 25 30 Arg <210> SEQ ID NO 118 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 118 Pro Ala Arg Leu Phe Ser Ala Leu Phe Arg Leu Ser Phe Ala Trp Phe 1 5 10 15 Pro Gly Ser Arg Cys Thr Cys Gly Leu Asp Gln Ser 20 25 <210> SEQ ID NO 119 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 119 Pro Ala Asn Leu Trp Pro Arg Ser Ala Cys Pro 1 5 10 <210> SEQ ID NO 120 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 120 Trp Gln Arg Cys Val Gln 1 5 <210> SEQ ID NO 121 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 121 Thr Leu Val Phe 1 <210> SEQ ID NO 122 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 122 Gln Val Pro Arg Phe Phe Ala Pro Pro Pro Leu Ala Ala Arg Leu Cys 1 5 10 15 Ala Arg <210> SEQ ID NO 123 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 123 Met Ser Gln Ser Ala 1 5 <210> SEQ ID NO 124 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 124 Ser Pro Thr Val Cys Ser Pro Pro Pro Val Val 1 5 10 <210> SEQ ID NO 125 <211> LENGTH: 32 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 125 Ser Arg Asp Arg Thr Cys Arg Cys Arg Ala Leu Glu Glu Leu Leu Leu 1 5 10 15 Leu Lys Ala Ile Leu Val Ile Leu Trp Arg Lys Ala Ile Trp Thr Ser 20 25 30 <210> SEQ ID NO 126 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 126 Ser Ala Glu Ser Arg Arg Ile 1 5 <210> SEQ ID NO 127 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 127 Ala Leu Tyr Ala Ala Ala Asn Thr Ala Gly Arg Pro Phe Ser Arg Arg 1 5 10 15 Cys <210> SEQ ID NO 128 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 128 Gly Pro His Phe Gly Trp Ser Ala Gln Ile Thr Ile Cys Ile Tyr Cys 1 5 10 15 Leu His Glu His Val 20 <210> SEQ ID NO 129 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 129 Leu Tyr His Lys Leu Tyr Ile Leu Asn Cys 1 5 10 <210> SEQ ID NO 130 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 130 Arg Arg Pro Trp Pro Arg Thr Gly Pro Val Gly Arg Ala Leu Ala Arg 1 5 10 15 Thr Ala Gly <210> SEQ ID NO 131 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 131 Thr Tyr Leu Leu Gln Ile 1 5 <210> SEQ ID NO 132 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 132 Ile Leu Gln Phe 1 <210> SEQ ID NO 133 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 133 Arg Glu Pro Phe 1 <210> SEQ ID NO 134 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 134 Tyr Thr Cys Val Asp Phe Ala Thr Thr Ile Val Phe 1 5 10 <210> SEQ ID NO 135 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 135 Arg Lys Leu Asn Leu Leu Trp 1 5 <210> SEQ ID NO 136 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 136 Ala Ile Ile Lys Tyr Gly Gly Thr Cys Ala Ala Thr Thr Leu Val Val 1 5 10 15 Met Asn Ala Asp Gly Ala Gly Leu Gly Ala Ser Gly 20 25 <210> SEQ ID NO 137 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 137 Asn Val Leu Arg Val Gln Arg Gly Lys His Arg Lys Ser Gln 1 5 10 <210> SEQ ID NO 138 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 138 Tyr Ser Phe Asp Leu His Ile Asn Gly Asp Phe Leu Asn Tyr Leu Ile 1 5 10 15 <210> SEQ ID NO 139 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 139 Ile Val Met Thr Pro Thr Thr Pro Arg Pro Arg 1 5 10 <210> SEQ ID NO 140 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 140 Leu Ala Ala Pro Arg Ala Val Arg 1 5 <210> SEQ ID NO 141 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 141 Arg Leu Pro Pro Cys Gly Arg Thr Arg Arg Ala Gly Gly Arg 1 5 10 <210> SEQ ID NO 142 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 142 Pro Ala Ala Cys Arg Thr Arg Arg Thr Ser Ile Cys Thr Pro Asn Asp 1 5 10 15 Arg Arg Ala Lys Ala Arg Arg Pro Pro Ser Gly Asn Ile Gly Lys Phe 20 25 30 Glu Asn Ile Tyr Ser Trp Val Val Cys Ala Tyr Leu Ser Trp Arg Trp 35 40 45 Ala Cys Thr Ser Glu Arg 50 <210> SEQ ID NO 143 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 143 Phe Ala Cys Lys Pro Lys Leu Asn His Cys Asp 1 5 10 <210> SEQ ID NO 144 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 144 Asn Val Val His Pro Arg Phe 1 5 <210> SEQ ID NO 145 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 145 Ser Cys Arg Arg Leu Asn Arg Ala Ile Glu Ser Ser Asp Gln Ser Val 1 5 10 15 Glu <210> SEQ ID NO 146 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 146 Cys Phe Leu Cys Ile Pro Glu Ser Ser Ala Ala Arg Ile Leu Thr Asn 1 5 10 15 <210> SEQ ID NO 147 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 147 Pro Ser Cys Lys Leu Val Ser Phe Asn Ala Thr Leu Ser Asn Asn Ile 1 5 10 15 Leu Cys Ile Ala Arg Gln Glu Leu Thr Met Arg Pro Leu Ser His Leu 20 25 30 Asn Thr Thr Met Ile Glu Ile Lys 35 40 <210> SEQ ID NO 148 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 148 Ile Ala Cys Asp Ala Thr Cys Thr Ile Cys Ala Arg Val Pro Ala Arg 1 5 10 15 Ala Leu Ile Val Ile Ser Phe Tyr Glu Ala Met Thr 20 25 <210> SEQ ID NO 149 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 149 Gln Arg Ser Arg Pro Lys Glu Leu Pro Thr Thr Lys Leu Pro Ser Met 1 5 10 15 Ser Val Thr Leu Lys Leu Leu Ser His Pro Ile Asp Arg 20 25 <210> SEQ ID NO 150 <211> LENGTH: 222 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 150 Ser Asn Gln Asp Arg Trp Cys Glu Lys Pro Arg Ser Met Ala Asn Ala 1 5 10 15 Ser Tyr Asn Val Trp Ser Pro Leu Ile Arg Ala Ser Cys Leu Asp Lys 20 25 30 Lys Ala Thr Tyr Leu Ile Asp Pro Asp Asp Phe Ile Asp Lys Leu Thr 35 40 45 Leu Thr Pro Tyr Thr Val Phe Tyr Asn Gly Gly Val Leu Val Lys Ile 50 55 60 Ser Gly Leu Arg Leu Tyr Met Leu Leu Thr Ala Pro Pro Thr Ile Asn 65 70 75 80 Glu Ile Lys Asn Ser Asn Phe Lys Lys Arg Ser Lys Arg Asn Ile Cys 85 90 95 Met Lys Glu Cys Val Glu Gly Lys Lys Asn Val Val Asp Met Leu Asn 100 105 110 Asn Lys Ile Asn Met Pro Pro Cys Ile Lys Lys Ile Leu Asn Asp Leu 115 120 125 Lys Glu Asn Asn Val Pro Arg Gly Gly Met Tyr Arg Lys Arg Phe Ile 130 135 140 Leu Asn Cys Tyr Ile Ala Asn Val Val Ser Cys Ala Lys Cys Glu Asn 145 150 155 160 Arg Cys Leu Ile Lys Ala Leu Thr His Phe Tyr Asn His Asp Ser Lys 165 170 175 Cys Val Gly Glu Val Met His Leu Leu Ile Lys Ser Gln Asp Val Tyr 180 185 190 Lys Pro Pro Asn Cys Gln Lys Met Lys Thr Val Asp Lys Leu Cys Pro 195 200 205 Phe Ala Gly Asn Cys Lys Gly Leu Asn Pro Ile Cys Asn Tyr 210 215 220 <210> SEQ ID NO 151 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 151 Ile Ile Lys Gln Leu 1 5 <210> SEQ ID NO 152 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 152 Met Leu Asn Leu Phe Phe Ile Asn Asp Thr Asn Gln Thr Gln Gln Glu 1 5 10 15 His Leu <210> SEQ ID NO 153 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 153 Leu Lys Thr Arg Ser Tyr Asn Arg 1 5 <210> SEQ ID NO 154 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 154 Asn His Phe Gln Met Ile His Ser 1 5 <210> SEQ ID NO 155 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 155 Phe Ala Thr Ile 1 <210> SEQ ID NO 156 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 156 Phe Tyr Phe His Ile Asn 1 5 <210> SEQ ID NO 157 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 157 Thr Pro Cys Arg Leu Leu Leu Arg Ile Pro Ser Leu Phe His Phe Ser 1 5 10 15 Pro His Lys Asn 20 <210> SEQ ID NO 158 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 158 His Ser Tyr Tyr Arg Ile His Ile Cys Ile Tyr Arg Ile Glu 1 5 10 <210> SEQ ID NO 159 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 159 Ile Phe Cys Cys His Lys Tyr Ile Cys Leu Phe 1 5 10 <210> SEQ ID NO 160 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 160 Tyr Arg Cys Ala 1 <210> SEQ ID NO 161 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 161 Phe Phe Cys Asn Leu Gln Gln Cys Tyr Phe Leu Val Val Leu Arg Ser 1 5 10 15 Val Leu Leu <210> SEQ ID NO 162 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 162 Leu Leu Asn Leu Tyr Asn Gln 1 5 <210> SEQ ID NO 163 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 163 Ile Trp Asp Arg Arg Phe Cys Thr Ile Cys Cys Arg His Ser Thr Gln 1 5 10 15 Leu Leu Leu Val Gln Leu His His Phe Leu Ala Ala Pro Asp 20 25 30 <210> SEQ ID NO 164 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 164 His Asn Phe Pro Lys Cys Cys Thr Asn Arg 1 5 10 <210> SEQ ID NO 165 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 165 Thr Lys Thr Val His Leu Pro Phe Leu Tyr Tyr Cys Leu Arg Ala Val 1 5 10 15 Val Cys Cys <210> SEQ ID NO 166 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 166 Asp Ala Gln Thr Asn Ile Thr Asn Trp Lys Cys Leu Ser Ile Tyr Ser 1 5 10 15 Cys <210> SEQ ID NO 167 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 167 Tyr His Gly Asp Asn 1 5 <210> SEQ ID NO 168 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 168 Asn Asp Asn His Leu Ala Asn Lys 1 5 <210> SEQ ID NO 169 <211> LENGTH: 331 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 169 Val Phe Tyr Cys Phe Arg Asn Ser Phe Val Ile Lys Lys Pro Ile Asn 1 5 10 15 Ile Pro Asp Tyr Ser Tyr Arg Pro Thr Ile Gly Arg Gly Ser Met Leu 20 25 30 Leu Val Asn Gln Ser His Gln Gly Phe Asn Lys Glu His Thr Ser Lys 35 40 45 Met Val Ser Ala Ile Val Leu Tyr Val Leu Leu Ala Ala Ala Ala His 50 55 60 Ser Ala Phe Ala Ala Asp Leu Gly Ser His His His His His His Ile 65 70 75 80 Glu Gly Arg Glu Phe Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu 85 90 95 Ala Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly His 100 105 110 Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln 115 120 125 Gly Leu Glu Trp Ile Gly Tyr Ile Asn Leu Ser Ser Gly Tyr Ile Lys 130 135 140 Tyr Asn Gln Glu Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser 145 150 155 160 Ser Asn Thr Ala Tyr Met His Leu Ser Ser Leu Thr Tyr Glu Asp Ser 165 170 175 Ala Val Tyr Tyr Cys Ala Arg Ala Ala Gln Ala Thr Thr Phe Asp Tyr 180 185 190 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser 195 200 205 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Ile Gln 210 215 220 Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr 225 230 235 240 Cys Lys Ala Ser Gln Asp Val Ser Thr Ala Val Gly Trp Tyr Gln Gln 245 250 255 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg 260 265 270 His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp 275 280 285 Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Leu Tyr 290 295 300 Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr 305 310 315 320 Lys Leu Gly Ile Lys Arg Ala Pro Gly Gly Cys 325 330 <210> SEQ ID NO 170 <211> LENGTH: 190 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 170 Arg Ser Asp Pro Phe Leu Gly Pro Gly Lys Asn Gln Lys Leu Thr Leu 1 5 10 15 Phe Lys Glu Ile Arg Asn Val Lys Pro Asp Thr Met Lys Leu Val Val 20 25 30 Gly Trp Lys Gly Lys Glu Phe Tyr Arg Glu Thr Trp Thr Arg Phe Met 35 40 45 Glu Asp Ser Phe Pro Ile Val Asn Asp Gln Glu Val Met Asp Val Phe 50 55 60 Leu Val Val Asn Met Arg Pro Thr Arg Pro Asn Arg Cys Tyr Lys Phe 65 70 75 80 Leu Ala Gln His Ala Leu Arg Cys Asp Pro Asp Tyr Val Pro His Asp 85 90 95 Val Ile Arg Ile Val Glu Pro Ser Trp Val Gly Ser Asn Asn Glu Tyr 100 105 110 Arg Ile Ser Leu Ala Lys Lys Gly Gly Gly Cys Pro Ile Met Asn Leu 115 120 125 His Ser Glu Tyr Thr Asn Ser Phe Glu Gln Phe Ile Asp Arg Val Ile 130 135 140 Trp Glu Asn Phe Tyr Lys Pro Ile Val Tyr Ile Gly Thr Asp Ser Ala 145 150 155 160 Glu Glu Glu Glu Ile Leu Leu Glu Val Ser Leu Val Phe Lys Val Lys 165 170 175 Glu Phe Ala Pro Asp Ala Pro Leu Phe Thr Gly Pro Ala Tyr 180 185 190 <210> SEQ ID NO 171 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 171 Asn Thr Ile His Cys Tyr 1 5 <210> SEQ ID NO 172 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 172 Ala Leu Asp Ser Val Arg Cys 1 5 <210> SEQ ID NO 173 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 173 Phe Thr Asp Asn Cys Cys Thr Tyr Phe Asn Asn Ser Leu Asn Leu 1 5 10 15 <210> SEQ ID NO 174 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 174 Ser Leu Gly Trp Tyr Val Arg Ala Lys Ile Lys 1 5 10 <210> SEQ ID NO 175 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 175 Phe Ser Ala Ser Leu Tyr Leu Asn Leu Asn Ile Lys Ser Ser Ile Asp 1 5 10 15 Leu <210> SEQ ID NO 176 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 176 Asn Arg Phe Arg Leu Val Ser Asn Lys Gly Cys Phe Ser Glu Pro Met 1 5 10 15 Ala Gly Leu Ser Asn Gly Phe Ser Leu Asn Ala Thr Lys Leu Ala Lys 20 25 30 Ser Cys Ser Ser Asn Leu Ala Leu Ser Ile Phe Val Cys Val Leu Phe 35 40 45 Cys Asn Lys Gly Ser Thr Ser Phe Lys Ile Leu Cys Ala Phe Val Phe 50 55 60 Leu Ser Ser Leu Ser Leu Val Tyr Asn 65 70 <210> SEQ ID NO 177 <211> LENGTH: 196 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 177 Leu Asp Val Asn Thr Leu Asn Lys Ala Trp Thr Tyr Leu Thr Ser Gly 1 5 10 15 Val Leu Ala Leu Leu Gly Arg Leu Ser Ser Ser Ser Gln Pro Ser Ser 20 25 30 Leu Glu Val Ala Ser Glu Asp Asp Phe Ala Ile Ala Thr Arg Arg Leu 35 40 45 Leu Ile Val Ser Ala Asn Thr Ser Ala Ile Lys Phe Val Val Glu Leu 50 55 60 Phe Gly Ile Ile Ser Asp Cys Gly Arg Phe Trp Ala Gly Phe Asn Leu 65 70 75 80 Thr Val Pro Asp Phe Asn Ser Asp Asn Thr Leu Glu Ser Asp Gly Ala 85 90 95 Gly Gly Gly Asn Ile Ser Asp Gly Lys Ser Thr Asn Gly Gly Gly Gly 100 105 110 Gly Ala Asp Asp Lys Ser Thr Ile Gly Gly Gly Ala Gly Gly Ala Gly 115 120 125 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Asp Ala Asp Gly Gly Leu 130 135 140 Gly Ser Asn Val Ser Leu Gly Asn Thr Val Gly Thr Ser Thr Ile Val 145 150 155 160 Leu Val Ser Gly Ala Val Phe Gly Leu Thr Gly Leu Arg Arg Val Arg 165 170 175 Phe Phe Ser Phe Leu Ile Ala Ser Asn Asn Cys Cys Leu Ser Ser Lys 180 185 190 Gly Ala Ala Gly 195 <210> SEQ ID NO 178 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 178 Gly Ser Val Gly Ile Gly Gly Ala Gly Gly Asn Ser Asp Ile Asp Gly 1 5 10 15 Gly Gly Gly Gly Gly Gly Ala Gly Met Leu Gly Thr Gly Glu Gly Gly 20 25 30 Gly Gly Gly Ala Ala Gly Ile Ile Cys Ser Gly Leu Val Cys Ser Arg 35 40 45 Thr Ile Val Gly Thr Gly Ala Gly Ala Ala Gly Cys Thr Thr Glu Gly 50 55 60 Arg Leu Leu Arg Gly Ser Ala Trp Gly Gly Gly Asn Ser Ile Leu 65 70 75 <210> SEQ ID NO 179 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 179 Leu Glu Tyr Lys Ser 1 5 <210> SEQ ID NO 180 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 180 Lys Ser Ala Ile Ser Ile Val Ile Ser Leu Ser Phe Thr Val Pro Ile 1 5 10 15 Phe Asn Asn Arg Ser Met 20 <210> SEQ ID NO 181 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 181 Ala Ile Val Leu 1 <210> SEQ ID NO 182 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 182 Arg Asp Cys Leu Lys Leu Arg Thr Pro Ile Thr Ser Leu Phe Ile Phe 1 5 10 15 Thr Thr Ala Leu 20 <210> SEQ ID NO 183 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 183 Trp Arg Asp Thr Ser Leu Ser Ser Thr Tyr Met Tyr Ala Leu Leu Ser 1 5 10 15 Lys Thr Ser Leu Ala Ser Phe Lys Ile Phe Lys Arg Thr Ser Leu Phe 20 25 30 Ser Thr Thr Val Leu Ser 35 <210> SEQ ID NO 184 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 184 Met Leu Phe Leu Ile Ile Cys Ala Ser Ala Val Ser Thr Arg Ser Lys 1 5 10 15 Asn <210> SEQ ID NO 185 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 185 Cys Ala Ser Ile Leu Leu Phe Leu Leu Leu Asn Lys 1 5 10 <210> SEQ ID NO 186 <211> LENGTH: 206 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 186 Asp Cys Thr Asp Ser Tyr Leu Arg Phe Val Met Ala Thr Thr Asn Ala 1 5 10 15 Thr Leu Gln Thr Leu Val Gln Phe Tyr Glu Asn Cys Lys Asn Val Lys 20 25 30 Thr Arg Tyr Lys Ile Ile Asn Gly Arg Phe Gly Lys Ile Ser Ile Leu 35 40 45 Ser His Lys Pro Thr Ser Lys Leu Tyr Leu Gln Lys Thr Ile Ser Ala 50 55 60 His Asn Phe Asn Ala Asp Glu Ile Lys Val His Gln Leu Met Ser Asp 65 70 75 80 His Pro Asn Phe Ile Lys Ile Tyr Phe Asn His Gly Ser Ile Asn Asn 85 90 95 Gln Val Ile Val Met Asp Tyr Ile Asp Cys Pro Asp Leu Phe Glu Thr 100 105 110 Leu Gln Ile Lys Gly Glu Leu Ser Tyr Gln Leu Val Ser Asn Ile Ile 115 120 125 Arg Gln Leu Cys Glu Ala Leu Asn Asp Leu His Lys His Asn Phe Ile 130 135 140 His Asn Asp Ile Lys Leu Glu Asn Val Leu Tyr Phe Glu Ala Leu Asp 145 150 155 160 Arg Val Tyr Val Cys Asp Tyr Gly Leu Cys Lys His Glu Asn Ser Leu 165 170 175 Ser Val His Asp Gly Thr Leu Glu Tyr Phe Ser Pro Glu Lys Ile Arg 180 185 190 His Thr Thr Met His Val Ser Phe Asp Trp Tyr Ala Ala Cys 195 200 205 <210> SEQ ID NO 187 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 ppeptie sequence <400> SEQUENCE: 187 His Thr Ser Cys 1 <210> SEQ ID NO 188 <211> LENGTH: 29 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 188 Pro Ala Val Arg Asn His Gly His Ser Cys Phe Leu Cys Glu Ile Val 1 5 10 15 Ile Arg Ser Gln Phe His Thr Thr Tyr Glu Pro Glu Ala 20 25 <210> SEQ ID NO 189 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 189 Ser Val Lys Pro Gly Val Pro Asn Glu 1 5 <210> SEQ ID NO 190 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 190 Ala Asn Ser His 1 <210> SEQ ID NO 191 <211> LENGTH: 61 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 191 Leu Arg Cys Ala His Cys Pro Leu Ser Ser Arg Glu Thr Cys Arg Ala 1 5 10 15 Ser Cys Ile Asn Glu Ser Ala Asn Ala Arg Gly Glu Ala Val Cys Val 20 25 30 Leu Gly Ala Leu Pro Leu Pro Arg Ser Leu Thr Arg Cys Ala Arg Ser 35 40 45 Phe Gly Cys Gly Glu Arg Tyr Gln Leu Thr Gln Arg Arg 50 55 60 <210> SEQ ID NO 192 <211> LENGTH: 141 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 192 Tyr Gly Tyr Pro Gln Asn Gln Gly Ile Thr Gln Glu Arg Thr Cys Glu 1 5 10 15 Gln Lys Ala Ser Lys Arg Pro Gly Thr Val Lys Arg Pro Arg Cys Trp 20 25 30 Arg Phe Ser Ile Gly Ser Ala Pro Leu Thr Ser Ile Thr Lys Ile Asp 35 40 45 Ala Gln Val Arg Gly Gly Glu Thr Arg Gln Asp Tyr Lys Asp Thr Arg 50 55 60 Arg Phe Pro Leu Glu Ala Pro Ser Cys Ala Leu Leu Phe Arg Pro Cys 65 70 75 80 Arg Leu Pro Asp Thr Cys Pro Pro Phe Ser Leu Arg Glu Ala Trp Arg 85 90 95 Phe Leu Ile Ala His Ala Val Gly Ile Ser Val Arg Cys Arg Ser Phe 100 105 110 Ala Pro Ser Trp Ala Val Cys Thr Asn Pro Pro Phe Ser Pro Thr Ala 115 120 125 Ala Pro Tyr Pro Val Thr Ile Val Leu Ser Pro Thr Arg 130 135 140 <210> SEQ ID NO 193 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 193 Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val Thr Gly Leu Ala 1 5 10 15 Glu Arg Gly Met 20 <210> SEQ ID NO 194 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 194 Ala Val Leu Gln Ser Ser 1 5 <210> SEQ ID NO 195 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 195 Ser Gly Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val Ser 1 5 10 15 Ala Leu Cys <210> SEQ ID NO 196 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 196 Ser Gln Leu Pro Ser Glu Lys Glu Leu Val Ala Leu Asp Pro Ala Asn 1 5 10 15 Lys Pro Pro Leu Val Ala Val Val Phe Leu Phe Ala Ser Ser Arg Leu 20 25 30 Arg Ala Glu Lys Lys Asp Leu Lys Lys Ile Leu 35 40 <210> SEQ ID NO 197 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 197 Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr Lys Thr His Val Lys 1 5 10 15 Gly Phe Trp Ser 20 <210> SEQ ID NO 198 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 198 Asp Tyr Gln Lys Gly Ser Ser Pro Arg Ser Phe 1 5 10 <210> SEQ ID NO 199 <211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 199 Ile Lys Asn Glu Val Leu Asn Gln Ser Lys Val Tyr Met Ser Lys Leu 1 5 10 15 Gly Leu Thr Val Thr Asn Ala 20 <210> SEQ ID NO 200 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 200 Ser Val Arg His Leu Ser Gln Arg Ser Val Tyr Phe Val His Pro 1 5 10 15 <210> SEQ ID NO 201 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 201 Leu Pro Asp Ser Pro Ser Cys Arg 1 5 <210> SEQ ID NO 202 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 202 Leu Arg Tyr Gly Arg Ala Tyr His Leu Ala Pro Val Leu Gln 1 5 10 <210> SEQ ID NO 203 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 203 Tyr Arg Glu Thr His Ala His Arg Leu Gln Ile Tyr Gln Gln 1 5 10 <210> SEQ ID NO 204 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 204 Thr Ser Gln Pro Glu Gly Pro Ser Ala Glu Val Val Leu Gln Leu Tyr 1 5 10 15 Pro Pro Pro Ser Ser Leu Leu Ile Val Ala Gly Lys Leu Glu 20 25 30 <210> SEQ ID NO 205 <211> LENGTH: 85 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 205 Val Val Arg Gln Leu Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln 1 5 10 15 Ala Ser Trp Cys His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro 20 25 30 Val Pro Asn Asp Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys 35 40 45 Lys Arg Leu Ala Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser Trp 50 55 60 Pro Gln Cys Tyr His Ser Trp Leu Trp Gln His Cys Ile Ile Leu Leu 65 70 75 80 Leu Ser Cys His Pro 85 <210> SEQ ID NO 206 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 206 Asp Ala Phe Leu 1 <210> SEQ ID NO 207 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 ppeptie sequence <400> SEQUENCE: 207 Leu Val Ser Thr Gln Pro Ser His Ser Glu Asn Ser Val Cys Gly Asp 1 5 10 15 Arg Val Ala Leu Ala Arg Arg Gln Tyr Gly Ile Ile Pro Arg His Ile 20 25 30 Ala Glu Leu 35 <210> SEQ ID NO 208 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 208 Lys Cys Ser Ser Leu Glu Asn Val Leu Arg Gly Glu Asn Ser Gln Gly 1 5 10 15 Ser Tyr Arg Cys 20 <210> SEQ ID NO 209 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 209 Asp Pro Val Arg Cys Asn Pro Leu Val His Pro Thr Asp Leu Gln His 1 5 10 15 Leu Leu Leu Ser Pro Ala Phe Leu Gly Glu Gln Lys Gln Glu Gly Lys 20 25 30 Met Pro Gln Lys Arg Glu 35 <210> SEQ ID NO 210 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 210 Gly Arg His Gly Asn Val Glu Tyr Ser Tyr Ser Ser Phe Phe Asn Ile 1 5 10 15 Ile Glu Ala Phe Ile Arg Val Ile Val Ser 20 25 <210> SEQ ID NO 211 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 211 Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys 1 5 10 <210> SEQ ID NO 212 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 212 Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys Lys 1 5 10 15 Pro Leu Leu Ser 20 <210> SEQ ID NO 213 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 213 Pro Ile Lys Ile Gly Val Ser Arg Gly Pro Phe Val Ser Arg Val Ser 1 5 10 15 Val Met Thr Val Lys Thr Ser Asp Thr Cys Ser Ser Arg Arg Arg Ser 20 25 30 Gln Leu Val Cys Lys Arg Met Pro Gly Ala Asp Lys Pro Val Arg Ala 35 40 45 Arg Gln Arg Val Leu Ala Gly Val Gly Ala Gly Leu Thr Met Arg His 50 55 60 Gln Ser Arg Leu Tyr 65 <210> SEQ ID NO 214 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 214 Glu Cys Thr Ile Cys Gly Val Lys Tyr Arg Thr Asp Ala 1 5 10 <210> SEQ ID NO 215 <211> LENGTH: 41 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 215 Gly Glu Asn Thr Ala Ser Gly Ala Ile Arg His Ser Gly Cys Ala Thr 1 5 10 15 Val Gly Lys Gly Asp Arg Cys Gly Pro Leu Arg Tyr Tyr Ala Ser Trp 20 25 30 Arg Lys Gly Asp Val Leu Gln Gly Asp 35 40 <210> SEQ ID NO 216 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: vector pACgp67-ScFv350 peptide sequence <400> SEQUENCE: 216 Arg Gln Gly Phe Pro Ser His Asp Val Val Lys Arg Arg Pro Val 1 5 10 15 <210> SEQ ID NO 217 <211> LENGTH: 350 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic VH nucleotide sequence <400> SEQUENCE: 217 gaggtgaagc ttctccagtc tggaggtggc ctggtgcagc ctggaggatc cctgaaactc 60 tcctgtgcag cctcaggaat cgattttagt agatactgga tgagttgggt tcggcgggct 120 ccagggaaag gactagaatg gattggagaa attaatccag atagcagtac aataaactat 180 gcaccatctc taaaggataa attcatcatc tccagagaca acgccaaaaa tacgctgtac 240 ctgcaaatga gcaaagtgag atctgaggac acagcccttt attactgtgc aagaggactg 300 ggacagaact tgactactgg ggccaaggca ccactctcac agtctcctca 350 <210> SEQ ID NO 218 <211> LENGTH: 336 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic VL nucleotide sequence <400> SEQUENCE: 218 gatattgtga tgacgcaggc tgcattctcc aatccagtca ctcttggaac atcagcttcc 60 atctcctgca ggtctagtaa gagtctccta catagtaatg gcatcactta tttgtattgg 120 tatctgcaga agccaggcca gtctcctcag ctcctgattt atcagatgtc caaccttgcc 180 tcaggagtcc cagacaggtt cagtagcagt gggtcaggaa ctgatttcac actgagaatc 240 agcagagtgg aggctgagga tgtgggtgtt tattactgtg ctcaaaatct agaacttccg 300 tggacgttcg gtggaggcac caagctggaa atcaaa 336 <210> SEQ ID NO 219 <211> LENGTH: 354 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic VH nucleotide sequence <400> SEQUENCE: 219 gaggtgaagc tggtggagtc tggaggaggc ttggtacagc ctgggggttc tctgagtctc 60 tcctgtgcag cttctggatt caccttcact gattactcca tgaactgggt ccgccagcct 120 ccagggaaga cacttgagtg gttggctttt attagaaaca aagctaatgg ttacacagca 180 gagtacagtg catctgtgaa gggtcggttc tccatctcca gagataattc ccaaagcatc 240 ctctatcttc aaatgaatgc cctgagagct gaggacagtg ccacttatta ctgtgcaagg 300 ggatggtatg ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctca 354 <210> SEQ ID NO 220 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic VH nucleotide sequence <400> SEQUENCE: 220 gaggttctgc tgcagcagtc tgtggcagag cttgtgaggc caggggcctc agtcaagttg 60 tcctgcatag tttctgactt caacattaaa cacacctata tgcactgggt gaaacagagg 120 cctgatcagg gcctggagtg gattggaagg attgatcctg cgaatggtaa aactatatat 180 gccccgacgt tccagggcaa ggccactata actgcggaca catcctccaa cacagcctac 240 ctgcatttca gcagcctgac atctgaggac gctgccatct attactgtgc tagagctggg 300 gctggctact ttgactactg gggccaaggc accactctca cagtctcctc a 351 <210> SEQ ID NO 221 <211> LENGTH: 321 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic VL nucleotide sequence <400> SEQUENCE: 221 gacatcttgc tgactcagtc tccagccatc ctgtctgtga gtccaggaga aagagtcagt 60 ttctcctgca gggccagtca gaacattggc acaagtattt actggtatca gcaaagaaca 120 aatggttctc caaggcttct cataaagtat gtttctgagt ctatctctgg gatcccttcc 180 aggtttagtg gcagtggatc agggacagag tttactctta gcatcaacag tgtggagtct 240 gaagatattg cagattatta ctgtcaacaa agtcatagtt ggccgctcac gttcggtgct 300 gggaccaagc tggagctgaa a 321 <210> SEQ ID NO 222 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative mitochondriotoxic motif <400> SEQUENCE: 222 Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys 1 5 10 <210> SEQ ID NO 223 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative peptide <400> SEQUENCE: 223 Cys Asn Gly Arg Cys 1 5 <210> SEQ ID NO 224 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative peptide <400> SEQUENCE: 224 Cys Gly Phe Glu Cys Val Arg Gln Cys Pro Glu Arg Cys 1 5 10 <210> SEQ ID NO 225 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 225 His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly 1 5 10 <210> SEQ ID NO 226 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 226 His Phe Lys Ile Gly Cys Lys His Ser Lys Ile Gly 1 5 10 <210> SEQ ID NO 227 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 227 His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly Ile Ile Gln Gln 1 5 10 15 Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 20 25 <210> SEQ ID NO 228 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 228 His Phe Lys Ile Gly Cys Lys His Ser Lys Ile Gly Ile Ile Gln Gln 1 5 10 15 Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 20 25 <210> SEQ ID NO 229 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 229 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly Ile 20 25 30 Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 45 <210> SEQ ID NO 230 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 230 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Lys Ile Gly Cys Lys His Ser Lys Ile Gly Ile 20 25 30 Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 45 <210> SEQ ID NO 231 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 231 Asp Thr Trp Thr Gly Val Glu Ala Ala Ile Arg Ile Leu Gln Gln Ala 1 5 10 15 Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly Ile 20 25 30 Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 45 <210> SEQ ID NO 232 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 232 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly 20 25 30 <210> SEQ ID NO 233 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 233 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Lys Ile Gly Cys Lys His Ser Lys Ile Gly 20 25 30 <210> SEQ ID NO 234 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Candida albicans <400> SEQUENCE: 234 Asp Ser His Ala Arg Lys Arg His His Gly Tyr Lys Arg Lys Phe His 1 5 10 15 Glu Lys His His Ser His Arg Gly Tyr 20 25 <210> SEQ ID NO 235 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Vespula lewisii <400> SEQUENCE: 235 Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 1 5 10 <210> SEQ ID NO 236 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 236 Leu Ser Arg Leu Leu Gly Lys Leu Pro Glu Leu Arg Thr Leu 1 5 10 <210> SEQ ID NO 237 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 237 Ala Thr Leu Asp Ala Leu Leu Ala Ala Leu Arg Arg Ile Gln 1 5 10 <210> SEQ ID NO 238 <211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 238 Arg Asn Ile Ala Arg His Leu Ala Gln Val Gly Asp Ser Met Arg Asp 1 5 10 15 Arg <210> SEQ ID NO 239 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 239 Lys Lys Leu Ser Glu Cys Leu Lys Arg Ile Gly Asp Glu Leu Asp Ser 1 5 10 15 <210> SEQ ID NO 240 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 240 Gly Gln Val Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg 1 5 10 15 <210> SEQ ID NO 241 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 241 Ala Leu Arg Phe Thr Ser Ala Arg Arg 1 5 <210> SEQ ID NO 242 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 242 Lys Thr His Val Lys Thr Ala Ser Leu Gly Leu Ala Gly Lys Ala 1 5 10 15 <210> SEQ ID NO 243 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 243 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 244 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 244 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 245 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 245 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 246 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 246 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 <210> SEQ ID NO 247 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 247 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 <210> SEQ ID NO 248 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 248 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 <210> SEQ ID NO 249 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 249 Leu Ala Ser Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr 1 5 10 15 Pro Leu <210> SEQ ID NO 250 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 250 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 251 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 251 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 252 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 252 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 253 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 253 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Pro Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 254 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 254 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 255 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 255 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 256 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 256 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly Ile 20 25 30 Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 45 <210> SEQ ID NO 257 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 257 Pro Ser Leu Arg Val Trp Arg Leu Cys Ala Arg Arg Leu Val 1 5 10 <210> SEQ ID NO 258 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 258 Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Arg Met Ser 1 5 10 15 Asp Glu Phe Val Asp Ser Phe Lys Lys 20 25 <210> SEQ ID NO 259 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: TOX peptide <400> SEQUENCE: 259 Gln Asp Ala Ser Thr Lys Lys Leu Ser Glu Cys Leu Lys Arg Ile Gly 1 5 10 15 Asp Glu Leu Asp Ser Asn Met Glu Leu 20 25 <210> SEQ ID NO 260 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 260 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 261 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 261 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 262 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 262 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn 1 5 10 <210> SEQ ID NO 263 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 263 Leu Ala Ser Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr 1 5 10 15 Pro Leu <210> SEQ ID NO 264 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 264 Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 265 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 265 Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 266 <211> LENGTH: 31 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 266 Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Ala Gly Asn Leu Ala Ser 1 5 10 15 Gly Gly Ala Ala Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 30 <210> SEQ ID NO 267 <211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: Antennapedia TOX peptide <400> SEQUENCE: 267 Arg Gln Ile Lys Ile Thr Phe Gln Asn Arg Arg Met Lys Thr Lys Lys 1 5 10 15 <210> SEQ ID NO 268 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 268 Ile Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 1 5 10 <210> SEQ ID NO 269 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 269 Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro 1 5 10 <210> SEQ ID NO 270 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 270 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 <210> SEQ ID NO 271 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Unknown Organism <220> FEATURE: <223> OTHER INFORMATION: Description of Unknown Organism: pep-1 TOX peptide <400> SEQUENCE: 271 Lys Glu Thr Trp Trp Glu Thr Trp Trp Thr Glu Trp 1 5 10 <210> SEQ ID NO 272 <211> LENGTH: 96 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 272 Met Glu Gln Ala Pro Glu Asp Gln Gly Pro Gln Arg Glu Pro Tyr Asn 1 5 10 15 Glu Trp Thr Leu Glu Leu Leu Glu Glu Leu Lys Ser Glu Ala Val Arg 20 25 30 His Phe Pro Arg Ile Trp Leu His Asn Leu Gly Gln His Ile Tyr Glu 35 40 45 Thr Tyr Gly Asp Thr Trp Ala Gly Val Glu Ala Ile Ile Arg Ile Leu 50 55 60 Gln Gln Leu Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser Arg 65 70 75 80 Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn Gly Ala Ser Arg Ser 85 90 95 <210> SEQ ID NO 273 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <220> FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION: (2) <223> OTHER INFORMATION: Phe or Ser <400> SEQUENCE: 273 His Xaa Arg Ile Gly 1 5 <210> SEQ ID NO 274 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 274 His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly 1 5 10 <210> SEQ ID NO 275 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 275 His Phe Arg Ile Gly 1 5 <210> SEQ ID NO 276 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Human immunodeficiency virus type 1 <400> SEQUENCE: 276 His Ser Arg Ile Gly 1 5 <210> SEQ ID NO 277 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Linker peptide <400> SEQUENCE: 277 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 <210> SEQ ID NO 278 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 278 Cys Asn Gly Arg Cys Gly Gly His Phe Arg Ile Gly Cys Arg His Ser 1 5 10 15 Arg Ile Gly <210> SEQ ID NO 279 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 279 Cys Asn Gly Arg Cys Gly Gly 1 5 <210> SEQ ID NO 280 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 280 Cys Asn Gly Arg Cys Gly Gly Asp Lys Arg Thr Gln Phe Trp Tyr Phe 1 5 10 15 Pro Gly Asn <210> SEQ ID NO 281 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 281 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly His Phe Arg Ile 1 5 10 15 Gly Cys Arg His Ser Arg Ile Gly 20 <210> SEQ ID NO 282 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 282 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly 1 5 10 <210> SEQ ID NO 283 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 283 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly Asp Lys Arg Thr 1 5 10 15 Gln Phe Trp Tyr Phe Pro Gly Asn 20 <210> SEQ ID NO 284 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 284 His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly 1 5 10 <210> SEQ ID NO 285 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <400> SEQUENCE: 285 Asp Lys Arg Thr Gln Phe Trp Tyr Phe Pro Gly Asn 1 5 10 <210> SEQ ID NO 286 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 6-His tag <400> SEQUENCE: 286 His His His His His His 1 5 <210> SEQ ID NO 287 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 287 gatcccatca tcaccaccac cac 23 <210> SEQ ID NO 288 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 288 attgaaggaa gagaattccc atg 23 <210> SEQ ID NO 289 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 289 gctgcagccc gggggatgtt aaa 23 <210> SEQ ID NO 290 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 290 cttccttcaa tgtggtggtg gtgatgatgg 30 <210> SEQ ID NO 291 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 291 gggctgcagc catgggaatt ct 22 <210> SEQ ID NO 292 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Primer <400> SEQUENCE: 292 gatctttaac atccccc 17 <210> SEQ ID NO 293 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 293 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe Ile His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly Ile 20 25 30 Ile Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 45 <210> SEQ ID NO 294 <211> LENGTH: 44 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 294 Asp Thr Trp Thr Gly Val Glu Ala Leu Ile Arg Ile Leu Gln Gln Leu 1 5 10 15 Leu Phe His Phe Ala Ile Gly Cys Arg His Ser Ala Ile Gly Ile Ile 20 25 30 Gln Gln Arg Arg Thr Arg Asn Gly Ala Ser Lys Ser 35 40 <210> SEQ ID NO 295 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 295 Cys Asn Gly Arg Cys Gly Gly His Phe Arg Ile Gly Cys Arg His Ser 1 5 10 15 Arg Ile Gly <210> SEQ ID NO 296 <211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 296 Cys Asn Gly Arg Cys Gly Gly His Phe Ala Ile Gly Cys Arg His Ser 1 5 10 15 Ala Ile Gly <210> SEQ ID NO 297 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 297 Cys Asn Gly Arg Cys Gly Gly Cys Asn Gly Arg Cys 1 5 10 <210> SEQ ID NO 298 <211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 298 Gly Gly His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly 1 5 10 <210> SEQ ID NO 299 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 299 Cys Asn Gly Arg Cys Gly Gly 1 5 <210> SEQ ID NO 300 <211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 300 Lys Glu Thr Trp Trp Glu Thr Trp Trp Thr Glu Trp Gly Gly His Phe 1 5 10 15 Arg Ile Gly Cys Arg His Ser Arg Ile Gly 20 25 <210> SEQ ID NO 301 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 301 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly His Phe Arg Ile 1 5 10 15 Gly Cys Arg His Ser Arg Ile Gly 20 <210> SEQ ID NO 302 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 302 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly His Phe Ala Ile 1 5 10 15 Gly Cys Arg His Ser Ala Ile Gly 20 <210> SEQ ID NO 303 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 303 Cys Asn Gly Arg Cys Gly Gly Asp Lys Arg Thr Gln Phe Trp Arg Tyr 1 5 10 15 Phe Pro Gly Asn 20 <210> SEQ ID NO 304 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 304 Cys Asn Gly Arg Cys Gly Gly Asp Lys Arg Thr Gln Phe Trp Arg Tyr 1 5 10 15 Phe Ala Gly Asn 20 <210> SEQ ID NO 305 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 305 Cys Asn Gly Arg Cys Gly Gly Asp Arg His Lys Gln Phe Trp Arg Tyr 1 5 10 15 Phe Pro Gly Asn 20 <210> SEQ ID NO 306 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 306 Cys Asn Gly Arg Cys Gly Gly Asp Lys His Thr Gln Phe Trp Arg Tyr 1 5 10 15 Phe Pro Gly Asn 20 <210> SEQ ID NO 307 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 307 Gly Gly Asp Lys Arg Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 15 <210> SEQ ID NO 308 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 308 Gly Gly Asp Arg His Lys Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 15 <210> SEQ ID NO 309 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 309 Gly Gly Asp Lys His Thr Gln Phe Trp Arg Tyr Phe Pro Gly Asn 1 5 10 15 <210> SEQ ID NO 310 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 310 Cys Asn Gly Arg Cys Gly Gly 1 5 <210> SEQ ID NO 311 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 311 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly Asp Lys Arg Thr 1 5 10 15 Gln Phe Trp Arg Tyr Phe Pro Gly Asn 20 25 <210> SEQ ID NO 312 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 312 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly Asp Lys Arg Thr 1 5 10 15 Gln Phe Trp Arg Tyr Phe Ala Gly Asn 20 25 <210> SEQ ID NO 313 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 313 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly Asp Arg His Lys 1 5 10 15 Gln Phe Trp Arg Tyr Phe Pro Gly Asn 20 25 <210> SEQ ID NO 314 <211> LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 314 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly Asp Lys His Thr 1 5 10 15 Gln Phe Trp Arg Tyr Phe Pro Gly Asn 20 25 <210> SEQ ID NO 315 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 315 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly 1 5 10 <210> SEQ ID NO 316 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 316 Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly Gly 1 5 10 <210> SEQ ID NO 317 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 317 Arg Lys Lys Arg Arg Gln Arg Arg Arg Asp Lys Arg Thr Gln Phe Trp 1 5 10 15 Arg Tyr Phe Ala Gly Asn 20 <210> SEQ ID NO 318 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 318 Arg Lys Lys Arg Arg Gln Arg Arg Arg Asp Lys Arg Thr Gln Phe Trp 1 5 10 15 Arg Tyr Phe Pro Gly Asn 20 <210> SEQ ID NO 319 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 319 Arg Lys Lys Arg Arg Gln Arg Arg Arg Asp Arg His Lys Gln Phe Trp 1 5 10 15 Arg Tyr Phe Ala Gly Asn 20 <210> SEQ ID NO 320 <211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 320 Arg Lys Lys Arg Arg Gln Arg Arg Arg Asp Lys His Thr Gln Phe Trp 1 5 10 15 Arg Tyr Phe Ala Gly Asn 20 <210> SEQ ID NO 321 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 321 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 <210> SEQ ID NO 322 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 322 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 <210> SEQ ID NO 323 <211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 323 Arg Lys Lys Arg Arg Gln Arg Arg Arg Leu Ala Ser Gly Gly Ala Ala 1 5 10 15 Gly Ala Thr Ser Leu Cys Phe Val Tyr Pro Leu 20 25 <210> SEQ ID NO 324 <211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 324 Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ala Trp Ser Asn Val Leu 1 5 10 15 Arg Gly Met Gly Gly Ala Phe Val Leu Val Leu Tyr 20 25 <210> SEQ ID NO 325 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide <220> FEATURE: <223> OTHER INFORMATION: N-term biotin <400> SEQUENCE: 325 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 

What is claimed is:
 1. Method for inducing or preventing the apoptosis of.eukaryotic cells comprising the homing on specific tissue cell population of a chimeric bifunctional molecule able to modulate-the activity of permeability transition pore complex (PTPC).
 2. A method according to claim 1, wherein said chimeric molecules modulate the activity of the permeability transition pore complex (PTPC) of a specific eukaryotic cell by the regulation of opening or the closing of said pore.
 3. A method according to claim 1 or 2, wherein said chimeric molecules comprising at least a first functional molecule and a second functional molecule, wherein said first functional molecule has the function to target specifically a tissue cell population, and the second functional molecule has the function to regulate the apoptosis activity linked to the permeability transition pore complex (PTPC) of said specific calls.
 4. A method according to claim 3, wherein said chimeric molecules comprising at least a first functional molecule and a second functional molecule, wherein said first functional molecule has the function to target and to enter specifically in a tissue cell population and the second functional molecule has the function to regulate the apoptosis activity linked to the permeability transition pore complex (PTPC) of said specific cells.
 5. A method according to claim 3, wherein said chimeric molecules comprising at least a first functional molecule and a second functional molecule, wherein said first functional molecule has the function to target and to enter specifically in a tissue cell population of interest and the second functional molecule has the function to target specifically and inducing or preventing the death of said cells by apoptosis by the regulation of the opening or the closing of the permeability transition pore complex (PTPC) of mitochondria or a fragment thereof.
 6. A method according to claim 4, wherein said chimeric molecule has the formula: Targ-Tox, wherein Tox is a viral or a retroviral apoptotic peptide or a peptidomimetic or a fragment of a protein that interacts with permeability transition pore complex (PTPC) of a specific eukaryotic cell to cause apoptosis of the cell; and Targ is chosen from: an antibody, an antibody fragment, arecombinant antibody fragment, M350/ScFv, V461/ScFv, a homing peptide, and any peptide chosen in Table III, wherein said molecule binds and enters the cell specifically.
 7. A method according to claim 5, wherein said chimeric molecule has the formula Targ-Save, wherein Save is a viral or a retroviral or a cellular antiapoptotic peptide or peptidomimetic or a fragment of protein that interacts with permeability transition pore complex (PTPC) of a specific eukaryotic cell to prevent the apoptosis of the cell with the proviso that when Save peptide is a viral peptide, Save is not vMIA protein of Cytomegalovirus; and Targ is chosen from: an antibody, an antibody fragment, a recombinant antibody fragment, M350/ScFv, a homing peptide, and any peptide chosen in Table III, wherein said molecule binds and enters the cell specifically.
 8. A method according to anyone of claims 1 to 7, wherein said chimeric molecules comprises a Mitochondrial Localisation Sequence (MLS), which has the function to address specifically the second functional molecule to mitochondrial or intermembrane space-of the mitochondria.
 9. A method according to claims 1, 2, 3, 4, 5, 6 and 8, wherein Tox is chosen from the group of peptides of Table I.
 10. A method according to claims 1, 2, 3, 4, 5, and 7, wherein Save is chosen from the group of peptides of Table II.
 11. A method according to any one of claims 1 to 10, wherein the second functional molecule of said chimeric molecules has the function to interact specifically with ANT of the PTPC of mitochondria also refers to as adenine nucleotide translocator isoforms 1, 2, or
 3. 12. A chimeric bifunctional molecule capable to enter specifically in a tissue cell population for induce or prevent death of said cell by apoptosis and comprising at least a first functional molecule covalently linked to a second functional molecule, wherein said first functional molecule has the function to target and to enter specifically in a tissue cell population of interest and the second functional molecule has the function to target specifically and inducing or preventing the death of said cells by apoptosis by the regulation of the opening or the closing of the permeability transition pore complex (PTPC) of mitochondria or a fragment thereof.
 13. A chimeric molecule according to claim 12 which has the formula: Targ-Tox, wherein Tox is a viral or a retroviral apoptotic peptide or peptidomimetic or a fragment of a protein that interacts with Permeability Transifion Pore Complex (PTPC) of a specific eukaryofic cell to cause apoptosis of the cell; and Targ is chosen from: an antibody, an antibody fragment, a recombinant antibody fragment, M350/ScFv, V461/ScFv, a homing peptide, and any peptide of Table III, wherein said molecule binds and enters the cell specifically.
 14. A chimeric molecule according to claim 12 which has of the formula Targ-Save Wherein Save is a viral or a retroviral or a cellular antiapoptotic peptide or peptidomimetic or a fragment of protein that interacts with Permeability Transition. Pore Complex (PTPC) of a specific eukaryotic cell to prevent apoptosis of the cell, with the proviso that when Save peptide is a viral peptide, Save is not vMIA protein of Cytomegalovirus; and Targ is chosen from: an antibody, an antibody fragment, a recombinant antibody fragment, M350/ScFv, a homing peptide, and any peptide of Table III, wherein said molecule binds and enters the cell specifically.
 15. A chimeric molecule according to any of claims 12 to 14 comprising a mitochondrial localisation sequence (MLS) which has the function to address specifically the second functional molecule to mitochondrial membranes or intermembrane space.
 16. A chimeric molecule according to claims 13 or 15, wherein Tox is chosen from the group of peptides of Table I.
 17. A chimeric molecule according to claims 14 and 15, wherein wherein Save is chosen from the group of peptides of Table II.
 18. A chimeric molecule according to claims 13, 15 and 16, wherein the Targ and Tox peptides are covalently bonded through a peptide linker comprising 3 to 18 amino acids.
 19. A chimeric molecule according to claims 14, 15 and 17, wherein the Targ and Save peptides are covalently bonded through a peptide linker comprising 3 to 18 amino acids.
 20. A vector encoding a chimeric molecule as claimed in any one of claims 12 to
 19. 21. A hybridoma secreting Targ according to claim 13 or 14 and deposited at the National Collection of Culture and Microorganism (C.N.C.M.) on Jan. 24, 2001, under the accession number n° I
 2617. 22. A purified monoclonal antibody encoded by the hybridoma of claim
 21. 23. A recombinant host cell comprising a vector as claimed in claim
 20. 24. A cancer cell having a tumor associated antigen on the surface thereof to which is bound the chimeric molecule as claimed in any one of claims 12 to
 19. 25. A method of determining the presence of a cancer cell having a tumor-associated antigen on the surface thereof in a biological sample comprising: a) contacting a biological sample of interest with a chimeric peptide molecule according to claims 12 to 19 under conditions to permit the binding between the chimeric peptide according to the invention and the antigen on the surface of the. cancer cell, b) detecting the binding by usual technique; and c) optionally quantifying the binding detected in step b).
 26. A method for inducing death by apoptosis in a tumoral or viral infected cell having a tumor-associated antigen on surface thereof in a biological sample comprising: contacting a biological sample of interest with a chimeric peptide molecule according to claims 16 or 17 under conditions to permit the binding between the chimeric peptide according to the invention and the antigen on the surface of the cancer cell and for a time sufficient to allow the entry inside the cell and death cell by apoptosis or viral infected cells.
 27. A method for prevent cell death by mitochondrial apoptosis comprising contacting a biological sample of interest with a chimeric molecule, molecule according to claims 17 or 19 under conditions to permit the binding between the chimeric molecule according to the invention and the cell of interest and for a time sufficient to allow the entry inside cell of interest and prevent the cell death by apoptosis.
 28. A method for prevent cell death according to claim 27, wherein the cells of interest are choosen among the following cell populations: neurons, cardiocytes, and hepatocytes.
 29. A method for identifying an active agent of interest that interacts with the activity of the permeability transition pore complex (PTPC) comprising a) contacting a biological sample containing cells with permeability transition pore complex (PTPC) with a chimeric peptide according to claims 12 to 19 in the presence of a candidate agent; and b) comparing the binding of the chimeric peptide with the permeability transition pore complex (PTPC) in absence of said agent. c) optionally, testing the activity of said selected agent on a preparation of a cellular extract comprising subcellular elements with the permeability transition pore complex (PTPC).
 30. A method for identifying an active agent of interest that interacts with ANT peptide of permeability transition pore complex (PTPC) comprising: d) contacting a biological sample containing cells with ANT peptide of permeability transition pore complex (PTPC) with a chimeric peptide according to claims 12 to 19 in the presence of a candidate agent; and e) comparing the binding of the chimeric peptide with the ANT peptide of the permeability transition pore complex (PTPC) in absence of said agent. f) optionally, testing the activity of said selected agent on a preparation of a cellular extract comprising subcellular elements with the ANT peptide of the permeability transition pore complex (PTPC).
 31. A method of identification of mitochondrial antigen, said antigen having the capacity to interact with a macromolecule or a molecule or a peptide carrying the characteristic of Tox according to claims 13 or
 16. 32. A method of identification of mitochondrial antigen, said antigen having the capacity to interact with a macromolecule or a molecule or a peptide carrying the characteristic of save according to claims 14 or
 17. 33. A method of treatment or of prevention of a pathological infection or disease comprising the administration to a patient of the pharmaceutical composition containing at least a chimeric molecule according to any of claims 12 to
 19. 34. A pharmaceutical composition comprising at least a chimeric molecule according to claims any of 12 to
 19. 